JP2003510344A - Prescription for menopausal women - Google Patents
Prescription for menopausal womenInfo
- Publication number
- JP2003510344A JP2003510344A JP2001527771A JP2001527771A JP2003510344A JP 2003510344 A JP2003510344 A JP 2003510344A JP 2001527771 A JP2001527771 A JP 2001527771A JP 2001527771 A JP2001527771 A JP 2001527771A JP 2003510344 A JP2003510344 A JP 2003510344A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- composition
- fatty acid
- derivative
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims abstract description 213
- 238000000034 method Methods 0.000 claims abstract description 96
- 230000009245 menopause Effects 0.000 claims abstract description 74
- 235000016709 nutrition Nutrition 0.000 claims abstract description 45
- 208000024891 symptom Diseases 0.000 claims abstract description 25
- -1 linoleic acid compound Chemical class 0.000 claims description 221
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 164
- 229930195729 fatty acid Natural products 0.000 claims description 164
- 239000000194 fatty acid Substances 0.000 claims description 164
- 239000000126 substance Substances 0.000 claims description 64
- 229940043430 calcium compound Drugs 0.000 claims description 50
- 150000001674 calcium compounds Chemical class 0.000 claims description 50
- 150000004665 fatty acids Chemical class 0.000 claims description 49
- 150000001875 compounds Chemical class 0.000 claims description 44
- 235000004626 essential fatty acids Nutrition 0.000 claims description 32
- 239000000262 estrogen Substances 0.000 claims description 30
- 229940011871 estrogen Drugs 0.000 claims description 30
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical class CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 29
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 29
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 28
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 25
- 239000013543 active substance Substances 0.000 claims description 25
- 239000002552 dosage form Substances 0.000 claims description 25
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 24
- 235000019152 folic acid Nutrition 0.000 claims description 24
- 239000011724 folic acid Substances 0.000 claims description 24
- 229940088594 vitamin Drugs 0.000 claims description 24
- 229930003231 vitamin Natural products 0.000 claims description 24
- 239000011782 vitamin Substances 0.000 claims description 24
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 23
- 229960004488 linolenic acid Drugs 0.000 claims description 23
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 21
- 239000003826 tablet Substances 0.000 claims description 21
- 235000013343 vitamin Nutrition 0.000 claims description 21
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 20
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 20
- 235000020778 linoleic acid Nutrition 0.000 claims description 20
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 20
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 19
- 229960000304 folic acid Drugs 0.000 claims description 19
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical class CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 17
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 claims description 17
- 208000001132 Osteoporosis Diseases 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 16
- 238000012377 drug delivery Methods 0.000 claims description 16
- 239000007903 gelatin capsule Substances 0.000 claims description 16
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 16
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 15
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 15
- 229930003268 Vitamin C Natural products 0.000 claims description 15
- 229930003427 Vitamin E Natural products 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 15
- 235000019154 vitamin C Nutrition 0.000 claims description 15
- 239000011718 vitamin C Substances 0.000 claims description 15
- 239000011709 vitamin E Substances 0.000 claims description 15
- 235000019165 vitamin E Nutrition 0.000 claims description 15
- 229940046009 vitamin E Drugs 0.000 claims description 15
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 14
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 14
- 239000011707 mineral Substances 0.000 claims description 14
- 235000010755 mineral Nutrition 0.000 claims description 14
- 229940012843 omega-3 fatty acid Drugs 0.000 claims description 14
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 13
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 13
- 230000000975 bioactive effect Effects 0.000 claims description 12
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 12
- 239000000186 progesterone Substances 0.000 claims description 12
- 229960003387 progesterone Drugs 0.000 claims description 12
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 11
- PYTMYKVIJXPNBD-OQKDUQJOSA-N 2-[4-[(z)-2-chloro-1,2-diphenylethenyl]phenoxy]-n,n-diethylethanamine;hydron;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(/Cl)C1=CC=CC=C1 PYTMYKVIJXPNBD-OQKDUQJOSA-N 0.000 claims description 11
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 11
- 229930003316 Vitamin D Natural products 0.000 claims description 11
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 11
- 229960003608 clomifene Drugs 0.000 claims description 11
- 239000011719 vitamin A Substances 0.000 claims description 11
- 235000019155 vitamin A Nutrition 0.000 claims description 11
- 239000011710 vitamin D Substances 0.000 claims description 11
- 235000019166 vitamin D Nutrition 0.000 claims description 11
- 229940045997 vitamin a Drugs 0.000 claims description 11
- 229940011671 vitamin b6 Drugs 0.000 claims description 11
- 229940046008 vitamin d Drugs 0.000 claims description 11
- 108010010803 Gelatin Proteins 0.000 claims description 10
- 238000013270 controlled release Methods 0.000 claims description 10
- 239000008273 gelatin Substances 0.000 claims description 10
- 229920000159 gelatin Polymers 0.000 claims description 10
- 235000019322 gelatine Nutrition 0.000 claims description 10
- 235000011852 gelatine desserts Nutrition 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 10
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 9
- 239000012867 bioactive agent Substances 0.000 claims description 9
- 150000002148 esters Chemical class 0.000 claims description 9
- 229930182833 estradiol Natural products 0.000 claims description 9
- 229960005309 estradiol Drugs 0.000 claims description 9
- 229940088597 hormone Drugs 0.000 claims description 9
- 239000005556 hormone Substances 0.000 claims description 9
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 9
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 9
- 235000019158 vitamin B6 Nutrition 0.000 claims description 9
- 239000011726 vitamin B6 Substances 0.000 claims description 9
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 8
- 235000001014 amino acid Nutrition 0.000 claims description 8
- 229940024606 amino acid Drugs 0.000 claims description 8
- 239000000835 fiber Substances 0.000 claims description 8
- 241000411851 herbal medicine Species 0.000 claims description 8
- 239000011777 magnesium Substances 0.000 claims description 8
- 229910052749 magnesium Inorganic materials 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- 239000000935 antidepressant agent Substances 0.000 claims description 7
- 229940127218 antiplatelet drug Drugs 0.000 claims description 7
- 229940049706 benzodiazepine Drugs 0.000 claims description 7
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 7
- 229910052742 iron Inorganic materials 0.000 claims description 7
- 235000006180 nutrition needs Nutrition 0.000 claims description 7
- 239000000932 sedative agent Substances 0.000 claims description 7
- 230000004799 sedative–hypnotic effect Effects 0.000 claims description 7
- 239000003204 tranquilizing agent Substances 0.000 claims description 7
- 230000002936 tranquilizing effect Effects 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 claims description 6
- PYTMYKVIJXPNBD-BTKVJIOYSA-N 2-[4-[(e)-2-chloro-1,2-diphenylethenyl]phenoxy]-n,n-diethylethanamine;hydron;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 PYTMYKVIJXPNBD-BTKVJIOYSA-N 0.000 claims description 6
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims description 6
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 6
- 206010065687 Bone loss Diseases 0.000 claims description 6
- 102000055006 Calcitonin Human genes 0.000 claims description 6
- 108060001064 Calcitonin Proteins 0.000 claims description 6
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 claims description 6
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims description 6
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 claims description 6
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 claims description 6
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 claims description 6
- 229930003779 Vitamin B12 Natural products 0.000 claims description 6
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 6
- 229940062527 alendronate Drugs 0.000 claims description 6
- 229940005513 antidepressants Drugs 0.000 claims description 6
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 6
- 229960004015 calcitonin Drugs 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 229960002286 clodronic acid Drugs 0.000 claims description 6
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 claims description 6
- 229940046989 clomiphene citrate Drugs 0.000 claims description 6
- 229960002896 clonidine Drugs 0.000 claims description 6
- 238000000576 coating method Methods 0.000 claims description 6
- 229960002568 ethinylestradiol Drugs 0.000 claims description 6
- 229940009626 etidronate Drugs 0.000 claims description 6
- 229960002985 medroxyprogesterone acetate Drugs 0.000 claims description 6
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical group C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 claims description 6
- 229960004296 megestrol acetate Drugs 0.000 claims description 6
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 claims description 6
- 229960001652 norethindrone acetate Drugs 0.000 claims description 6
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims description 6
- 229940046231 pamidronate Drugs 0.000 claims description 6
- 235000017807 phytochemicals Nutrition 0.000 claims description 6
- 229930000223 plant secondary metabolite Natural products 0.000 claims description 6
- 229940019375 tiludronate Drugs 0.000 claims description 6
- 235000019163 vitamin B12 Nutrition 0.000 claims description 6
- 239000011715 vitamin B12 Substances 0.000 claims description 6
- 208000002500 Primary Ovarian Insufficiency Diseases 0.000 claims description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 5
- 150000001557 benzodiazepines Chemical class 0.000 claims description 5
- 235000013339 cereals Nutrition 0.000 claims description 5
- 230000007812 deficiency Effects 0.000 claims description 5
- 239000007938 effervescent tablet Substances 0.000 claims description 5
- 229940014144 folate Drugs 0.000 claims description 5
- 229940028286 ibadronate Drugs 0.000 claims description 5
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims description 5
- 206010036601 premature menopause Diseases 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 4
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims description 4
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 4
- 229940093797 bioflavonoids Drugs 0.000 claims description 4
- 239000007910 chewable tablet Substances 0.000 claims description 4
- 239000011651 chromium Substances 0.000 claims description 4
- 229910052804 chromium Inorganic materials 0.000 claims description 4
- 239000010949 copper Substances 0.000 claims description 4
- 229910052802 copper Inorganic materials 0.000 claims description 4
- 230000003111 delayed effect Effects 0.000 claims description 4
- 239000003118 drug derivative Substances 0.000 claims description 4
- 238000013265 extended release Methods 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 230000002209 hydrophobic effect Effects 0.000 claims description 4
- 230000000977 initiatory effect Effects 0.000 claims description 4
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 4
- 229960000310 isoleucine Drugs 0.000 claims description 4
- 229940040129 luteinizing hormone Drugs 0.000 claims description 4
- 238000012423 maintenance Methods 0.000 claims description 4
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 4
- 239000011733 molybdenum Substances 0.000 claims description 4
- 229910052750 molybdenum Inorganic materials 0.000 claims description 4
- 230000000926 neurological effect Effects 0.000 claims description 4
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 claims description 4
- 239000006014 omega-3 oil Substances 0.000 claims description 4
- 239000011669 selenium Substances 0.000 claims description 4
- 229910052711 selenium Inorganic materials 0.000 claims description 4
- 239000004474 valine Substances 0.000 claims description 4
- 239000011701 zinc Substances 0.000 claims description 4
- 229910052725 zinc Inorganic materials 0.000 claims description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 3
- 102000009151 Luteinizing Hormone Human genes 0.000 claims description 3
- 108010073521 Luteinizing Hormone Proteins 0.000 claims description 3
- 206010027304 Menopausal symptoms Diseases 0.000 claims description 3
- 239000011668 ascorbic acid Substances 0.000 claims description 3
- 235000010323 ascorbic acid Nutrition 0.000 claims description 3
- 229960005070 ascorbic acid Drugs 0.000 claims description 3
- 239000007894 caplet Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 239000011859 microparticle Substances 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 229940125723 sedative agent Drugs 0.000 claims description 3
- 235000013618 yogurt Nutrition 0.000 claims description 3
- NDNUANOUGZGEPO-UHFFFAOYSA-N (s)-2-propylpiperidine Chemical compound CCCC1CCCCN1 NDNUANOUGZGEPO-UHFFFAOYSA-N 0.000 claims description 2
- AMFMJCAPWCXUEI-UHFFFAOYSA-M 1-ethylpyridin-1-ium;chloride Chemical compound [Cl-].CC[N+]1=CC=CC=C1 AMFMJCAPWCXUEI-UHFFFAOYSA-M 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 150000001299 aldehydes Chemical class 0.000 claims description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical group [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 2
- HSNWZBCBUUSSQD-UHFFFAOYSA-N amyl nitrate Chemical compound CCCCCO[N+]([O-])=O HSNWZBCBUUSSQD-UHFFFAOYSA-N 0.000 claims description 2
- 125000000129 anionic group Chemical group 0.000 claims description 2
- 239000002374 bone meal Substances 0.000 claims description 2
- 229940036811 bone meal Drugs 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- 125000005313 fatty acid group Chemical group 0.000 claims description 2
- 150000002433 hydrophilic molecules Chemical class 0.000 claims description 2
- 150000003856 quaternary ammonium compounds Chemical class 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 claims description 2
- 238000011269 treatment regimen Methods 0.000 claims description 2
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 claims 6
- 229940050549 fiber Drugs 0.000 claims 6
- 239000006186 oral dosage form Substances 0.000 claims 6
- 239000003270 steroid hormone Substances 0.000 claims 6
- 230000001430 anti-depressive effect Effects 0.000 claims 5
- 230000001624 sedative effect Effects 0.000 claims 4
- 229940125725 tranquilizer Drugs 0.000 claims 4
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 2
- 235000014106 fortified food Nutrition 0.000 claims 2
- 235000011962 puddings Nutrition 0.000 claims 2
- OIDIRWZVUWCCCO-UHFFFAOYSA-N 1-ethylpyridin-1-ium Chemical compound CC[N+]1=CC=CC=C1 OIDIRWZVUWCCCO-UHFFFAOYSA-N 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 claims 1
- 241000237502 Ostreidae Species 0.000 claims 1
- 239000003435 antirheumatic agent Substances 0.000 claims 1
- 210000000436 anus Anatomy 0.000 claims 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims 1
- 239000001354 calcium citrate Substances 0.000 claims 1
- 229960004106 citric acid Drugs 0.000 claims 1
- 229940015872 ibandronate Drugs 0.000 claims 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims 1
- 235000020636 oyster Nutrition 0.000 claims 1
- 235000013337 tricalcium citrate Nutrition 0.000 claims 1
- 150000002266 vitamin A derivatives Chemical class 0.000 claims 1
- 150000003700 vitamin C derivatives Chemical class 0.000 claims 1
- 150000003712 vitamin E derivatives Chemical class 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 22
- 239000011575 calcium Substances 0.000 description 22
- 229960005069 calcium Drugs 0.000 description 22
- 229910052791 calcium Inorganic materials 0.000 description 22
- 238000009472 formulation Methods 0.000 description 20
- 239000003921 oil Substances 0.000 description 17
- 235000019198 oils Nutrition 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 8
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- 208000002720 Malnutrition Diseases 0.000 description 7
- 235000015872 dietary supplement Nutrition 0.000 description 7
- 235000018343 nutrient deficiency Nutrition 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229940091250 magnesium supplement Drugs 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 150000003710 vitamin D derivatives Chemical class 0.000 description 6
- HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 description 5
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 5
- 235000021298 Dihomo-γ-linolenic acid Nutrition 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 description 5
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 5
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 5
- 229960003284 iron Drugs 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 239000002207 metabolite Substances 0.000 description 5
- 239000004014 plasticizer Substances 0.000 description 5
- 230000009747 swallowing Effects 0.000 description 5
- 150000003722 vitamin derivatives Chemical class 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 4
- 240000002234 Allium sativum Species 0.000 description 4
- 241001083548 Anemone Species 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 235000021342 arachidonic acid Nutrition 0.000 description 4
- 229940114079 arachidonic acid Drugs 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 4
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 4
- 229960002733 gamolenic acid Drugs 0.000 description 4
- 235000004611 garlic Nutrition 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 235000012424 soybean oil Nutrition 0.000 description 4
- 239000003549 soybean oil Substances 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 3
- 206010036618 Premenstrual syndrome Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 150000002170 ethers Chemical class 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 125000005456 glyceride group Chemical group 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 229960003987 melatonin Drugs 0.000 description 3
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 3
- 229940029985 mineral supplement Drugs 0.000 description 3
- 235000020786 mineral supplement Nutrition 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 235000019156 vitamin B Nutrition 0.000 description 3
- 235000019195 vitamin supplement Nutrition 0.000 description 3
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- 241000906543 Actaea racemosa Species 0.000 description 2
- 235000002566 Capsicum Nutrition 0.000 description 2
- 240000008574 Capsicum frutescens Species 0.000 description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- 244000307700 Fragaria vesca Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 240000004670 Glycyrrhiza echinata Species 0.000 description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 2
- 241000721662 Juniperus Species 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 244000179291 Mahonia aquifolium Species 0.000 description 2
- 235000019484 Rapeseed oil Nutrition 0.000 description 2
- 241000124033 Salix Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000320380 Silybum Species 0.000 description 2
- 235000010841 Silybum marianum Nutrition 0.000 description 2
- 244000044822 Simmondsia californica Species 0.000 description 2
- 235000004433 Simmondsia californica Nutrition 0.000 description 2
- 102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000004067 bulking agent Substances 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000001390 capsicum minimum Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 229940107218 chromium Drugs 0.000 description 2
- 235000005301 cimicifuga racemosa Nutrition 0.000 description 2
- 239000007891 compressed tablet Substances 0.000 description 2
- 229940108928 copper Drugs 0.000 description 2
- 235000000639 cyanocobalamin Nutrition 0.000 description 2
- 229960002104 cyanocobalamin Drugs 0.000 description 2
- 239000011666 cyanocobalamin Substances 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- ZINJLDJMHCUBIP-UHFFFAOYSA-N ethametsulfuron-methyl Chemical compound CCOC1=NC(NC)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)C(=O)OC)=N1 ZINJLDJMHCUBIP-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000021323 fish oil Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 159000000011 group IA salts Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 229940010454 licorice Drugs 0.000 description 2
- 239000000944 linseed oil Substances 0.000 description 2
- 235000021388 linseed oil Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007472 neurodevelopment Effects 0.000 description 2
- 239000000820 nonprescription drug Substances 0.000 description 2
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 2
- 208000015124 ovarian disease Diseases 0.000 description 2
- 201000004535 ovarian dysfunction Diseases 0.000 description 2
- 231100000543 ovarian dysfunction Toxicity 0.000 description 2
- 229940055726 pantothenic acid Drugs 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 235000008160 pyridoxine Nutrition 0.000 description 2
- 239000011677 pyridoxine Substances 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000003760 tallow Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 235000014393 valine Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
- 240000004731 Acer pseudoplatanus Species 0.000 description 1
- 235000002754 Acer pseudoplatanus Nutrition 0.000 description 1
- 240000000073 Achillea millefolium Species 0.000 description 1
- 235000007754 Achillea millefolium Nutrition 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 240000006054 Agastache cana Species 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 244000208874 Althaea officinalis Species 0.000 description 1
- 235000006576 Althaea officinalis Nutrition 0.000 description 1
- 235000009328 Amaranthus caudatus Nutrition 0.000 description 1
- 240000001592 Amaranthus caudatus Species 0.000 description 1
- 244000061520 Angelica archangelica Species 0.000 description 1
- 240000007087 Apium graveolens Species 0.000 description 1
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 1
- 235000010591 Appio Nutrition 0.000 description 1
- 235000003130 Arctium lappa Nutrition 0.000 description 1
- 244000294263 Arctium minus Species 0.000 description 1
- 235000008078 Arctium minus Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003439 Artificial menopause Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 235000007689 Borago officinalis Nutrition 0.000 description 1
- 240000004355 Borago officinalis Species 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 244000056139 Brassica cretica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000273930 Brevoortia tyrannus Species 0.000 description 1
- 235000005881 Calendula officinalis Nutrition 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 240000006432 Carica papaya Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000005747 Carum carvi Nutrition 0.000 description 1
- 240000000467 Carum carvi Species 0.000 description 1
- 239000010369 Cascara Substances 0.000 description 1
- 235000006693 Cassia laevigata Nutrition 0.000 description 1
- 244000025596 Cassia laevigata Species 0.000 description 1
- 241000269333 Caudata Species 0.000 description 1
- 241000205586 Caulophyllum thalictroides Species 0.000 description 1
- 235000005940 Centaurea cyanus Nutrition 0.000 description 1
- 240000004385 Centaurea cyanus Species 0.000 description 1
- 241000169597 Chamaelirium luteum Species 0.000 description 1
- 240000003538 Chamaemelum nobile Species 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 235000007542 Cichorium intybus Nutrition 0.000 description 1
- 244000298479 Cichorium intybus Species 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 241000252203 Clupea harengus Species 0.000 description 1
- 241000555825 Clupeidae Species 0.000 description 1
- 241001454694 Clupeiformes Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 244000234623 Coprinus comatus Species 0.000 description 1
- 235000004439 Coprinus comatus Nutrition 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- 235000015655 Crocus sativus Nutrition 0.000 description 1
- 244000124209 Crocus sativus Species 0.000 description 1
- 235000009852 Cucurbita pepo Nutrition 0.000 description 1
- 240000001980 Cucurbita pepo Species 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- 235000017788 Cydonia oblonga Nutrition 0.000 description 1
- 240000004784 Cymbopogon citratus Species 0.000 description 1
- 235000017897 Cymbopogon citratus Nutrition 0.000 description 1
- 235000018783 Dacrycarpus dacrydioides Nutrition 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
- 240000003173 Drymaria cordata Species 0.000 description 1
- 244000133098 Echinacea angustifolia Species 0.000 description 1
- 241001632410 Eleutherococcus senticosus Species 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 241000195955 Equisetum hyemale Species 0.000 description 1
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 244000166124 Eucalyptus globulus Species 0.000 description 1
- 235000014066 European mistletoe Nutrition 0.000 description 1
- 239000001653 FEMA 3120 Substances 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 206010016260 Fatty acid deficiency Diseases 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 235000012641 Fragaria vesca subsp vesca Nutrition 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 241000556215 Frangula purshiana Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000237858 Gastropoda Species 0.000 description 1
- 235000007297 Gaultheria procumbens Nutrition 0.000 description 1
- 240000001238 Gaultheria procumbens Species 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 235000005717 Grindelia squarrosa Nutrition 0.000 description 1
- 244000259229 Grindelia squarrosa Species 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 241000208680 Hamamelis mollis Species 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 241000218228 Humulus Species 0.000 description 1
- 244000267823 Hydrangea macrophylla Species 0.000 description 1
- 235000014486 Hydrangea macrophylla Nutrition 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 244000141009 Hypericum perforatum Species 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 235000010650 Hyssopus officinalis Nutrition 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 235000013740 Juglans nigra Nutrition 0.000 description 1
- 244000184861 Juglans nigra Species 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000005993 Lactuca saligna Species 0.000 description 1
- 235000003127 Lactuca serriola Nutrition 0.000 description 1
- 235000006173 Larrea tridentata Nutrition 0.000 description 1
- 244000073231 Larrea tridentata Species 0.000 description 1
- 241000255777 Lepidoptera Species 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 241000208672 Lobelia Species 0.000 description 1
- 241000219745 Lupinus Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 235000002823 Mahonia aquifolium Nutrition 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
- 208000017657 Menopausal disease Diseases 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 244000024873 Mentha crispa Species 0.000 description 1
- 235000014749 Mentha crispa Nutrition 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 241000121185 Monodon monoceros Species 0.000 description 1
- 235000003805 Musa ABB Group Nutrition 0.000 description 1
- 240000005561 Musa balbisiana Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 235000009134 Myrica cerifera Nutrition 0.000 description 1
- 240000009023 Myrrhis odorata Species 0.000 description 1
- 235000007265 Myrrhis odorata Nutrition 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 235000017879 Nasturtium officinale Nutrition 0.000 description 1
- 240000005407 Nasturtium officinale Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 235000010676 Ocimum basilicum Nutrition 0.000 description 1
- 240000007926 Ocimum gratissimum Species 0.000 description 1
- 235000004263 Ocotea pretiosa Nutrition 0.000 description 1
- 241000219925 Oenothera Species 0.000 description 1
- 235000004496 Oenothera biennis Nutrition 0.000 description 1
- 235000011203 Origanum Nutrition 0.000 description 1
- 240000000783 Origanum majorana Species 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 235000011925 Passiflora alata Nutrition 0.000 description 1
- 235000000370 Passiflora edulis Nutrition 0.000 description 1
- 235000011922 Passiflora incarnata Nutrition 0.000 description 1
- 240000002690 Passiflora mixta Species 0.000 description 1
- 235000013750 Passiflora mixta Nutrition 0.000 description 1
- 235000013731 Passiflora van volxemii Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 244000062780 Petroselinum sativum Species 0.000 description 1
- 241000594009 Phoxinus phoxinus Species 0.000 description 1
- 235000009074 Phytolacca americana Nutrition 0.000 description 1
- 240000007643 Phytolacca americana Species 0.000 description 1
- 235000008124 Picea excelsa Nutrition 0.000 description 1
- 235000012550 Pimpinella anisum Nutrition 0.000 description 1
- 244000003162 Pinus excelsa Species 0.000 description 1
- 235000008596 Pinus excelsa Nutrition 0.000 description 1
- 240000007263 Pinus koraiensis Species 0.000 description 1
- 235000008578 Pinus strobus Nutrition 0.000 description 1
- 235000015266 Plantago major Nutrition 0.000 description 1
- 244000134552 Plantago ovata Species 0.000 description 1
- 235000003421 Plantago ovata Nutrition 0.000 description 1
- 235000006485 Platanus occidentalis Nutrition 0.000 description 1
- 241000222350 Pleurotus Species 0.000 description 1
- 244000236480 Podophyllum peltatum Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 240000005809 Prunus persica Species 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 241000287531 Psittacidae Species 0.000 description 1
- 239000009223 Psyllium Substances 0.000 description 1
- 241000219100 Rhamnaceae Species 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 244000152640 Rhipsalis cassutha Species 0.000 description 1
- 235000012300 Rhipsalis cassutha Nutrition 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 241001092459 Rubus Species 0.000 description 1
- 235000017848 Rubus fruticosus Nutrition 0.000 description 1
- 235000015422 Rumex crispus ssp. crispus Nutrition 0.000 description 1
- 235000015426 Rumex crispus ssp. fauriei Nutrition 0.000 description 1
- 244000207667 Rumex vesicarius Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- 244000009660 Sassafras variifolium Species 0.000 description 1
- 241000269821 Scombridae Species 0.000 description 1
- 240000006661 Serenoa repens Species 0.000 description 1
- 235000005318 Serenoa repens Nutrition 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 244000061457 Solanum nigrum Species 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 235000005865 Symphytum officinale Nutrition 0.000 description 1
- 240000002299 Symphytum officinale Species 0.000 description 1
- 241001104043 Syringa Species 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 240000000785 Tagetes erecta Species 0.000 description 1
- 240000001949 Taraxacum officinale Species 0.000 description 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 244000053655 Thunbergia mysorensis Species 0.000 description 1
- 240000002657 Thymus vulgaris Species 0.000 description 1
- 235000007303 Thymus vulgaris Nutrition 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 235000015724 Trifolium pratense Nutrition 0.000 description 1
- 235000004424 Tropaeolum majus Nutrition 0.000 description 1
- 240000001260 Tropaeolum majus Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 240000000143 Turnera diffusa Species 0.000 description 1
- 240000000377 Tussilago farfara Species 0.000 description 1
- 235000004869 Tussilago farfara Nutrition 0.000 description 1
- 244000274883 Urtica dioica Species 0.000 description 1
- 235000009108 Urtica dioica Nutrition 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 235000010599 Verbascum thapsus Nutrition 0.000 description 1
- 244000178289 Verbascum thapsus Species 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- 206010047791 Vulvovaginal dryness Diseases 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 241000269959 Xiphias gladius Species 0.000 description 1
- 235000004552 Yucca aloifolia Nutrition 0.000 description 1
- 235000012044 Yucca brevifolia Nutrition 0.000 description 1
- 235000017049 Yucca glauca Nutrition 0.000 description 1
- 240000005780 Yucca gloriosa Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- ZOJBYZNEUISWFT-UHFFFAOYSA-N allyl isothiocyanate Chemical compound C=CCN=C=S ZOJBYZNEUISWFT-UHFFFAOYSA-N 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 239000004178 amaranth Substances 0.000 description 1
- 235000012735 amaranth Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000019513 anchovy Nutrition 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229910052586 apatite Inorganic materials 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 239000010480 babassu oil Substances 0.000 description 1
- 150000007656 barbituric acids Chemical class 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229940038481 bee pollen Drugs 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 235000021029 blackberry Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229940078480 calcium levulinate Drugs 0.000 description 1
- 239000001362 calcium malate Substances 0.000 description 1
- 229940016114 calcium malate Drugs 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940069978 calcium supplement Drugs 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- QXDHJHQRJCJRAU-UHFFFAOYSA-N calcium;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Ca].OC(=O)CC(O)(C(O)=O)CC(O)=O QXDHJHQRJCJRAU-UHFFFAOYSA-N 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940071704 cascara sagrada Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000011436 cob Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- LDHQCZJRKDOVOX-NSCUHMNNSA-N crotonic acid Chemical compound C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 229960002380 dibutyl phthalate Drugs 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 235000014134 echinacea Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- 239000003687 estradiol congener Substances 0.000 description 1
- 238000009164 estrogen replacement therapy Methods 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000004459 forage Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229940098330 gamma linoleic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 235000007400 gumweed Nutrition 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 235000019514 herring Nutrition 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical group C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005481 linolenic acid group Chemical group 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 235000020640 mackerel Nutrition 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 150000002681 magnesium compounds Chemical class 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000012254 magnesium hydroxide Nutrition 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 235000001035 marshmallow Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 229960001207 micronized progesterone Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 235000019508 mustard seed Nutrition 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 229940055076 parasympathomimetics choline ester Drugs 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
- 235000011197 perejil Nutrition 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 229940070687 psyllium Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 235000013526 red clover Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000013974 saffron Nutrition 0.000 description 1
- 239000004248 saffron Substances 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 229940119224 salmon oil Drugs 0.000 description 1
- 235000019512 sardine Nutrition 0.000 description 1
- 125000005471 saturated fatty acid group Chemical group 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 239000010018 saw palmetto extract Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 229940048730 senega Drugs 0.000 description 1
- 229940124513 senna glycoside Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000021335 sword fish Nutrition 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical group CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000001585 thymus vulgaris Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- LDHQCZJRKDOVOX-UHFFFAOYSA-N trans-crotonic acid Natural products CC=CC(O)=O LDHQCZJRKDOVOX-UHFFFAOYSA-N 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000004952 turnera diffusa Nutrition 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 201000006669 vulvar dystrophy Diseases 0.000 description 1
- 229940118846 witch hazel Drugs 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- GKIRPKYJQBWNGO-QPLCGJKRSA-N zuclomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(/Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-QPLCGJKRSA-N 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Immunology (AREA)
Abstract
Description
【0001】
(発明の背景)
(発明の分野)
本発明は、栄養支持の向上および/または閉経症状からの解放を提供する目的
で、閉経前の女性および閉経期の女性が使用するための新規組成物、並びに、そ
の使用法に関する。BACKGROUND OF THE INVENTION Field of the Invention The present invention is a novel composition for use by premenopausal and menopausal women for the purpose of providing improved nutritional support and / or relief from menopausal symptoms. It relates to a composition and its use.
【0002】
(関連分野の記載)
女性の一生の生殖段階から非生殖段階への移行である閉経は、主に、月経の停
止により特徴づけられる。しかし、閉経は、多くの急性および慢性容態にも関連
しているので、単に生殖能を失う以上のはるかに大きな事を意味することになる
。閉経症候群は、女性の生体におけるホルモン平衡および栄養欠乏から生じる、
多くの多様でしばしば非常に重苦しい症状からなる。Description of the Related Art Menopause, the transition from reproductive to non-reproductive stages in a woman's life, is characterized primarily by cessation of menstruation. However, because menopause is also associated with many acute and chronic conditions, it would mean much more than just loss of fertility. Menopause syndrome results from hormonal balance and nutritional deficiencies in the female body,
It consists of many diverse and often very severe symptoms.
【0003】
血管運動不安定性に続発する顔面潮紅および発汗は、女性の75%が罹患して
いる。疲労、不眠、被刺激性および神経質という心理的および情動的症状が一般
的である。顔面潮紅の反復による障害に起因する睡眠不足は、疲労および被刺激
性の一因となる。眩暈、知覚異常、および、動悸および頻脈という心臓症状も生
じ得;心疾患の発生率は増加する。他の一般的な症状は、吐気、便秘、下痢、関
節痛および筋肉痛を含む。メルクマニュアル、1793(第16版、1992)
。Flushing and sweating secondary to vasomotor instability affect 75% of women. Psychological and emotional symptoms of fatigue, insomnia, irritability and nervousness are common. Insufficient sleep due to recurrent disorders of hot flushes contributes to fatigue and irritation. Dizziness, paresthesia, and cardiac symptoms of palpitation and tachycardia may also occur; the incidence of heart disease increases. Other common symptoms include nausea, constipation, diarrhea, arthralgia and myalgia. Merck Manual, 1793 (16th edition, 1992)
.
【0004】
閉経は、骨折増加および脊柱虚脱を生じる、骨粗鬆症、すなわち、骨密度の減
少も特徴とする。骨減少は、35才あたりで始まる。この減少は、45から55
才のあたりで一般に起こる、閉経期中に加速する。骨量減少は、閉経後毎年平均
1〜2%である。主な部位は椎骨(これはかがみおよび背痛を生じる前部の虚脱
を示す)、臀部および手関節である。メルクマニュアル1793(第16版、1
992)。骨粗鬆症は数十年かけて発達し、ピーク骨量並びに骨減少度に関連す
る。Menopause is also characterized by osteoporosis, or loss of bone density, which results in increased fractures and spinal collapse. Bone loss begins around age 35. This decrease is 45 to 55
Accelerates during menopause, which commonly occurs around the age of. Bone loss averages 1-2% each year after menopause. The main sites are the vertebrae, which represent the anterior collapse that causes flexion and back pain, the hips and wrists. Merck Manual 1793 (16th edition, 1
992). Osteoporosis develops over decades and is associated with peak bone mass as well as bone loss.
【0005】
エストロゲン補充療法が、閉経の症状の軽減に使用されてきた。メルクマニュ
アル1793(第16版、1992)。しかし、エストロゲン療法には限界があ
る。エストロゲン療法の副作用が極めて重篤である場合もある。これらの副作用
は、乳癌などの特定の癌の危険性の増加を含む。エストロゲンはまた、特定の子
宮体癌にも関与している。黄体ホルモンによる処置は、これらの有害な副作用を
打ち消すことが示されているが、前記のエストロゲン−黄体ホルモンの処方計画
で処置した閉経後の女性は、望ましくない子宮出血を経験することが多い。さら
に、ホルモン療法単独では、女性の一生のこの期間中の多様で高い栄養要求を満
たすには不十分である。適切な栄養摂取も必要である。Estrogen replacement therapy has been used to alleviate the symptoms of menopause. Merck Manual 1793 (16th edition, 1992). However, estrogen therapy has its limitations. The side effects of estrogen therapy can be very serious. These side effects include an increased risk of certain cancers such as breast cancer. Estrogens are also involved in certain endometrial cancers. Although treatment with luteinizing hormone has been shown to counteract these adverse side effects, postmenopausal women treated with the estrogen-luteinizing hormone regimen described above often experience undesirable uterine bleeding. Moreover, hormonal therapy alone is not sufficient to meet the diverse and high nutritional needs of women during their lifetime. Proper nutrition is also needed.
【0006】
適切な栄養摂取は、次第に、閉経期の女性に重要となっている。例えば、適切
なカルシウム摂取により骨粗鬆症は予防される。さらに、特定のビタミンおよび
ミネラルにより、カルシウム吸収および利用は増強される。しかし、女性にカル
シウムを提供するビタミンおよびミネラル補充は当分野で既知であるが、慣用的
な補充物では、閉経期の女性の他の栄養要求を満たすことができない。特に、慣
用的な補充物は、閉経を受けている女性が一般に経験する、疲労または倦怠の症
状を処置するのに特に有用である、特定の脂肪酸を欠いている。脂肪酸は、生命
の活動を支持するのに不可欠である。なぜなら、生体は、3つの脂肪酸を有する
1分子のグリセロールである、トリグリセリドからそのエネルギーを引き出して
いるからである。リノール酸およびリノレン酸は特に、生体の機能に不可欠な2
つの脂肪酸である。栄養補充物へのこれらの2つの脂肪酸の包含が特に重要であ
る。なぜなら、それらは、生体によって産生されず、食物を通して供給しなけれ
ばならないからである。しかし、慣用的な栄養補充物は、これらの2つの脂肪酸
を含むことができない。Proper nutrition is increasingly important for menopausal women. For example, proper calcium intake prevents osteoporosis. In addition, certain vitamins and minerals enhance calcium absorption and utilization. However, while vitamin and mineral supplements that provide calcium to women are known in the art, conventional supplements cannot meet the other nutritional needs of menopausal women. In particular, conventional supplements lack certain fatty acids that are particularly useful in treating the symptoms of fatigue or malaise commonly experienced by women undergoing menopause. Fatty acids are essential for supporting life's activities. This is because the living body extracts its energy from triglyceride, which is one molecule of glycerol having three fatty acids. Linoleic acid and linolenic acid are especially important for the functioning of the body.
Are two fatty acids. The inclusion of these two fatty acids in the nutritional supplement is of particular importance. Because they are not produced by the body and must be fed through food. However, conventional nutritional supplements cannot contain these two fatty acids.
【0007】
種々の形で、種々の目的の脂肪酸の使用が以前に開示されている。Horro
binらは、有効量のγ−リノレン酸および/またはジホモ−γ−リノレン酸の
一方または両方を女性に投与する、子宮内膜症の予防または処置法を開示してい
る。特に、脂肪酸は、酸それ自体の形で、またはエステル、アミド、塩、または
生体内で酸に変換され得る任意の他の機能的誘導体として投与し得、天然源由来
でも合成源由来でもよい。The use of fatty acids in various forms and for various purposes has been previously disclosed. Horro
Bin et al. disclose a method for the prevention or treatment of endometriosis in which a female is administered with an effective amount of one or both of γ-linolenic acid and / or dihomo-γ-linolenic acid. In particular, the fatty acids may be administered in the form of the acid itself or as an ester, amide, salt, or any other functional derivative that can be converted to the acid in vivo, and may be from a natural or synthetic source.
【0008】
Maxsonら、米国特許第4,900,734号は、経口投与用のエストラ
ジオールおよびプロゲステロンを含む医薬組成物を開示している。特に、医薬組
成物は、微細化プロゲステロン懸濁液を含む、油媒体に溶かしたエストラジオー
ルを含む。さらに、油媒体は、多不飽和脂肪酸のグリセリドが多い。特に、リノ
ール酸およびリノレン酸は、特に効果的な多不飽和脂肪酸として開示されている
。これらのステロイドの組合せ投与は、閉経期の女性の処置における、補充ホル
モン療法に有用であると開示されている。Maxson et al., US Pat. No. 4,900,734 disclose pharmaceutical compositions containing estradiol and progesterone for oral administration. In particular, the pharmaceutical composition comprises estradiol dissolved in an oil medium, including a micronized progesterone suspension. Furthermore, the oil medium is high in glycerides of polyunsaturated fatty acids. In particular, linoleic acid and linolenic acid are disclosed as particularly effective polyunsaturated fatty acids. The combined administration of these steroids is disclosed to be useful for replacement hormone therapy in the treatment of menopausal women.
【0009】
Cohen、米国特許第4,945,103号は、十分な投与量のメラトニン
を投与して、PMSに関連した症状を軽減することを含む、閉経前症候群(PM
S)に罹患している女性を処置する方法を開示している。特に、Cohenは、
プロゲステロンを、メラトニンと組合せ投与できることを開示している。さらに
、メラトニンは、女性に経口、非経口で、または、インプラントの形で投与でき
る。Cohenは、PMSは、ビタミンB複合体、特にビタミンB6(ピロキシ
ジン)、または必須脂肪酸、特にリノレン酸の栄養欠乏に連関し得ると特に開示
している。Cohen, US Pat. No. 4,945,103, includes premenopausal syndrome (PM) which involves administering a sufficient dose of melatonin to reduce symptoms associated with PMS.
A method of treating a woman suffering from S) is disclosed. In particular, Cohen
It is disclosed that progesterone can be administered in combination with melatonin. In addition, melatonin can be administered to women orally, parenterally or in the form of implants. Cohen specifically discloses that PMS can be associated with a nutritional deficiency of vitamin B complexes, especially vitamin B6 (pyroxidine), or essential fatty acids, especially linolenic acid.
【0010】
Horrobin、米国特許第5,380,757号は、外陰ジストロフィー
および/または膣乾燥の処置法を開示し、この医薬は、所望により、n−6また
はn−3シリーズの他の必須脂肪酸と共に、γ−リノレン酸(GIA)および/
またはジホモ−γ−リノレン酸(DGIA)を含む。Horrobinは、食事
中のリノール酸の欠乏は、皮膚の萎縮および角質増殖を生じ得ると開示している
。Horrobin, US Pat. No. 5,380,757 discloses a method of treating vulvar dystrophy and / or vaginal dryness, which medicament optionally comprises other essential fatty acids of the n-6 or n-3 series. Together with γ-linolenic acid (GIA) and /
Alternatively, it contains dihomo-γ-linolenic acid (DGIA). Horrobin discloses that deficiency in dietary linoleic acid can result in atrophy and hyperkeratosis of the skin.
【0011】
Miyamotoら、米国特許第5,461,170号は、分枝飽和脂肪酸お
よび/またはミリスチン酸残基を有するグリセリド調製物を、その液体油および
/または固体化粧品で使用するために開示している。特に、Miyamotoら
は、リパーゼの存在下で、ポリオールおよび分枝脂肪酸の部分エステルを、直鎖
脂肪酸またはその低級アルコールエステルと反応することにより製造される、混
合酸基を有する、ポリオール脂肪酸エステルを開示している。得られたグリセリ
ド混合物は、分枝飽和脂肪酸基および直鎖の脂肪酸基を有する、大量のジグリセ
リドを含む。参考文献は、特に、リノール酸またはリノレン酸および/または閉
経を開示していない。Miyamoto et al., US Pat. No. 5,461,170, discloses glyceride preparations having branched saturated fatty acids and / or myristic acid residues for use in their liquid oils and / or solid cosmetics. ing. In particular, Miyamoto et al. Disclose a polyol fatty acid ester having a mixed acid group, which is produced by reacting a partial ester of a polyol and a branched fatty acid with a linear fatty acid or a lower alcohol ester thereof in the presence of lipase. is doing. The resulting glyceride mixture contains large amounts of diglycerides with branched saturated fatty acid groups and linear fatty acid groups. The reference does not particularly disclose linoleic acid or linolenic acid and / or menopause.
【0012】
Sultenfuss、米国特許第5,514,382号は、ビタミンA、β
−カロテン、ナイアシン、リボフラビン、パントテン酸、ピリドキシン、シアノ
コバラミン、ビオチン、パラアミノ安息香酸、イノシトール、コリン、カルシウ
ム、クロム、銅、ヨウ素、鉄、マグネシウム、マンガン、モリブデン、セレン、
亜鉛、およびバイオフラボノイドを含む、女性用の毎日のビタミンおよびミネラ
ル補充物を開示している。40才以上の女性では、鉄を所望により含める。Sultenfuss, US Pat. No. 5,514,382 describes vitamin A, β
-Carotene, niacin, riboflavin, pantothenic acid, pyridoxine, cyanocobalamin, biotin, para-aminobenzoic acid, inositol, choline, calcium, chromium, copper, iodine, iron, magnesium, manganese, molybdenum, selenium,
Discloses daily vitamin and mineral supplements for women, including zinc, and bioflavonoids. For women over 40, iron is optionally included.
【0013】
Shylankevich、米国特許第5,569,459号は、月経前症候
群、閉経期障害の軽減、および、エストロゲン産生刺激に使用できる、種々のビ
タミン、ミネラル、および生薬抽出物を含む、組成物を開示している。特に、本
発明は、イソフラボン群の天然大豆植物エストロゲンを含む、前記医薬組成物お
よび食事補充物に関する。Shylankevich, US Pat. No. 5,569,459, is a composition comprising various vitamins, minerals, and herbal extracts that can be used to alleviate premenstrual syndrome, menopausal disorders, and stimulate estrogen production. Is disclosed. In particular, the invention relates to said pharmaceutical composition and dietary supplement comprising natural soybean phytoestrogens of the isoflavone group.
【0014】
女性用のビタミンは、40才以上の女性用のカルシウム/ビタミン/ミネラル
補充物を開示している。特に、「40才以上」の調合は、「より良好な利用およ
び吸収を確実にする」日中および/または夜の調合に該当する、成分を含む、組
成物を開示している。一般用医薬品の米国医薬品便覧(第9版、1988)71
8。Vitamin for Women discloses calcium / vitamin / mineral supplements for women over the age of 40. In particular, "40+" formulations disclose compositions, including ingredients, that fall under day and / or night formulations that "ensure better utilization and absorption." Handbook of OTC Drugs (9th Edition, 1988) 71
8.
【0015】
しかし、以前に開示された処方は、種々の理由から不十分である。特に、以前
に開示されたどの処方も、閉経前および閉経期の女性の必要性を満たすように特
別にテーラーメードされた量の必須脂肪酸またはカルシウムなどの重要な成分を
含んでいない。さらに、以前に開示された処方は、種々の成分の互いの比率の重
要性を開示していない。それ故、閉経期の女性の必要性を満たすように特別にテ
ーラーメードされた処方が必要である。さらに、閉経前および閉経期の女性の必
要性を満たすように特別に適合した薬物送達処方計画が必要である。However, the previously disclosed formulations are inadequate for various reasons. In particular, none of the previously disclosed formulations contain important ingredients such as essential fatty acids or calcium specifically tailored to meet the needs of premenopausal and menopausal women. Moreover, the previously disclosed formulations do not disclose the importance of the ratio of the various ingredients to each other. Therefore, there is a need for specially tailored prescriptions to meet the needs of menopausal women. Further, there is a need for drug delivery regimens that are specifically adapted to meet the needs of premenopausal and menopausal women.
【0016】
(発明の要約)
本発明の対象の組成物は、閉経の直前、最中および後の女性に特別にテーラー
メードされた、処方および薬物送達処方計画を提供することにより、現在入手可
能な栄養補充物の欠乏を克服する。本発明の組成物は、所望により種々のビタミ
ンおよびミネラルと組合せた、重量な比および量で、脂肪酸などの種々の成分の
新規組合せを含む。SUMMARY OF THE INVENTION The subject compositions of the present invention are currently available by providing a tailor-made, prescription and drug delivery regimen to women immediately before, during and after menopause. Overcome the lack of nutritional supplements. The compositions of the present invention include novel combinations of various ingredients such as fatty acids, in weight ratios and amounts, optionally in combination with various vitamins and minerals.
【0017】
本発明の対象の1つの実施形態は、単一または複数の投与単位で、閉経期の女
性に投与する組成物であって、
これは、約10mgから約1,000mgの量の、リノール酸化合物、リノレ
ン酸化合物、ドコサヘキサエン酸化合物、ω−3脂肪酸化合物、ω−2脂肪酸化
合物、その誘導体および組合せからなる群から選択される必須脂肪酸化合物;
約400mgから約2500mgの量のカルシウム化合物またはその誘導体;
約0.4mgから約5.0mgの量の葉酸化合物またはその誘導体を含み;
ここで、必須脂肪酸化合物と、カルシウム化合物またはその誘導体の重量比は
、約1:0.4から250である。One embodiment of the present subject matter is a composition for administration to a menopausal woman in single or multiple dosage units, which is in an amount of about 10 mg to about 1,000 mg, An essential fatty acid compound selected from the group consisting of linoleic acid compounds, linolenic acid compounds, docosahexaenoic acid compounds, ω-3 fatty acid compounds, ω-2 fatty acid compounds, derivatives and combinations thereof; calcium compounds in an amount of about 400 mg to about 2500 mg or A derivative thereof; comprising a folic acid compound or a derivative thereof in an amount of about 0.4 mg to about 5.0 mg; wherein the weight ratio of the essential fatty acid compound to the calcium compound or a derivative thereof is about 1: 0.4 to 250. is there.
【0018】
本発明の対象の別の実施形態は、閉経期の女性に投与するための組成物であっ
て、
これは、約10mgから約1,000mgの量のリノール酸化合物、その誘導
体およびその組合せからなる群から選択された第一脂肪酸化合物;
約10mgから約1,000mgの量のリノレン酸化合物、その誘導体および
その組合せからなる群から選択された第二脂肪酸化合物;
約10mgから約1,000mgの量のドコサヘキサエン酸化合物、ω−3脂
肪酸、ω−2脂肪酸、その誘導体およびその組合せからなる群から選択された第
三脂肪酸化合物;
約400mgから約2500mgの量のカルシウム化合物またはその誘導体;
約0.4mgから約5.0mgの量の葉酸化合物またはその誘導体を含み、
ここで、前記第一と第二脂肪酸化合物の量の合計と、前記第三脂肪酸化合物の
量の重量比は、約1:0.5から1.5であり;そして
前記第一、第二および第三脂肪酸化合物の量の合計と、前記カルシウム化合物
またはその誘導体の量の重量比は、約1:0.4から50である。Another embodiment of the subject of the present invention is a composition for administration to a menopausal woman, which comprises a linoleic acid compound, its derivatives and their derivatives in an amount of about 10 mg to about 1,000 mg. A first fatty acid compound selected from the group consisting of combinations; a second fatty acid compound selected from the group consisting of linolenic acid compounds, derivatives thereof and combinations thereof in an amount of about 10 mg to about 1,000 mg; about 10 mg to about 1, A third fatty acid compound selected from the group consisting of docosahexaenoic acid compounds, ω-3 fatty acids, ω-2 fatty acids, derivatives thereof and combinations thereof in an amount of 000 mg; calcium compounds or derivatives thereof in an amount of about 400 mg to about 2500 mg; Comprising a folate compound or derivative thereof in an amount of 0.4 mg to about 5.0 mg, wherein the first and second fatty acids are The weight ratio of the total amount of compound to the amount of the third fatty acid compound is about 1: 0.5 to 1.5; and the total amount of the first, second and third fatty acid compounds. The weight ratio of the amount of the calcium compound or its derivative is about 1: 0.4 to 50.
【0019】
本発明の対象のさらなる実施形態は、閉経期の女性に投与するための組成物で
あって、
約10mgから約1,000mgの量のリノール酸化合物、その誘導体および
その組合せからなる群から選択される第一脂肪酸化合物;
約10mgから約1,000mgの量のリノレン酸化合物、その誘導体および
その組合せからなる群から選択される第二脂肪酸化合物;
約10mgから約1,000mgの量のドコサヘキサエン酸化合物、ω−3脂
肪酸、ω−2脂肪酸、その誘導体およびその組合せからなる群から選択される第
三脂肪酸化合物;
約400mgから約2500mgの量のカルシウム化合物またはその誘導体;
約0.4mgから約5.0mgの量の葉酸化合物またはその誘導体;
約25mgから約500mgの量のビタミンC化合物またはその誘導体;
約10mgから約500mgの量のビタミンE化合物またはその誘導体を含み
、
ここで、前記第一および第二脂肪酸化合物の量の合計と、前記第三脂肪酸化合
物の量の重量比は、約1:0.5から1.5であり;そして
前記第一、第二および第三脂肪酸化合物の量の合計と、前記カルシウム化合物
またはその誘導体の量の重量比は、約1:0.4から50である。A further embodiment of the present subject matter is a composition for administration to a menopausal woman, the group consisting of linoleic acid compounds, their derivatives and combinations thereof in an amount of about 10 mg to about 1,000 mg. A first fatty acid compound selected from: a second fatty acid compound selected from the group consisting of linolenic acid compounds, derivatives thereof and combinations thereof in an amount of about 10 mg to about 1,000 mg; and an amount of about 10 mg to about 1,000 mg. A third fatty acid compound selected from the group consisting of docosahexaenoic acid compounds, omega-3 fatty acids, omega-2 fatty acids, derivatives thereof and combinations thereof; calcium compounds or derivatives thereof in an amount of about 400 mg to about 2500 mg; from about 0.4 mg Folic acid compound or derivative thereof in an amount of about 5.0 mg; Vitamin in an amount of about 25 mg to about 500 mg A C compound or a derivative thereof; comprising a vitamin E compound or a derivative thereof in an amount of about 10 mg to about 500 mg, wherein the weight ratio of the total amount of the first and second fatty acid compounds to the amount of the third fatty acid compound. Is about 1: 0.5 to 1.5; and the weight ratio of the sum of the amounts of the first, second and third fatty acid compounds to the amount of the calcium compound or its derivative is about 1: 0. 4 to 50.
【0020】
本発明の対象のまたさらなる実施形態は、閉経期の女性に投与するための組成
物であって、
約10mgから約1,000mgの量のリノール酸化合物、その誘導体および
その組合せからなる群から選択される第一脂肪酸化合物;
約10mgから約1,000mgの量のリノレン酸化合物、その誘導体および
その組合せからなる群から選択される第二脂肪酸化合物;
約10mgから約1,000mgの量のドコサヘキサンエン酸化合物、ω−3
脂肪酸、ω−2脂肪酸、その誘導体およびその組合せからなる群から選択される
第三脂肪酸化合物;
約400mgから約2500mgの量のカルシウム化合物またはその誘導体;
約0.4mgから約5.0mgの量の葉酸化合物またはその誘導体;
約25mgから約500mgの量のビタミンC化合物またはその誘導体;
約10mgから約500mgの量のビタミンE化合物またはその誘導体;
約2,500IUから約6,500IUの量のビタミンA化合物またはその誘
導体を含み、
ここで、前記第一および第二脂肪酸化合物の量の合計と、前記第三脂肪酸化合
物の量の重量比は、約1:0.5から1.5であり;そして
前記第一、第二および第三脂肪酸化合物の量の合計と、前記カルシウム化合物
またはその誘導体の量の重量比は、約1:0.4から50である。Yet another embodiment of the present subject matter is a composition for administration to a menopausal woman, which comprises a linoleic acid compound, its derivatives and combinations thereof in an amount of about 10 mg to about 1,000 mg. A first fatty acid compound selected from the group; a second fatty acid compound selected from the group consisting of linolenic acid compounds, derivatives thereof and combinations thereof in an amount of about 10 mg to about 1,000 mg; and an amount of about 10 mg to about 1,000 mg. Docosahexaneenoic acid compound, ω-3
A tertiary fatty acid compound selected from the group consisting of fatty acids, ω-2 fatty acids, derivatives and combinations thereof; calcium compounds or derivatives thereof in an amount of about 400 mg to about 2500 mg; and amounts of about 0.4 mg to about 5.0 mg. Folic acid compound or derivative thereof; Vitamin C compound or derivative thereof in amount of about 25 mg to about 500 mg; Vitamin E compound or derivative thereof in amount of about 10 mg to about 500 mg; Vitamin A in amount of about 2,500 IU to about 6,500 IU A compound or derivative thereof, wherein the weight ratio of the sum of the amounts of the first and second fatty acid compounds to the amount of the third fatty acid compound is about 1: 0.5 to 1.5; and The weight ratio of the total amount of the first, second and third fatty acid compounds and the amount of the calcium compound or its derivative is 1: 0.4 to 50.
【0021】
本発明の対象の別の実施形態は、閉経期の女性に投与するための組成物であっ
て、
約10mgから約1,000mgの量のリノール酸化合物、その誘導体および
その組合せからなる群から選択される第一脂肪酸化合物;
約10mgから約1,000mgの量のリノレン酸化合物、その誘導体および
その組合せからなる群から選択される第二脂肪酸化合物;
約10mgから約1,000mgの量のドコサヘキサエン酸化合物、ω−3脂
肪酸、ω−2脂肪酸、その誘導体およびその組合せからなる群から選択される第
三脂肪酸化合物;
約400mgから約2500mgの量のカルシウム化合物またはその誘導体;
約0.4mgから約5.0mgの量の葉酸化合物またはその誘導体;
約25mgから約500mgの量のビタミンC化合物またはそのエステル誘導
体;
約10mgから約500mgの量のビタミンE化合物またはその誘導体;
約10mgから約50mgの量のビタミンB6化合物またはその誘導体;
約25mcgから約75mcgの量のビタミンB12化合物またはその誘導体
;
約200IUから約625IUの量のビタミンD化合物またはその誘導体を含
み、
前記の第一および第二脂肪酸化合物の量の合計と、前記第三脂肪酸化合物の量
の重量比は、約1:0.5から1.5であり;そして
前記の第一、第二および第三脂肪酸化合物の量の合計と、前記カルシウム化合
物またはその誘導体の量の重量比は、約1:0.4から50である。Another embodiment of the present subject matter is a composition for administration to a menopausal woman, which comprises a linoleic acid compound, its derivatives and combinations thereof in an amount of about 10 mg to about 1,000 mg. A first fatty acid compound selected from the group; a second fatty acid compound selected from the group consisting of linolenic acid compounds, derivatives thereof and combinations thereof in an amount of about 10 mg to about 1,000 mg; and an amount of about 10 mg to about 1,000 mg. A third fatty acid compound selected from the group consisting of docosahexaenoic acid compound, ω-3 fatty acid, ω-2 fatty acid, derivative thereof and combinations thereof; calcium compound or derivative thereof in an amount of about 400 mg to about 2500 mg; To about 5.0 mg of a folic acid compound or derivative thereof; vitamin C in an amount of about 25 mg to about 500 mg. Compound or ester derivative thereof; Vitamin E compound or derivative thereof in amount of about 10 mg to about 500 mg; Vitamin B6 compound or derivative thereof in amount of about 10 mg to about 50 mg; Vitamin B12 compound or amount thereof in amount of about 25 mcg to about 75 mcg Derivative; Vitamin D compound or derivative thereof in an amount of about 200 IU to about 625 IU, wherein the weight ratio of the total amount of the first and second fatty acid compounds to the amount of the third fatty acid compound is about 1: 0. And a weight ratio of the sum of the amounts of the first, second and third fatty acid compounds to the amount of the calcium compound or its derivative is about 1: 0.4 to 50. is there.
【0022】
本発明のさらに別の実施形態は、閉経期の女性に投与するための組成物であっ
て、
閉経期の症状を治療するための生物活性物質;
約400mgから約2500mgの量のカルシウム化合物またはその誘導体;
約0.4mgから約5.0mgの量の葉酸化合物またはその誘導体を含む。Yet another embodiment of the present invention is a composition for administration to a menopausal woman comprising a bioactive agent for treating menopausal symptoms; calcium in an amount of about 400 mg to about 2500 mg. A compound or derivative thereof; comprising a folate compound or derivative thereof in an amount of about 0.4 mg to about 5.0 mg.
【0023】
本発明のさらなる実施形態は薬物送達療法であって、
所定の期間で閉経期の女性に投与する、第一の生物活性物質を含む、第一投与
形;
前記の第一投与形と同時に閉経期の女性に投与する、第二の生物活性物質を含
む第二投与形を含み、
ここで、前記の第一生物活性物質および前記の第二生物活性物質は非適合性の
物質である。A further embodiment of the present invention is a drug delivery therapy comprising: a first dosage form comprising a first bioactive agent for administration to a menopausal woman for a predetermined period of time; A second dosage form comprising a second bioactive agent for simultaneous administration to a menopausal woman, wherein said first bioactive agent and said second bioactive agent are incompatible substances .
【0024】
本発明の対象の追加の実施形態は、閉経期の女性に栄養補助を提供する方法で
あって、
女性に必須脂肪酸化合物を、閉経期の開始の始まる期間中に投与し、前記の必
須脂肪酸化合物は、リノール酸化合物、リノレン酸化合物、ドコサヘキサエン酸
化合物、ω−3脂肪酸化合物、ω−2脂肪酸化合物、その誘導体およびその組合
せからなる群から選択され;
約400mgから約2500mgのカルシウム化合物またはその誘導体を女性
に、閉経期の開始の始まる期間中に投与し;
約0.4mgから約5.0mgの葉酸化合物またはその誘導体を女性に、閉経
期の開始の始まる期間中に投与することを含み、そして、
必須脂肪酸化合物と、カルシウム化合物またはその誘導体の重量比は、約1:
0.4から250である。An additional embodiment of the present subject matter is a method of providing nutritional support to a menopausal woman, wherein the woman is administered an essential fatty acid compound during the beginning of the onset of menopause, wherein The essential fatty acid compounds are selected from the group consisting of linoleic acid compounds, linolenic acid compounds, docosahexaenoic acid compounds, ω-3 fatty acid compounds, ω-2 fatty acid compounds, derivatives thereof and combinations thereof; about 400 mg to about 2500 mg of calcium compounds or Administering the derivative to a woman during the onset of the onset of menopause; about 0.4 mg to about 5.0 mg of a folate compound or derivative thereof to a woman during the onset of the onset of menopause. And the weight ratio of the essential fatty acid compound to the calcium compound or its derivative is about 1:
0.4 to 250.
【0025】
本発明の対象の別の実施形態は、閉経期の女性に栄養補助を提供する方法であ
って、
女性に第一脂肪酸化合物を、閉経期の開始の始まる期間中に投与し、前記の第
一脂肪酸化合物は、リノール酸化合物、その誘導体およびその組合せからなる群
から選択され;
前記女性に第二脂肪酸化合物を、閉経期の開始の始まる期間中に投与し、前記
の第二脂肪酸化合物は、リノレン酸化合物、その誘導体およびその組合せからな
る群から選択され;
前記女性に第三脂肪酸化合物を、閉経期の開始の始まる期間中に投与し、前記
の第三脂肪酸化合物は、ドコサヘキサエン酸化合物、ω−3脂肪酸、ω−2脂肪
酸、その誘導体およびその組合せからなる群から選択され、前記の第三の脂肪酸
化合物は、女性に、前記の第一および第二脂肪酸化合物と共に提供され;
約400mgから2500mgのカルシウム化合物またはその誘導体を前記女
性に投与することを含み、
ここでの前記の第一および第二脂肪酸化合物の量の合計と、前記の第三脂肪酸
化合物の量の重量比は、約1:0.5から1.5であり;そして
ここでの前記の第一、第二および第三脂肪酸化合物の合計と、前記カルシウム
化合物またはその誘導体の量の重量比は、約1:0.4から50である。Another embodiment of the present subject matter is a method of providing nutritional support to a menopausal woman, wherein the female is administered a first fatty acid compound during the beginning of the onset of menopause, wherein The first fatty acid compound of is selected from the group consisting of linoleic acid compounds, derivatives thereof and combinations thereof; said second fatty acid compound being administered to said woman during the beginning of the onset of menopause, said second fatty acid compound being Is selected from the group consisting of linolenic acid compounds, derivatives thereof and combinations thereof; the female is administered a tertiary fatty acid compound during the beginning of the onset of menopause, and the tertiary fatty acid compound is a docosahexaenoic acid compound. , An omega-3 fatty acid, an omega-2 fatty acid, a derivative thereof and a combination thereof, wherein the third fatty acid compound is Comprising administering to said woman about 400 mg to 2500 mg of a calcium compound or derivative thereof, wherein the sum of the amounts of said first and second fatty acid compounds, and said third fatty acid compound The weight ratio of the amounts is about 1: 0.5 to 1.5; and the weight ratio of the sum of the above first, second and third fatty acid compounds to the amount of the above calcium compound or derivative thereof. Is about 1: 0.4 to 50.
【0026】
本発明のさらに別の実施形態は、閉経に関連した症状を軽減しつつ、閉経期の
女性に栄養補助を提供する方法であって、
女性に第一脂肪酸化合物を、閉経期の開始の始まる期間中に投与し、前記の第
一脂肪酸化合物は、リノール酸化合物、その誘導体およびその組合せからなる群
から選択され;
前記女性に第二脂肪酸化合物を、閉経期の開始の始まる期間中に投与し、前記
の第二脂肪酸化合物は、リノレン酸化合物、その誘導体およびその組合せからな
る群から選択され;
前記女性に第三脂肪酸化合物を、閉経期の開始の始まる期間中に投与し、前記
の第三脂肪酸化合物は、ドコサヘキサエン酸化合物、ω−3脂肪酸、ω−2脂肪
酸、その誘導体およびその組合せからなる群から選択され、前記の第三の脂肪酸
化合物は、女性に、前記の第一および第二脂肪酸化合物と共に提供され;
約400mgから2500mgのカルシウム化合物またはその誘導体を前記女
性に投与し;
非栄養活性物質を前記女性に投与することを含み、
ここでの前記の第一および第二脂肪酸化合物の量の合計と、前記の第三脂肪酸
化合物の量の重量比は、約1:0.5から1.5であり;そして
ここでの前記の第一、第二および第三脂肪酸化合物の量の合計と、前記カルシ
ウム化合物またはその誘導体の量の重量比は、約1:0.4から50である。Yet another embodiment of the present invention is a method of providing nutritional support to a menopausal woman while reducing symptoms associated with menopause, the method comprising providing a female with a first fatty acid compound and initiating menopause. The first fatty acid compound is selected from the group consisting of linoleic acid compounds, derivatives thereof and combinations thereof; the second fatty acid compound is administered to the woman during the beginning of menopause. And the second fatty acid compound is selected from the group consisting of linolenic acid compounds, derivatives and combinations thereof; the third fatty acid compound is administered to the woman during the beginning of the onset of menopause, and The third fatty acid compound is selected from the group consisting of docosahexaenoic acid compound, ω-3 fatty acid, ω-2 fatty acid, derivatives thereof and combinations thereof, wherein the third fatty acid compound is female , Provided with said first and second fatty acid compounds; administering about 400 mg to 2500 mg of a calcium compound or derivative thereof to said woman; comprising administering a non-nutritional active substance to said woman, wherein: The weight ratio of the sum of the amounts of the first and second fatty acid compounds to the amount of the third fatty acid compound is about 1: 0.5 to 1.5; and the first, second And the weight ratio of the total amount of the tertiary fatty acid compound and the amount of the calcium compound or its derivative is about 1: 0.4 to 50.
【0027】
さらなる実施形態は、閉経の開始を遅延する方法であって、必須脂肪酸を閉経
前の女性に投与することを含み、ここでの前記脂肪酸は、リノール酸化合物、リ
ノレン酸化合物、ドコサヘキサエン酸化合物、ω−3脂肪酸化合物、ω−2脂肪
酸化合物、その誘導体およびその組合せからなる群から選択され;前記必須脂肪
酸は、閉経の開始を遅延するに十分な量で投与する。A further embodiment is a method of delaying the onset of menopause, which comprises administering an essential fatty acid to a pre-menopausal woman, wherein the fatty acid is a linoleic acid compound, a linolenic acid compound, docosahexaenoic acid. Selected from the group consisting of compounds, omega-3 fatty acid compounds, omega-2 fatty acid compounds, derivatives thereof and combinations thereof; the essential fatty acids are administered in an amount sufficient to delay the onset of menopause.
【0028】
またさらなる実施形態は、閉経に関連した症状を軽減しつつ、閉経期の女性に
栄養補助を提供する方法であって、
女性に脂肪酸化合物を、閉経期開始の始まる期間中に投与し、前記の脂肪酸化
合物は、リノール酸化合物、リノレン酸化合物、ドコサヘキサエン酸化合物、ω
−3脂肪酸、ω−2脂肪酸、その誘導体およびその組合せからなる群から選択さ
れ;
約400mgから2500mgのカルシウム化合物またはその誘導体を前記女
性に投与し;そして
非栄養活性物質を前記女性に投与することを含む。[0028] A yet further embodiment is a method of providing nutritional support to a menopausal woman while alleviating symptoms associated with menopause, wherein the fatty acid compound is administered to the woman during the beginning of the onset of menopause. , The fatty acid compounds are linoleic acid compounds, linolenic acid compounds, docosahexaenoic acid compounds, ω
-3 fatty acids, ω-2 fatty acids, derivatives thereof and combinations thereof; about 400 mg to 2500 mg of calcium compounds or derivatives thereof administered to said woman; and non-nutritional active substance administered to said woman including.
【0029】
別の実施形態は、早期閉経の可能性を低下する方法であって、必須脂肪酸を閉
経前の女性に投与することを含み、前記脂肪酸は、リノール酸化合物、リノレン
酸化合物、ドコサヘキサエン酸化合物、ω−3脂肪酸化合物、ω−2脂肪酸化合
物、その誘導体およびその組合せからなる群から選択され;前記の必須脂肪酸は
、早期閉経の危険性を低下するに十分な量で投与する。[0029] Another embodiment is a method of reducing the likelihood of premature menopause, comprising administering an essential fatty acid to a pre-menopausal woman, wherein the fatty acid is a linoleic acid compound, a linolenic acid compound, docosahexaenoic acid. Selected from the group consisting of compounds, omega-3 fatty acid compounds, omega-2 fatty acid compounds, derivatives thereof and combinations thereof; said essential fatty acids are administered in an amount sufficient to reduce the risk of premature menopause.
【0030】
追加の実施形態は、栄養補助を閉経前の女性または閉経期の女性に提供する方
法であって、閉経前の女性または閉経期の女性に、閉経の症状を治療するための
生物活性物質を投与し;閉経前の女性または閉経期の女性に、約400mgから
約2500mgの量のカルシウム化合物またはその誘導体を投与し;そして、閉
経前の女性または閉経期の女性に、約0.4mgから約5.0mgの量の葉酸化
合物またはその誘導体を投与することを含む。An additional embodiment is a method of providing nutritional support to a pre-menopausal or menopausal woman, wherein the pre-menopausal or menopausal woman is provided with a biological activity for treating symptoms of menopause. Administering a substance; to a pre-menopausal or menopausal woman, a calcium compound or derivative thereof in an amount of about 400 mg to about 2500 mg; and to a pre-menopausal or menopausal woman about 0.4 mg. To administering about 5.0 mg of a folic acid compound or derivative thereof.
【0031】
(発明の詳細な説明)
本明細書に使用したような「閉経期の女性」は、卵巣機能不全を経験した全て
の女性を意味する。卵巣機能不全は、低いエストロゲンレベル(エストラジオー
ル)または上昇した性腺刺激ホルモンレベル(卵胞刺激ホルモン)について血液
検査により測定できる。閉経が生じると、それは女性の一生において続く。「閉
経」なる語は、閉経後または閉経後の期間も包含する。「閉経」なる語は、自然
閉経または人工的閉経も包含する。Detailed Description of the Invention "Menopausal woman" as used herein means any woman who has experienced ovarian dysfunction. Ovarian dysfunction can be measured by blood tests for low estrogen levels (estradiol) or elevated gonadotropin levels (follicle stimulating hormone). When menopause occurs, it continues in a woman's life. The term "menopause" also includes post-menopausal or post-menopausal periods. The term "menopause" also includes natural or artificial menopause.
【0032】
「閉経前の女性」は、閉経開始の5年前に始まる期間中の全ての女性を意味す
る。“Pre-menopausal woman” means all women during the period beginning five years before the onset of menopause.
【0033】
「栄養保存」は、閉経期の女性の使用できる、ビタミン、ミネラルおよび他の
栄養分のレベルを意味する。“Nutrition preservation” means the levels of vitamins, minerals and other nutrients available to menopausal women.
【0034】
「栄養状態」は、任意の栄養欠乏の存在または非存在、または別の言葉で言え
ば、生理的栄養要求が、欠乏が回避されるように満足されている程度を意味する
。“Nutrition status” means the presence or absence of any nutritional deficiency, or, in other words, the degree to which physiological nutritional requirements are satisfied such that deficiency is avoided.
【0035】
「神経的発達を最適化」は、薬物、手術等のあらゆる非天然物質または手順を
使用することなく、天然プロセスを介して可能である、最高度の神経学的発達の
獲得を意味する。“Optimal neurodevelopment” means the acquisition of the highest degree of neurological development possible through natural processes without the use of any non-natural substances or procedures such as drugs, surgery. To do.
【0036】
「生物活性物質」は、薬物、活性治療物質、代謝物、医薬、ビタミン、または
ミネラルを含む任意の物質または物質群で、疾病または病気の治療、予防、診断
、治癒または緩和に使用する任意の物質、解剖学的構造または生理的機能に影響
を及ぼす任意の物質、または動物に対する外的影響の衝撃を改変する任意の物質
、またはその代謝物を意味し、本明細書に使用したような、「活性物質」、「治
療物質」、「作用物」、「活性作用物」、「薬物」、「薬剤」、「医薬」、「医
薬品」および他のこのようなる維持した用語を包含する。“Bioactive substance” is any substance or group of substances including drugs, active therapeutic substances, metabolites, pharmaceuticals, vitamins or minerals, used for the treatment, prevention, diagnosis, cure or alleviation of diseases or disorders. Used herein, any substance that affects anatomical structure or physiological function, or any substance that modifies the impact of external influences on an animal, or a metabolite thereof. Such as "active agent,""therapeuticagent,""agent,""activeagent,""drug,""drug,""pharmaceutical,""pharmaceutical," and other such retained terms. To do.
【0037】
「非栄養活性物質」は、薬物、活性治療物質、代謝物、または医薬を含む任意
の物質または物質群、または、疾病または病気の処置、予防、診断、治癒または
緩和に使用する任意の他の物質、解剖学的構造または生理的機能に影響を及ぼす
任意の物質、または、動物に対する外的影響の衝撃を改変する任意の物質、また
はその代謝物を意味し、それは、本明細書に使用したような、ビタミン、ミネラ
ルまたは任意の他の栄養化合物または組成物ではない。“Non-nutritive active substance” is any substance or group of substances, including drugs, active therapeutic substances, metabolites, or drugs, or any used for the treatment, prevention, diagnosis, cure or alleviation of a disease or condition. Other substance, any substance that affects anatomical structure or physiological function, or any substance that modifies the impact of external influences on an animal, or a metabolite thereof, which is used herein. No vitamins, minerals or any other nutritional compounds or compositions as used in.
【0038】
「特定の生理的必要性」は、他のクラスとは識別されるような、閉経期の女性
、閉経前の女性、閉経後の女性等などのあるクラスの人による、特定の栄養分の
特定のレベルの独特な要求を意味する。“Specific physiological need” refers to a specific nutritional content by a class of persons, such as menopausal women, premenopausal women, postmenopausal women, etc., as distinguished from other classes. Means the unique demands of a particular level of.
【0039】
「生物学的に許容される」は、ヒトが摂取するのに安全であることを意味する
。“Biologically acceptable” means safe for human consumption.
【0040】
「保存非適合性物質」は、物質が負に相互作用するために、1投与単位で一緒
に製剤化できないか、または直接接触して一緒に保存できない物質、並びに、物
質の投与量の合計が嚥下には大きすぎる1投与単位を生じるので、1投与単位に
一緒に製剤化できない物質も意味する。この用語はまた、直接接触して保存し得
る物質も意味するが、物質の1つは、好ましくは、他の物質に好ましくないかま
たは非適合性である1投与形に製剤化する。保存非適合性はまた、少なくとも1
つの物質が処方箋医薬物質であり、少なくとも1つの物質が一般用医薬物質であ
る、2つ以上の物質を意味する。“Storage incompatible substance” means a substance that cannot be formulated together in one dosage unit or stored together in direct contact because the substances interact negatively, as well as the dose of the substance. It also means substances that cannot be co-formulated into a single dosage unit, as the sum of these results in a single dosage unit that is too large for swallowing. The term also refers to substances that can be stored in direct contact, but one of the substances is preferably formulated in a dosage form that is either unfavorable or incompatible with the other substance. Storage incompatibility also has at least 1
By two or more substances, one substance is a prescription drug substance and at least one substance is a over-the-counter drug substance.
【0041】
「保存非適合性」は、上記に定義したような、保存非適合性物質間に存在する
、状態を意味する。“Storage-incompatible” means a condition existing between storage-incompatible substances, as defined above.
【0042】
本発明の対象の組成物は、数個の特異的で新規で意外な利点を提供する。第一
に、製剤によって、閉経期の女性に、閉経期間中に適切なエネルギーが確実に提
供される。第二に、処方によって、閉経期の女性は、両方の彼女の将来の使用の
ための適切な脂肪酸保存を維持することができる。第三に、脂肪酸によって、閉
経期の女性の神経学的維持が最適化される。第四に、閉経期直前に投与すると、
本発明の組成物は、女性の生体に負荷される生理的要求およびストレスの増加に
対して準備する。さらに、本発明の組成物は、閉経期前後として知られる閉経の
初期の段階中の女性に、栄養補助を提供する。最後に、本発明の組成物は、閉経
に関連した疾患および前記疾患から生じる症状の危険性を最小限にするのに役立
つ。The subject compositions of the present invention offer several specific, novel and surprising advantages. First, the formulation ensures that menopausal women are provided with the proper energy during menopause. Second, the prescription allows a menopausal woman to maintain an adequate fatty acid reserve for both her future uses. Third, fatty acids optimize neurological maintenance in menopausal women. Fourth, when administered just before menopause,
The compositions of the present invention prepare for increased physiological demands and stresses placed on a female organism. In addition, the compositions of the present invention provide nutritional support to women during the early stages of menopause, known as peri-menopause. Finally, the compositions of the invention serve to minimize the risk of menopause-related diseases and the symptoms resulting from said diseases.
【0043】
本発明の対象は、一部、互いに特定の量および比率である特定の脂肪酸を有す
る組成物を、女性に、閉経直前、最中および後に投与すると、女性は、最適な栄
養補助が得られるだろうという発見に基づく。特に、閉経期の女性の食事を、下
記した処方を用いて、閉経の症状が実際に起こる時、または好ましくは閉経が一
般に予期される時の直前に開始してある期間、補充することにより、女性は、確
実に、現在および将来に使用する適切な必須脂肪酸を有するだろう。脂肪酸補充
物は、閉経期の女性に追加の健康利点を付与するための、ビタミンおよびミネラ
ルをさらに含み得る。ヒトに利点を与えることに加えて、本発明はまた、非ヒト
哺乳動物にも利点を与え得る。本発明の組成物は、動物の飼料、丸薬形、または
他の適切な投与形で、前記哺乳動物に投与できる。The subject of the present invention, when administered to a woman immediately before, during, and after menopause, a composition having, in part, specific fatty acids in specific amounts and ratios to each other, the woman receives optimal nutritional support. Based on the finding that it will be obtained. In particular, by supplementing the diet of a menopausal woman with the prescription described below, for a period of time beginning just before the symptoms of menopause actually occur, or preferably when menopause is generally expected, Women will certainly have the proper essential fatty acids to use now and in the future. Fatty acid supplements may further include vitamins and minerals to provide additional health benefits to menopausal women. In addition to benefiting humans, the present invention may also benefit non-human mammals. The compositions of the present invention can be administered to the mammal in animal feed, pill form, or other suitable dosage form.
【0044】
理論により限定されることなく、本発明の組成物は、1つ以上の天然の生物学
的経路において刺激または重要な役割を果たす。例えば、アラキドン酸カスケー
ドは、閉経期の女性の健康の支持および維持に重要な役割を果たし得る。特に、
アラキドン酸カスケードでは、リノール酸は、最初に、γ−リノレン酸に変換さ
れ、次いでジホモ−γ−リノレン酸およびアラキドン酸などのさらなる代謝物に
変換され、これは、以下に概略を示したように、それぞれ一および二系列のプロ
スタグランジンの前駆体である。Without being limited by theory, the compositions of the invention play a stimulating or important role in one or more natural biological pathways. For example, the arachidonic acid cascade may play an important role in supporting and maintaining the health of menopausal women. In particular,
In the arachidonic acid cascade, linoleic acid is first converted to γ-linolenic acid and then to further metabolites such as dihomo-γ-linolenic acid and arachidonic acid, which are outlined below. , Are precursors of the prostaglandins of the one and two series, respectively.
【0045】[0045]
【化1】
本発明の組成物は、必須脂肪酸化合物を含み得る。脂肪酸化合物は、リノール
酸化合物、その誘導体、または、リノール酸および/またはリノレン酸誘導体の
任意の組合せであり得る。脂肪酸化合物は、リノレン酸化合物、その誘導体およ
び/またはリノレン酸および/またはリノール酸誘導体の組合せであり得る。脂
肪酸化合物は、ドコサヘキサエン酸化合物、ω−3脂肪酸化合物、ω−2脂肪酸
化合物、その誘導体またはその組合せであり得る。脂肪酸はさらに、上記に考察
した脂肪酸の任意の組合せであり得る。[Chemical 1] The composition of the present invention may include an essential fatty acid compound. The fatty acid compound can be a linoleic acid compound, its derivatives, or any combination of linoleic acid and / or linolenic acid derivatives. The fatty acid compound can be a combination of linolenic acid compounds, their derivatives and / or linolenic acid and / or linoleic acid derivatives. The fatty acid compound can be a docosahexaenoic acid compound, an omega-3 fatty acid compound, an omega-2 fatty acid compound, a derivative thereof or a combination thereof. The fatty acid can further be any combination of the fatty acids discussed above.
【0046】
好ましくは、脂肪酸化合物は、約10mgから1,000mgの範囲の量で組
成物中に存在する。より好ましくは、脂肪酸化合物は、他の脂肪酸化合物とは独
立的に、約15mgから200mgの範囲の量で組成物中に存在する。さらによ
り好ましくは、脂肪酸化合物は、他の脂肪酸化合物とは独立的に、約20mgか
ら約100mgの範囲の量で組成物中に存在する。最も好ましくは、脂肪酸化合
物は、他の脂肪酸化合物とは独立的に、約25mgから50mgの範囲の量で組
成物中に存在する。Preferably, the fatty acid compound is present in the composition in an amount in the range of about 10 mg to 1,000 mg. More preferably, the fatty acid compound is present in the composition in an amount ranging from about 15 mg to 200 mg, independent of other fatty acid compounds. Even more preferably, the fatty acid compound is present in the composition in an amount ranging from about 20 mg to about 100 mg, independent of other fatty acid compounds. Most preferably, the fatty acid compound is present in the composition in an amount ranging from about 25 mg to 50 mg, independent of other fatty acid compounds.
【0047】
3つの脂肪酸化合物が、互いに重要な比率で、本発明の組成物中に存在し得る
。好ましくは、前記の第一および第二脂肪酸化合物の量の合計と、前記の第三脂
肪酸化合物の量の重量比は、約1:0.5から1.5である。より好ましくは、
前記の第一および第二脂肪酸化合物の量の合計と、前記の第三脂肪酸化合物の量
の重量比は約1:0.7から1.3である。さらにより好ましくは前記の第一お
よび第二脂肪酸化合物の量の合計と、前記の第三脂肪酸化合物の量の重量比は、
約1:0.9から1.2である。最も好ましくは、前記の第一および第二脂肪酸
化合物の量の合計と、前記の第三脂肪酸化合物の量の重量比は、約1:0.9か
ら1.1である。The three fatty acid compounds may be present in the composition of the invention in a ratio important to one another. Preferably, the weight ratio of the sum of the amounts of the first and second fatty acid compounds to the amount of the third fatty acid compounds is about 1: 0.5 to 1.5. More preferably,
The weight ratio of the sum of the amounts of the first and second fatty acid compounds to the amount of the third fatty acid compounds is about 1: 0.7 to 1.3. Even more preferably, the weight ratio of the total amount of the first and second fatty acid compounds and the amount of the third fatty acid compound is
It is about 1: 0.9 to 1.2. Most preferably, the weight ratio of the sum of the amounts of the first and second fatty acid compounds to the amount of the third fatty acid compounds is about 1: 0.9 to 1.1.
【0048】
本発明の組成物は、必須脂肪酸と反応して、生化学的に活性な化合物を形成す
る、任意の化合物を取込み得る。好ましくは、化合物は、例えば、スフィンゴミ
エリン、ミエリン、その誘導体およびその組合せを含むがこれに限定されない、
栄養的必要性を満たす化合物である。The composition of the present invention may incorporate any compound that will react with the essential fatty acids to form the biochemically active compound. Preferably, the compound includes, but is not limited to, for example, sphingomyelin, myelin, derivatives thereof and combinations thereof,
A compound that meets nutritional needs.
【0049】
本発明に使用する脂肪酸化合物誘導体の特定のクラスは、リノール酸のリン脂
質エステル、リノール酸のエーテル、リノール酸のステロール誘導体、リノレン
酸のリン脂質エステル、リノレン酸のエーテル、リノレン酸のステロール誘導体
およびその組合せを含むがこれに限定されない。Specific classes of fatty acid compound derivatives for use in the present invention include phospholipid esters of linoleic acid, ethers of linoleic acid, sterol derivatives of linoleic acid, phospholipid esters of linolenic acid, ethers of linolenic acid, linolenic acid. Including but not limited to sterol derivatives and combinations thereof.
【0050】
本発明に使用する非制限的な例示的脂肪酸化合物は、リノール酸のホスファチ
ダルコリンエステル、リノール酸のホスファチダルエーテル、リノール酸のシポ
ールステロールエステル、リノレン酸のホスファチダルコリンエステル、リノレ
ン酸のホスファチダルエーテル、リノレン酸のシポールステロールエステル、お
よびその組合せを含むがこれに限定されない。Non-limiting exemplary fatty acid compounds for use in the present invention include phosphatidal choline esters of linoleic acid, phosphatidal ethers of linoleic acid, cypolsterol esters of linoleic acid, phosphatidal choline of linolenic acid. Including but not limited to esters, phosphatidal ethers of linolenic acid, cypolsterol esters of linolenic acid, and combinations thereof.
【0051】
本発明の組成物は、カルシウム化合物、その誘導体、またはカルシウム化合物
とその誘導体の任意の組合せを含む。好ましくは、カルシウムは、約400mg
から約2,500mgの範囲の量で組成物中に存在する。より好ましくは、カル
シウムは、約600mgから約1,800mgの範囲の量で組成物中に存在する
。さらにより好ましくは、カルシウムは、約800mgから約1600mgの範
囲の量で組成物中に存在する。最も好ましくは、カルシウムは、約1,000m
gから約1400mgの範囲の量で組成物中に存在する。The composition of the present invention comprises a calcium compound, a derivative thereof, or any combination of a calcium compound and a derivative thereof. Preferably, the calcium is about 400 mg
To about 2,500 mg in the composition. More preferably, calcium is present in the composition in an amount in the range of about 600 mg to about 1800 mg. Even more preferably, calcium is present in the composition in an amount in the range of about 800 mg to about 1600 mg. Most preferably, the calcium is about 1,000 m
It is present in the composition in an amount ranging from g to about 1400 mg.
【0052】 本発明における、全脂肪酸と全カルシウム含量の比率は、重要な特徴である。[0052] The ratio of total fatty acid to total calcium content in the present invention is an important feature.
【0053】
3つの脂肪酸化合物が存在する場合、好ましくは、第一、第二および第三脂肪
酸化合物の量の合計と、前記カルシウム化合物またはその誘導体の量の重量比は
、約1:0.4から50である。より好ましくは、第一、第二および第三脂肪酸
化合物の量の合計と、前記カルシウム化合物またはその誘導体の量の重量比は、
約1:4から20である。さらにより好ましくは、第一、第二および第三脂肪酸
化合物の量の合計と、前記カルシウム化合物またはその誘導体の量の重量比は、
約1:7から15である。最も好ましくは、第一、第二および第三脂肪酸化合物
の量の合計と、前記カルシウム化合物またはその誘導体の量の重量比は、約1:
10から14である。When three fatty acid compounds are present, preferably the weight ratio of the sum of the amounts of the first, second and third fatty acid compounds to the amount of said calcium compound or its derivative is about 1: 0.4. To 50. More preferably, the weight ratio of the total amount of the first, second and third fatty acid compounds to the amount of the calcium compound or its derivative is
It is about 1: 4 to 20. Even more preferably, the weight ratio of the total amount of the first, second and third fatty acid compounds to the amount of the calcium compound or its derivative is
It is about 1: 7 to 15. Most preferably, the weight ratio of the sum of the amounts of the first, second and third fatty acid compounds to the amount of said calcium compound or its derivative is about 1:
10 to 14.
【0054】
本発明の対象の脂肪酸は、それ自体で、または本明細書に後に詳述したように
、生物学的に許容されまた生理的に均等な誘導体として使用し得る。請求項にお
ける言及を含む、任意の脂肪酸に対する言及は、前記誘導体の形である場合には
、酸に対する言及も含むと捉える。均等物は、生体の生合成経路への移行により
実証され、これは、酸それ自体またはその天然グリセリドエステルの効果に対応
する効果により証明される。従って、有用な誘導体の間接的な同定は、生体での
脂肪酸それ自体の価値ある効果を有することによるが、例えば、γ−リノレン酸
からジホモ−γ−リノレン酸および次いでアラキドン酸への変換は、直接的に、
本発明の対象が関する当分野の普通程度の技術力を有する者には公知の標準的な
技術により、血液、体脂肪、または他の組織での濃度のガスクロマトグラフィー
解析により示すことができる。The fatty acids of the present invention may be used on their own or as a biologically acceptable and physiologically equivalent derivative, as further detailed herein. References to any fatty acid, including references in the claims, are also understood to include reference to acid when in the form of the derivative. Equivalents are demonstrated by the transition into the biosynthetic pathway of the body, which is evidenced by a corresponding effect of the acid itself or its natural glyceride ester. Thus, the indirect identification of useful derivatives is due to the valuable effects of fatty acids themselves in the living body, for example the conversion of γ-linolenic acid to dihomo-γ-linolenic acid and then arachidonic acid directly,
Gas chromatographic analysis of concentrations in blood, body fat, or other tissues can be demonstrated by standard techniques known to those of ordinary skill in the art to which the subject matter of the present invention pertains.
【0055】
本発明の対象に使用したような、リノール酸の誘導体は、リノール酸の塩、リ
ノール酸のアルカリ塩、リノール酸のエステルおよびその組合せを含むがこれに
限定されない。本発明の対象に使用したような、リノレン酸の誘導体は、リノレ
ン酸の塩、リノレン酸のアルカリ塩、リノレン酸のエステル、およびその組合せ
を含むがこれに限定されない。本明細書の塩およびアルカリ塩は、医薬使用に許
容される、通常使用される有機または無機塩を意味する。非制限的な例示的リノ
レン酸は、γ−リノール酸およびジホモ−γ−リノレン酸を含む。Derivatives of linoleic acid, as used in the context of the present invention, include, but are not limited to, salts of linoleic acid, alkali salts of linoleic acid, esters of linoleic acid and combinations thereof. Derivatives of linolenic acid, as used in the context of the present invention, include, but are not limited to, salts of linolenic acid, alkali salts of linolenic acid, esters of linolenic acid, and combinations thereof. Salts and alkaline salts herein refer to the commonly used organic or inorganic salts that are acceptable for pharmaceutical use. Non-limiting exemplary linolenic acids include γ-linoleic acid and dihomo-γ-linolenic acid.
【0056】
本発明の対象の脂肪酸は、天然または合成油、脂肪、ワックスまたはその組合
せを含むがこれに限定されない、任意の起源であり得る。さらに、本明細書の脂
肪酸は、非硬化油、部分硬化油、完全硬化油またはその組合せから得られ得るが
、これに限定されない。非制限的な例示的な脂肪酸の起源は、種油、魚油または
海産物油、アブラナ油、植物油、ベニバナ油、ヒマワリ油、キンレンカ種油、か
らし種油、オリーブ油、ゴマ油、大豆油、コーン油、落花生油、綿実油、ぬか油
、ババス実油、パーム油、エルカ酸の低い菜種油、パーム核油、ルピナス油、コ
コナッツ油、アマニ油、オオマツヨイグサ油、ホホバ、獣脂、牛脂、バター、ニ
ワトリ脂、ラード、酪農乳脂肪、シアバターまたはその組合せを含む。具体的な
非制限的な例示的な魚油または海産物油源は、貝油、マグロ油、サバ油、サケ油
、メンハーデン、アンチョビー、ニシン、マス、イワシ、またはその組合せを含
む。好ましくは、脂肪酸源は、魚油または海産物油、大豆油またはアマニ油であ
る。The fatty acids of the present invention can be of any origin, including but not limited to natural or synthetic oils, fats, waxes or combinations thereof. Further, the fatty acids herein may be obtained from, but not limited to, non-hardened oil, partially hardened oil, fully hardened oil or combinations thereof. Non-limiting exemplary sources of fatty acids include seed oil, fish oil or marine oil, rapeseed oil, vegetable oil, safflower oil, sunflower oil, nasturtium seed oil, mustard seed oil, olive oil, sesame oil, soybean oil, corn oil, Peanut oil, cottonseed oil, bran oil, babassu oil, palm oil, rapeseed oil with low erucic acid, palm kernel oil, lupine oil, coconut oil, linseed oil, evening primrose oil, jojoba, tallow, beef tallow, butter, chicken fat, lard, Contains dairy milk fat, shea butter or combinations thereof. Specific non-limiting exemplary fish or marine oil sources include shellfish oil, tuna oil, mackerel oil, salmon oil, menhaden, anchovy, herring, trout, sardines, or combinations thereof. Preferably, the fatty acid source is fish oil or marine oil, soybean oil or linseed oil.
【0057】
カルシウム化合物は、炭酸カルシウム、硫酸カルシウム、酸化カルシウム、水
酸化カルシウム、カルシウムアパタイト、クエン酸−リンゴ酸カルシウム、骨ミ
ール、牡蠣殻、グルコン酸カルシウム、乳酸カルシウム、リン酸カルシウム、レ
ブリン酸カルシウム等の、公知の任意のカルシウム補充物を含むがこれに限定さ
れない。本明細書に使用したような、カルシウム化合物の誘導体は、カルシウム
の塩、カルシウムのアルカリ塩、カルシウムのエステル、およびその組合せを含
むがこれに限定されない。本明細書の塩およびアルカリ塩は、医薬使用に許容さ
れる、通常使用される有機または無機塩を意味する。本発明の組成物のカルシウ
ムは、限定されることなく、任意の起源であり得る。The calcium compound includes calcium carbonate, calcium sulfate, calcium oxide, calcium hydroxide, calcium apatite, citric acid-calcium malate, bone meal, oyster shell, calcium gluconate, calcium lactate, calcium phosphate, calcium levulinate, and the like. Includes, but is not limited to, any known calcium supplement. As used herein, derivatives of calcium compounds include, but are not limited to, salts of calcium, alkali salts of calcium, esters of calcium, and combinations thereof. Salts and alkaline salts herein refer to the commonly used organic or inorganic salts that are acceptable for pharmaceutical use. The calcium of the composition of the present invention can be of any origin, without limitation.
【0058】
葉酸も、本発明の対象の組成物に取込む。好ましくは、葉酸は、約0.4mg
から約5.0mgの範囲の量で存在する。より好ましくは、葉酸は、約0.6m
gから約1.3mgの範囲の量で存在する。さらにより好ましくは、葉酸は、約
0.8mgから約1.2mgの範囲の量で存在する。最も好ましくは、葉酸は、
約0.9mgから約1.1mgの範囲の量で存在する。Folic acid is also incorporated into the subject compositions of the present invention. Preferably, folic acid is about 0.4 mg
To about 5.0 mg. More preferably, the folic acid is about 0.6 m
It is present in amounts ranging from g to about 1.3 mg. Even more preferably, folic acid is present in an amount in the range of about 0.8 mg to about 1.2 mg. Most preferably, folic acid is
It is present in an amount ranging from about 0.9 mg to about 1.1 mg.
【0059】
本発明の組成物は、所望により、追加のビタミンおよび生物学的に許容される
ミネラルを含み得る。本発明の組成物に包含するための、非制限的な例示的なビ
タミンおよび生物学的に許容されるミネラルおよびその誘導体は、ビタミンA、
Bビタミン群、ビタミンC、ビタミンD、ビタミンE、ビタミンK、鉄、カルシ
ウム、マグネシウム、カリウム、銅、クロム、亜鉛、モリブデン、ヨウ素、ホウ
素、セレン、マンガン、バイオフラボノイド、その誘導体またはその組合せを含
む。これらのビタミンおよびミネラルは、限定されることなく、任意の起源また
は起源の組合せから得られ得る。非制限的な例示的なBビタミン群は、チアミン
、ナイアシンアミド、ピリドキシン、リボフラビン、シアノコバラミン、ビオチ
ン、パントテン酸、またはその組合せを含むがこれに限定されない。繊維、炭水
化物、脂肪、タンパク質、アミノ酸、その誘導体およびその組合せを含むがこれ
に限定されない、他の栄養的に活性な化合物も存在し得る。The compositions of the present invention may optionally include additional vitamins and biologically acceptable minerals. Non-limiting exemplary vitamins and biologically acceptable minerals and derivatives thereof for inclusion in the compositions of the present invention include vitamin A,
B vitamins, vitamin C, vitamin D, vitamin E, vitamin K, iron, calcium, magnesium, potassium, copper, chromium, zinc, molybdenum, iodine, boron, selenium, manganese, bioflavonoids, derivatives or combinations thereof . These vitamins and minerals can be obtained, without limitation, from any source or combination of sources. Non-limiting exemplary B vitamins include but are not limited to thiamine, niacinamide, pyridoxine, riboflavin, cyanocobalamin, biotin, pantothenic acid, or combinations thereof. Other nutritionally active compounds may also be present, including but not limited to fiber, carbohydrates, fats, proteins, amino acids, their derivatives and combinations thereof.
【0060】
ビタミンCが本発明の対象の組成物に存在する場合、好ましくは、約10mg
から約600mgの範囲の量で存在する。より好ましくは、ビタミンCは、約2
5mgから約500mgの範囲の量で存在する。さらにより好ましくは、ビタミ
ンCは、約25mgから約50mgの範囲の量で即時放出形で存在する。最も好
ましくは、ビタミンCは、約250mgから約500mgの範囲の量で制御放出
形で存在する。When Vitamin C is present in the subject composition of the present invention, preferably about 10 mg.
Present in an amount ranging from about 600 mg. More preferably, the vitamin C is about 2
Present in amounts ranging from 5 mg to about 500 mg. Even more preferably, Vitamin C is present in immediate release form in an amount in the range of about 25 mg to about 50 mg. Most preferably, Vitamin C is present in controlled release form in an amount in the range of about 250 mg to about 500 mg.
【0061】
ビタミンEが本発明の対象の組成物に存在する場合、好ましくは、約5mgか
ら約500mgの範囲の量で存在する。より好ましくは、ビタミンEは、約10
mgから約400mgの範囲の量で存在する。さらにより好ましくは、ビタミン
Eは、約250mgから約400mgの範囲の量で制御放出形で存在する。最も
好ましくは、ビタミンEは、約10mgから約50mgの範囲の量で即時放出形
で存在する。When Vitamin E is present in the subject compositions of the present invention, it is preferably present in an amount ranging from about 5 mg to about 500 mg. More preferably, the vitamin E is about 10
Present in amounts ranging from mg to about 400 mg. Even more preferably, Vitamin E is present in controlled release form in an amount ranging from about 250 mg to about 400 mg. Most preferably, Vitamin E is present in immediate release form in an amount ranging from about 10 mg to about 50 mg.
【0062】
ビタミンB6も、本発明の対象の組成物に存在し得る。ビタミンB6は、好ま
しくは、約5mgから約200mgの範囲の量で存在する。より好ましくは、ビ
タミンB6は、約10mgから約50mgの範囲の量で存在する。さらにより好
ましくは、ビタミンB6は、約15mgから約40mgの範囲の量で存在する。
最も好ましくは、ビタミンB6は、20mgから約30mgの範囲の量で制御放
出形で存在する。Vitamin B6 may also be present in the subject compositions of the present invention. Vitamin B6 is preferably present in an amount in the range of about 5 mg to about 200 mg. More preferably, vitamin B6 is present in an amount in the range of about 10 mg to about 50 mg. Even more preferably, vitamin B6 is present in an amount in the range of about 15 mg to about 40 mg.
Most preferably, vitamin B6 is present in controlled release form in an amount in the range of 20 mg to about 30 mg.
【0063】
ビタミンB12も、本発明の組成物に取込み得る。好ましくは、ビタミンB1
2は、約25mcgから75mcgの範囲の量で存在する。より好ましくは、ビ
タミンB12は、約35mcgから約65mcgの範囲の量で存在する。さらに
より好ましくは、ビタミンB12は、約40mcgから約60mcgの範囲の量
で存在する。最も好ましくは、ビタミンB12は、約45mcgから約55mc
gの範囲の量で存在する。Vitamin B12 may also be incorporated into the compositions of the present invention. Preferably vitamin B1
2 is present in amounts ranging from about 25 mcg to 75 mcg. More preferably, Vitamin B12 is present in an amount ranging from about 35 mcg to about 65 mcg. Even more preferably, vitamin B12 is present in an amount in the range of about 40 mcg to about 60 mcg. Most preferably, the vitamin B12 is about 45 mcg to about 55 mc.
It is present in amounts in the range of g.
【0064】
ビタミンDも本発明の組成物に取込み得る。好ましくは、ビタミンDは、約2
00IUから約625IUの範囲の量で存在する。より好ましくは、ビタミンD
は、約300IUから約500IUの範囲の量で存在する。さらにより好ましく
は、ビタミンDは、約350IUから約450IUの範囲の量で存在する。最も
好ましくは、ビタミンDは、約375IUから約425IUの範囲の量で存在す
る。Vitamin D may also be incorporated into the compositions of the present invention. Preferably, the vitamin D is about 2
Present in amounts ranging from 00 IU to about 625 IU. More preferably vitamin D
Is present in an amount ranging from about 300 IU to about 500 IU. Even more preferably, Vitamin D is present in an amount in the range of about 350 IU to about 450 IU. Most preferably, Vitamin D is present in an amount ranging from about 375 IU to about 425 IU.
【0065】
ビタミンAも本発明の組成物に取込み得る。好ましくは、ビタミンAは、約2
,500IUから約6,500IUの範囲の量で組成物中に存在する。より好ま
しくは、ビタミンAは、約4,000IUから約6,000IUの範囲の量で組
成物中に存在する。さらにより好ましくは、ビタミンAは、約4,500IUか
ら約5,500IUの範囲の量で組成物中に存在する。最も好ましくは、ビタミ
ンAは、約4,750IUから約5,250IUの範囲の量で組成物中に存在す
る。Vitamin A may also be incorporated into the compositions of the present invention. Preferably, the vitamin A is about 2
, 500 IU to about 6,500 IU is present in the composition. More preferably, Vitamin A is present in the composition in an amount in the range of about 4,000 IU to about 6,000 IU. Even more preferably, Vitamin A is present in the composition in an amount in the range of about 4,500 IU to about 5,500 IU. Most preferably, Vitamin A is present in the composition in an amount in the range of about 4,750 IU to about 5,250 IU.
【0066】
マグネシウムは、存在する場合には、好ましくは、約25mgから約400m
gの範囲の量で本発明の対象の組成物中に存在する。より好ましくは、マグネシ
ウムは、約25mgから約100mgの範囲の量で即時放出形で本発明の対象の
組成物中に存在する。さらにより好ましくは、マグネシウムは、約100mgか
ら約400mgの範囲の量で制御放出形の本発明の対象の組成物中に存在する。
本発明の対象に取込み得る許容されるマグネシウム化合物は、ステアリン酸マグ
ネシウム、炭酸マグネシウム、酸化マグネシウム、水酸化マグネシウムおよび硫
酸マグネシウムを含むがこれに限定されない。Magnesium, when present, is preferably from about 25 mg to about 400 m
It is present in the subject composition of the invention in an amount in the range of g. More preferably, magnesium is present in the subject compositions of the invention in immediate release form in an amount in the range of about 25 mg to about 100 mg. Even more preferably, magnesium is present in the controlled release form of the subject compositions of the present invention in an amount ranging from about 100 mg to about 400 mg.
Acceptable magnesium compounds that may be incorporated within the scope of the present invention include, but are not limited to, magnesium stearate, magnesium carbonate, magnesium oxide, magnesium hydroxide and magnesium sulfate.
【0067】
本発明の対象の組成物はまた、ホルモン、ステロイド、繊維、エストロゲン、
黄体ホルモン、鎮静催眠剤、バルビツール酸類、ベンゾジアゼピン類、抗うつ剤
、精神安定剤、鎮静剤、骨粗鬆症剤、抗血小板剤、アミノビスホスホネート、生
薬、生薬誘導体、植物誘導体、植物化学物質誘導体およびその組合せを含むがこ
れに限定されない、1つ以上の生物活性物質または治療物質を含み得る。The composition of matter of the invention also comprises hormones, steroids, fibers, estrogens,
Lutein hormone, sedative hypnotics, barbituric acids, benzodiazepines, antidepressants, tranquilizers, sedatives, osteoporosis agents, antiplatelet agents, aminobisphosphonates, herbal medicines, herbal medicine derivatives, plant derivatives, phytochemical derivatives and combinations thereof Can include one or more bioactive or therapeutic agents, including but not limited to.
【0068】
非栄養的活性物質がホルモンである場合、ホルモンは、約0.15mgから約
11.25mgの範囲の投与量で投与する。非栄養的活性物質が骨粗鬆症剤であ
る場合、骨粗鬆症剤は、約2.5mgから約60mgの範囲の投与量で投与する
。When the non-nutritionally active substance is a hormone, the hormone is administered at a dose ranging from about 0.15 mg to about 11.25 mg. When the non-nutritionally active substance is an osteoporosis agent, the osteoporosis agent is administered at a dose ranging from about 2.5 mg to about 60 mg.
【0069】
非限定的な例示的治療物質は、酢酸メドロキシプロゲステロン、酢酸メゲスト
ロール、クロニジン、酢酸ノルエチンドロン、エチニルエストラジオール、複合
型エストロゲン、天然エストロゲン、合成エストロゲン、エストラジオール、プ
ロゲステロン、クロミフェン、クエン酸クロミフェン、ズクロミフェン、クエン
酸ズクロミフェン、エンクロミフェン、クエン酸エンクロミフェン、アスピリン
、カルシトニン、アレンドロネート、エチドロネート、パミドロネート、クロド
ロネート、チルドロネート、レジドロネート、イバドロネートおよびその組合せ
を含むがこれに限定されない。Non-limiting exemplary therapeutic agents are medroxyprogesterone acetate, megestrol acetate, clonidine, norethindrone acetate, ethinyl estradiol, complex estrogens, natural estrogens, synthetic estrogens, estradiol, progesterone, clomiphene, clomiphene citrate. , Zuclomiphene, zuclomiphene citrate, enclomiphene, enclomiphene citrate, aspirin, calcitonin, alendronate, etidronate, pamidronate, clodronate, tiludronate, ledronate, ibadronate and combinations thereof.
【0070】
非限定的な例示的生薬および生薬誘導体は、キンミズヒキ、アルファルファ、
アロエ、アマランス、アンゲリカ、アニス、メギ、バジル、シロヤマモモ、ハチ
花粉、樺、イブキトラノオ、ブラックベリー、ブラックコホッシュ、ブラックウ
ォールナット、オオアザミ、ブルーコホッシュ、ブルークマツヅラ、ヒヨドリバ
ナ、ルリヂサ、ブフ(ミカン科アガソスマ属の木)、クロウメモドキ、シロネ、
ゴボウ、トウガラシ、トウガラシの実、キャラウェー、カスカラサグラダ、イヌ
ハッカ、セロリ、センタウリー(シマセンブリの一種)、カモミール、チャパラ
ル、ハコベ、チコリー、チンチョナ、チョウジノキ、フキタンポポ、コンフリー
、トウモロコシの毛、ジバムギ、クランプバーグ、クガイソウ、シアニ、ヤグル
マソウ、ダミアナ、タンポポ、デブルスクロー、ドンクァイ、エキナシア、オオ
グルマ、マオウ、ユーカリ、オオマツヨイグサ、コゴメグサ、フォルスユニコー
ン、ウイキョウ、コロハ、ゴマノハグサ、アマニ、ニンニク、ゲンチアナ、ショ
ウガ、ニンジン、ヒドラスチス、ゴツコーラ、ガムウィード、サンザシ、ホップ
、ニガハッカ、セイヨウワサビ、つくし、hoshouwu、アジサイ、ヒソッ
プ、アイスランドゴケ、トチャカ、ホホバ、ビャクシン、コブ、レディズスリッ
パー、レモングラス、甘草、ロベリア、マンドレーク、マリーゴールド、マジョ
ラム、マシュマロ、ヤドリギ、ビロードモウズイカ、カラシナ、ミリス、ネット
ル、オートストロー、ヒイラギメギ、パパイヤ、パセリ、トケイソウ、モモ、ペ
ニローヤル、ペパーミント、ツルニチソウ、オオバコ、ヤナギトウワタ、ヤマゴ
ボウ、アメリカサンショウ、オオバコ、カッシア、セイヨウナツユキソウ、アカ
ツメクサ、ヨーロッパイチゴ、レッドモンドクレー、大黄、バラの実、ローズマ
リー、ヘンルーダ、ベニバナ、サフラン、セージ、セントジョンズワート(オト
ギリ草属の草木)、サルサ、サッサフラス、ノコギリパルメット、エゾナミキ、
セネガ、センナ、ナズナ、アカニレ、スペアミント、カンショウ、スクォーバイ
ン、スチリンギア、イチゴ、タヒボ、タイム、ウバウルシ、カノコソウ、スミレ
、クレソン、カシの樹皮、ホワイトパインの樹皮、ワイルドチェリー、ワイルド
レタス、野生の山芋、柳、ウィンターグリーン、マンサク、カコウチョロギ、ヨ
モギ、ノコギリソウ、イエロードック、サンタ草、ユッカおよびその組合せを含
む。本明細書に使用したような生薬誘導体は、生薬抽出物、葉、花および根など
のこれに限定されない植物および植物部分から得られた物質を意味する。好まし
くは、生薬または生薬誘導体は、ブラックコホッシュ、甘草、フォルスユニコー
ン、シベリアニンジン、サルサ、スクォーバイン、オオアザミおよびその組合せ
である。Non-limiting exemplary herbal medicines and herbal medicines include quince, alfalfa,
Aloe, amaranth, angelica, anise, barberry, basil, bayberry, bee pollen, birch, ibukitoranoo, blackberry, black cohosh, black walnut, milk thistle, blue cohosh, blue pine vine, syringa butterflies, borage (Asteraceae). Tree), buckthorn, cirone,
Burdock, capsicum, capsicum, caraway, cascara sagrada, narwhal, celery, centauri (a kind of shrimp), chamomile, chaparral, chickweed, chicory, chinchona, cypress, coltsfoot, comfrey, corn hair, buckwheat, clamp Burgh, Black swordfish, Cyani, Cornflower, Damiana, Dandelion, Deburs claw, Donquai, Echinacea, Greater gourd, Eucalyptus, Evening primrose, Forage unicorn, Pleurotus serrata, Coprinus comatus, Amani, Garlic, Anemone, Garlic, Anemone, Garlic, Anemone, Garlic, Anemone , Gumweed, hawthorn, hop, mint minnow, horseradish, horsetail, hoshowu, hydrangea, hyssop, iceland go , Tochaka, jojoba, juniper, juniper, cobb, lady's slipper, lemongrass, licorice, lobelia, mandrake, marigold, marjoram, marshmallow, mistletoe, velvet mullein, mustard, millis, nettle, oat straw, holly barberry, papaya, parsley, passionflower. , Peach, penile royal, peppermint, periwinkle, plantain, Salix macaw, pokeweed, American salamander, psyllium, cassia, sycamore, red clover, european strawberry, redmond clay, rhubarb, rosemary, henruda, safflower, Saffron, sage, St. John's wort (plants of the genus Otogiri), salsa, Sassafras, saw palmetto, Ezo namiki,
Senega, Senna, Nazuna, Akanile, Spearmint, Kansho, Squabine, Styringia, Strawberry, Tahibo, Thyme, Uva Urushi, Valercum, Violet, Watercress, Oak Bark, White Pine Bark, Wild Cherry, Wild Lettuce, Wild Yam, Willow , Wintergreen, witch hazel, mossy chopwort, mugwort, yarrow, yellow dock, santa grass, yucca and combinations thereof. Crude drug derivative as used herein means a substance obtained from plants and plant parts such as, but not limited to, crude drug extracts, leaves, flowers and roots. Preferably, the crude drug or crude drug derivative is black cohosh, licorice, false unicorn, Siberian ginseng, salsa, squaline, milk thistle and combinations thereof.
【0071】
種々の添加物を、本発明の組成物に取込み得る。本発明の組成物の任意選択の
添加物は、デンプン、糖、脂肪、抗酸化剤、アミノ酸、タンパク質、核酸、電解
質、その誘導体またはその組合せを含むがこれに限定されない。Various additives can be incorporated into the compositions of the present invention. Optional additives to the compositions of the present invention include, but are not limited to, starch, sugars, fats, antioxidants, amino acids, proteins, nucleic acids, electrolytes, derivatives thereof or combinations thereof.
【0072】
非限定的な例示的な本発明の対象のアミノ酸は、ヒスチジン、イソロイシン、
ロイシン、リジン、メチオニン、フェニルアラニン、トレオニン、トリプトファ
ン、バリン、アラニン、アルギニン、アスパラギン、アスパラギン酸、システイ
ン、グルタミン酸、グルタミン、グリシン、プロリン、セリン、チロシン、その
誘導体およびその組合せを含む。好ましくは、存在するアミノ酸は、ロイシン、
イソロイシン、バリン、その誘導体またはその組合せである。Non-limiting exemplary amino acids of the invention are histidine, isoleucine,
Includes leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine, alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, proline, serine, tyrosine, derivatives thereof and combinations thereof. Preferably, the amino acid present is leucine,
Isoleucine, valine, a derivative thereof or a combination thereof.
【0073】
本発明の対象の組成物、方法および薬物送達処方計画は、保存非適合性の物質
、特に、閉経前および閉経期の女性の必要性にテーラーメードした保存非適合性
の物質の同時投与を容易にし得る。保存非適合性物質は、物質が負の様式で相互
作用するために、1つの投与単位に一緒に製剤化できないか、または、直接接触
して一緒に保存できない、任意の物質、並びにまた、物質の投与量の合計が嚥下
には大きすぎる1投与単位を生じるので、1投与単位に一緒に製剤化できない物
質も意味する。保存非適合性物質はまた、直接接触して保存し得るが、しかし、
物質の1つは好ましくは、他の物質に好ましくないかまたは非適合性である、物
質も含む。保存非適合性物質はまた、限定されることなく、任意の保存非適合性
物質を含み得る。The subject compositions, methods and drug delivery regimens of the present invention provide for the co-administration of preservative incompatible substances, particularly preservative incompatible substances tailored to the needs of premenopausal and menopausal women. Can be facilitated. A storage incompatible substance is any substance that cannot be formulated together in one dosage unit or stored together in direct contact because the substances interact in a negative manner, and also the substance It also means a substance that cannot be co-formulated into a single dosage unit, as the total dosage of 1 results in a single dosage unit that is too large for swallowing. Storage Incompatible materials can also be stored in direct contact, but
One of the substances preferably also comprises substances which are unfavorable or incompatible with the other substances. Storage incompatible materials may also include, without limitation, any storage incompatible materials.
【0074】
例えば、保存非適合性物質は、疎水性化合物および親水性化合物、オレフィン
化合物および非オレフィン化合物、pH感受性化合物および非pH感受性化合物
、無水環境を必要とする物質、非無水環境を必要とする物質、酸性薬物および塩
基性薬物、発泡錠および水分含量の高い薬物または投与形、ゼラチンカプセルお
よびアルデヒド、4級アンモニウム化合物およびアニオン性物質または上記の任
意の組合せであり得る。For example, storage incompatible substances require hydrophobic and hydrophilic compounds, olefin and non-olefin compounds, pH-sensitive and non-pH-sensitive compounds, substances that require an anhydrous environment, non-anhydrous environments. Substances, acidic and basic drugs, effervescent tablets and high water content drugs or dosage forms, gelatin capsules and aldehydes, quaternary ammonium compounds and anionic substances or any combination of the above.
【0075】
保存非適合性物質はまた、物質の投与量の合計が嚥下には大きすぎる1投与単
位を生じるので、1投与単位に一緒に製剤化できない物質も含む。本発明の対象
の組成物、方法および薬物送達処方計画は、1つのパッケージに、全ての物質お
よび投与量を一緒に維持しつつ、大きな投与量を、快適に嚥下するに十分小さな
複数回の投与量に分離することによりこの問題に対処する。Storage-incompatible substances also include substances that cannot be co-formulated together in a single dosage unit because the total dose of the material results in a single dosage unit that is too large for swallowing. The subject compositions, methods and drug delivery regimens of the present invention allow for the administration of large doses in multiple doses small enough to comfortably swallow while maintaining all substances and doses together in one package. This problem is addressed by segregating into quantities.
【0076】
非限定的な例示的保存非適合性物質は、アスコルビン酸および水酸化アルミニ
ウム、アスコルビン酸および重炭酸ナトリウム、クエン酸および炭酸ナトリウム
、葉酸および炭酸カルシウム、活性炭および硝酸アミル、ゼラチンカプセルおよ
びホルムアルデヒド、ゼラチンカプセルおよびグルタルアルデヒド、塩化コニシ
ンおよび石鹸、塩化エチルピリジニウムおよびステアリン酸ナトリウム、ω脂肪
酸およびその組合せを含むがこれに限定されない。Non-limiting exemplary storage incompatible materials are ascorbic acid and aluminum hydroxide, ascorbic acid and sodium bicarbonate, citric acid and sodium carbonate, folic acid and calcium carbonate, activated carbon and amyl nitrate, gelatin capsules and formaldehyde. , Gelatin capsules and glutaraldehyde, conicin chloride and soaps, ethylpyridinium chloride and sodium stearate, omega fatty acids and combinations thereof, but not limited thereto.
【0077】
また、本発明の対象の栄養的組成物において、投与形について、当分野の普通
程度の技術的理解力を有する者には公知の任意の放出形を合わせることが可能で
ある。これらは、即時放出、延長放出、間欠的放出、変動放出、制御放出、時限
放出、持続放出、遅延放出、長時間作用、およびその組合せを含むがこれに限定
されない。即時放出、延長放出、間欠的放出、変動放出、制御放出、時限放出、
持続放出、遅延放出、長時間作用特徴およびその組合せを得る能力は、普通の熟
練者に利用可能な公知の手順および技術を用いて実施する。放出特徴を得るため
の、これらの具体的な各技術または手順は、本発明の対象の発明の態様を構成せ
ず、それは全部、当分野の普通程度の技術的理解力を有する者には公知である。
本明細書に使用したような、「制御放出形」は、制御放出用に製剤化された少な
くとも1つの成分を有する、任意の形を意味する。本明細書に使用したような「
即時放出形」は、即時放出用に製剤化された全てのその成分を有する任意の形を
意味する。In addition, in the nutritional composition of the subject of the present invention, it is possible to combine the dosage form with any release form known to those having ordinary skill in the art. These include, but are not limited to, immediate release, extended release, intermittent release, modified release, controlled release, timed release, sustained release, delayed release, long acting, and combinations thereof. Immediate release, extended release, intermittent release, variable release, controlled release, timed release,
The ability to obtain sustained release, delayed release, long acting characteristics and combinations thereof is carried out using known procedures and techniques available to one of ordinary skill in the art. Each of these specific techniques or procedures for obtaining a release profile does not constitute an inventive aspect of the subject matter of this invention, all of which are known to those of ordinary skill in the art. Is.
As used herein, "controlled release form" means any form that has at least one component formulated for controlled release. As used herein
"Immediate release form" means any form that has all its components formulated for immediate release.
【0078】
当分野の普通程度の技術的理解力を有する者には公知の任意の生物学的に許容
される投与形が、本発明の対象と考えられる。前記投与形の例は、咀嚼錠、急速
溶解錠、発泡錠、復元可能な粉末、エリキシル、液体、溶液、懸濁液、エマルシ
ョン、錠剤、多層錠剤、二重層錠剤、カプセル、軟ゼラチンカプセル、硬ゼラチ
ンカプセル、キャプレット、甘味錠剤、咀嚼甘味錠剤、ビーズ、粉末、顆粒、粒
子、微粒子、分散性顆粒、カシェ(カプセル)、潅注液、坐剤、クリーム、局所
剤、吸入剤、エアゾール吸入剤、パッチ、粒子性吸入剤、インプラント、貯蔵イ
ンプラント、経口摂取物、注射液、点滴液、ヘルスバー、糖菓、動物の飼料、シ
リアル、ヨーグルト、シリアルコーティング、食物、栄養食物、機能的食物およ
びその組合せを含むがこれに限定されない。上記の投与形の調製物は、当分野の
普通程度の技術的理解力を有する者には公知である。Any biologically acceptable dosage form known to one of ordinary skill in the art is considered to be the subject of this invention. Examples of said dosage forms are chewable tablets, fast-dissolving tablets, effervescent tablets, reconstitutable powders, elixirs, liquids, solutions, suspensions, emulsions, tablets, multi-layer tablets, double-layer tablets, capsules, soft gelatin capsules, hard tablets. Gelatin capsules, caplets, sweet tablets, chew sweet tablets, beads, powder, granules, particles, microparticles, dispersible granules, cachets (capsules), irrigation solutions, suppositories, creams, topical agents, inhalants, aerosol inhalants, Patches, particulate inhalants, implants, depot implants, ingestion, injections, infusions, health bars, confectionery, animal feed, cereals, yogurts, cereal coatings, foods, nutritious foods, functional foods and combinations thereof. Including but not limited to. Preparations of the above dosage forms are known to those of ordinary skill in the art.
【0079】
以下の手順は、本発明の対象の範囲内に該当する処方を調製する許容される方
法を示すがこれに限定されない。例えば、動物の飼料は、当分野の普通程度の技
術的理解力を有する者に公知の方法により製造し得る。動物の飼料は、処方を、
結合成分と混合して、可塑塊を形成することにより調製し得る。次いで、塊を、
高圧力下で押出して、管状(または「スパゲッティ様の」)構造を形成し、これ
をペレットサイズに切断し、乾燥する。The following procedures illustrate, but are not limited to, acceptable methods of preparing formulations that fall within the scope of the present invention. For example, animal feed may be manufactured by methods known to those of ordinary skill in the art. Animal feed, prescription,
It may be prepared by mixing with a binding component to form a plastic mass. Then the lumps,
Extruded under high pressure to form a tubular (or "spaghetti-like") structure that is cut into pellet size and dried.
【0080】
急速溶解錠は、例えば、処方を、経口投与後に通常30秒以内に生じる錠剤の
溶解または崩壊を促進する、糖およびセルロース誘導体などの物質と混合するこ
とにより調製し得るがこれに限定されない。Rapid-dissolving tablets may be prepared, for example, by mixing the formulation with substances such as sugars and cellulose derivatives that promote dissolution or disintegration of the tablet, which usually occurs within 30 seconds after oral administration, but are not limited thereto. Not done.
【0081】
シリアルコーティングは、例えば、シリアル製剤を、ペレット、フレーク、ま
たは他の幾何学形状に形成した後に、正確なスプレーコーティング装置下を通過
させて、活性成分と賦形剤の膜を、形成したエレメントの表面上に沈着すること
により調製し得るがこれに限定されない。次いで、かくして処理した単位を乾燥
して、シリアルコーティングを形成する。Serial coatings include, for example, forming a cereal formulation into pellets, flakes, or other geometric shapes and then passing under a precise spray coating apparatus to form a film of active ingredient and excipients. It can be prepared by, but is not limited to, depositing on the surface of the prepared element. The unit thus treated is then dried to form a serial coating.
【0082】
例えば、ヘルスバーは、処方と賦形剤(例えば、結合剤、充填剤、香味剤、着
色剤等)を可塑塊が粘稠となるまで混合することにより調製し得るがこれに限定
されない。次いで、塊を延展または成型し、「キャンディーバー」形状を形成し
、次いでこれを乾燥し、固形化し、最終生成物を形成する。For example, a health bar may be prepared by, but not limited to, mixing the formulation and excipients (eg, binders, fillers, flavors, colorants, etc.) until the plastic mass becomes viscous. Not done. The mass is then spread or molded to form a "candy bar" shape, which is then dried and solidified to form the final product.
【0083】
軟ゲルまたは軟ゼラチンカプセルを、例えば、処方を適切な媒体(植物油が一
般に使用される)に分散し、粘度の高い混合物を形成することにより調製し得る
が、これに限定されない。次いで、この混合物を、軟ゲル工業の専門家には既知
の技術および機械を使用して、ゼラチンをベースとしたフィルムでカプセル化す
る。次いで、こうして形成した工業単位を乾燥し、一定重量とする。Soft gels or soft gelatin capsules may be prepared, for example but not limited to, by dispersing the formulation in a suitable vehicle (vegetable oils are commonly used) to form a viscous mixture. The mixture is then encapsulated with a gelatin-based film using techniques and machinery known to those in the soft gel industry. The industrial unit thus formed is then dried to constant weight.
【0084】
咀嚼錠は、例えば、処方を、嚥下ではなく咀嚼するための比較的軟らかく香味
のある錠剤投与形を形成するように設計された賦形剤と混合することにより調製
し得るが、これに限定されない。慣用的な錠剤機械および手順(これは、直接的
な圧縮および造粒、すなわち、または圧縮前のスラッグの両方である)を利用で
きる。医薬固体投与形製造に関与する人は、プロセスに熟知し、咀嚼可能な投与
形として使用される機械は、医薬産業で非常に一般的な投与形である。Chewable tablets may be prepared, for example, by mixing the formulation with an excipient designed to form a relatively soft and flavorful tablet dosage form for chewing rather than swallowing. Not limited to. Conventional tablet machines and procedures are available, which are both direct compression and granulation, or slugs prior to compression. Those involved in the manufacture of solid pharmaceutical dosage forms are familiar with the process, and machines used as chewable dosage forms are very common dosage forms in the pharmaceutical industry.
【0085】
フィルムコーティング錠は、例えば、回転パンコーティング法または空気懸濁
法などの技術を使用して錠剤をコーティングし、錠剤上に連続的フィルム層を沈
着することにより調製し得るがこれに限定されない。この手順は、しばしば、錠
剤の美的外見を向上するために実施されるが、錠剤の嚥下を向上するために、ま
たは、不快な匂いまたは味を遮蔽するために、または、不体裁にコーティングさ
れていない錠剤の通常の特性を向上するために実施し得る。Film-coated tablets may be prepared by, for example, coating tablets using techniques such as spin pan coating or air suspension, and depositing a continuous film layer on the tablets. Not done. This procedure is often performed to improve the aesthetic appearance of the tablet, but to improve swallowing of the tablet, to mask unpleasant odors or tastes, or to be uncoated. It can be carried out to improve the usual properties of tablets.
【0086】
圧縮錠剤は、処方を、崩壊品質に結合品質を加えるための賦形剤と混合するこ
とにより調製し得るがこれに限定されない。混合物は直接圧縮または造粒し、次
いで、当産業の専門家には極めて公知の方法および機械を使用して圧縮する。次
いで、得られた圧縮錠剤投与単位を、市場の必要性、すなわち単位投与量、ロー
ル、バルク瓶、ブリスターパック等に従ってパッケージングする。Compressed tablets may be prepared by, but not limited to, mixing the formulation with excipients to add binding quality to disintegration quality. The mixture is directly compressed or granulated and then compressed using methods and machinery well known to those skilled in the art. The resulting compressed tablet dosage unit is then packaged according to market need, ie unit dose, roll, bulk bottle, blister pack, etc.
【0087】
本発明の対象は、経口、口内、舌下、直腸、非経口、局所、吸入、注射および
経皮を含むがこれに限定されない、任意の経路による投与用に製剤化された栄養
的組成物に関する。栄養的組成物の物理化学的特性、その処方、および投与経路
は吸収に重要である。吸収は、投与部位から全身循環への栄養的組成物の移動の
プロセスを意味する。大半の経口投与した栄養的組成物は、主に簡便性、経済性
、安定性、および患者の許容性から、錠剤またはカプセル剤の形である。それら
は、吸収が起こり得る前に、崩壊および溶解しなければならない。上記の投与経
路または投与形のいずれかと共に本発明の対象を使用することは、普通程度の技
術的理解力を有する者には利用可能な公知の手順および技術を使用して実施され
る。The subject matter of the present invention is a nutritional formulation formulated for administration by any route, including but not limited to oral, buccal, sublingual, rectal, parenteral, topical, inhalation, injection and transdermal. It relates to a composition. The physicochemical properties of the nutritional composition, its formulation, and route of administration are important for absorption. Absorption refers to the process of transfer of a nutritional composition from the site of administration to the systemic circulation. Most orally administered nutritional compositions are in the form of tablets or capsules primarily for convenience, economy, stability, and patient acceptance. They must disintegrate and dissolve before absorption can occur. The use of the subject matter of the invention with any of the routes or dosage forms described above is carried out using known procedures and techniques available to those of ordinary skill in the art.
【0088】
本発明の対象は、多種多様の物質から調製し得る、生物学的に許容される担体
の使用を考える。それに限定されずに、前記物質は、特定の医薬組成物を調製す
るための、希釈剤、結合剤、および粘着剤、潤滑剤、可塑剤、崩壊剤、着色剤、
増量剤、香味剤、甘味剤および種々の物質、例えば緩衝剤および吸着剤を含む。The subject of the present invention contemplates the use of biologically acceptable carriers which can be prepared from a wide variety of substances. Without being limited thereto, the substances are diluents, binders and adhesives, lubricants, plasticizers, disintegrants, colorants, for the preparation of particular pharmaceutical compositions.
Includes bulking agents, flavoring agents, sweetening agents and various substances such as buffering agents and adsorbing agents.
【0089】
結合剤は、多種多様の物質、例えばヒドロキシプロピルメチルセルロース、エ
チルセルロース、または他の適切なセルロース誘導体、ポビドン、アクリルおよ
びメタクリル酸コポリマー、医薬的グレーズ、ガム、乳清などのミルク誘導体、
デンプン、および誘導体、並びに当分野の普通程度の技術的理解力を有する者に
は公知の他の慣用的な結合剤から選択し得る。例示的な非限定的な溶媒は、水、
エタノール、イソプロピルアルコール、塩化メチレンまたはその混合物および組
合せである。例示的な非限定的な増量物質は、糖、ラクトース、ゼラチン、デン
プン、および二酸化ケイ素を含む。Binders can be a wide variety of substances such as hydroxypropylmethylcellulose, ethylcellulose, or other suitable cellulose derivatives, povidone, acrylic and methacrylic acid copolymers, pharmaceutical glazes, gums, milk derivatives such as whey, and the like.
It may be selected from starch, and derivatives, and other conventional binders known to those of ordinary skill in the art. An exemplary, non-limiting solvent is water,
Ethanol, isopropyl alcohol, methylene chloride or mixtures and combinations thereof. Exemplary non-limiting bulking agents include sugar, lactose, gelatin, starch, and silicon dioxide.
【0090】
溶解修飾系で使用する可塑剤は、好ましくは、有機溶媒に予め溶かし、溶液形
で添加する。好ましい可塑剤は、フタル酸ジエチル、セバシン酸ジエチル、クエ
ン酸トリエチル、クロトン酸、プロピレングリコール、フタル酸ブチル、セバシ
ン酸ジブチル、ヒマシ油およびその混合物からなる群から選択し得るが、これに
限定されない。明らかなように、可塑剤は、疎水性、並びに、親水性でもよい。
水不溶性疎水性物質、例えばフタル酸ジエチル、セバシン酸ジエチルおよびヒマ
シ油を使用して、ビタミンB6およびビタミンCなどの水溶性ビタミンの放出を
遅延する。これに対し、水不溶性ビタミンを使用する場合には、親水性可塑剤を
使用し、これは、カプセル化フィルムの溶解、表面中のチャネルの作製を補助し
、栄養的組成物の放出を補助する。The plasticizer used in the dissolution modification system is preferably previously dissolved in an organic solvent and added in the form of a solution. Preferred plasticizers may be selected from, but not limited to, the group consisting of diethyl phthalate, diethyl sebacate, triethyl citrate, crotonic acid, propylene glycol, butyl phthalate, dibutyl sebacate, castor oil and mixtures thereof. As will be appreciated, the plasticizer may be hydrophobic as well as hydrophilic.
Water insoluble hydrophobic materials such as diethyl phthalate, diethyl sebacate and castor oil are used to delay the release of water soluble vitamins such as vitamin B6 and vitamin C. In contrast, when using water-insoluble vitamins, a hydrophilic plasticizer is used, which helps dissolve the encapsulating film, create channels in the surface, and help release the nutritional composition. .
【0091】
本発明の対象の組成物は、一部、すなわち分画した投与量で、24時間の期間
中に1回以上、24時間の期間中に1投与量、24時間の期間中に2回の投与量
、または24時間の期間中に2回以上の投与量で投与し得る。分画した、2また
は他の複数回の投与量は、同時に、または24時間の期間中の異なる時間に摂取
し得る。投与量は、互いに関して、または、異なる投与時間での個々の成分に関
して不均一な投与量であり得る。例えば、限定されることなく、朝の投与量のカ
ルシウムの量は、夕方の投与量のカルシウムの量とは異なる。A composition of the subject matter of the present invention is a partial, or fractionated dose, one or more times during a 24 hour period, one dose during a 24 hour period, and 2 during a 24 hour period. It may be given in one dose or in two or more doses over a 24 hour period. Fractionated, two or other multiple doses may be taken simultaneously or at different times during a 24-hour period. Dosages can be heterogeneous with respect to each other or with respect to the individual components at different administration times. For example, without limitation, the amount of calcium in the morning dose is different from the amount of calcium in the evening dose.
【0092】
本発明の組成物は、ヒトおよび他の哺乳動物により使用されるものである。投
与量は、体重に従って調整し、従って、体重を基礎にして、本明細書で示し得る
。例えば、処方が、55kgの個体に関して約10〜1000mgの範囲を明記
した場合、その範囲を、35kgの個体では、約6.3〜63mg(例えば、よ
り低い範囲限界=(35kg/55kg)*10mg=6.3mg)に調整する
だろう。小数部分は、最も近い整数に四捨五入し得る。上記のように、従って、
本発明の組成物は、そのサイズに関係なく、任意の哺乳動物を含む、任意の個体
について適切であるように適合し得る。The compositions of the present invention are for use by humans and other mammals. Dosages may be adjusted according to body weight and thus presented herein on a weight basis. For example, if a formulation specifies a range of about 10-1000 mg for a 55 kg individual, that range would be about 6.3-63 mg for a 35 kg individual (eg, lower range limit = (35 kg / 55 kg) * 10 mg. = 6.3 mg). The fractional part may be rounded to the nearest whole number. As above, so
The compositions of the present invention may be adapted as suitable for any individual, including any mammal, regardless of size.
【0093】
本発明の組成物は、閉経期の女性の特定の生理的必要性を満たすように適応す
る。例えば、処方は、必須脂肪酸などのこれに限定されない栄養的または食事的
補充物には一般にまたは適切に対処されない、閉経期の女性の特定の栄養的必要
性に焦点をあてることができる。鉄およびカルシウムは、存在する場合には、過
剰な投与量に伴い得る不快な副作用を最小限にしつつ、閉経期の女性に栄養的利
点を最適化するような量で提供される。処方はさらに、より高い特異性のために
、個々の女性の特定の必要性、遺伝的素因または同定された欠乏症、一般的にま
たはケースバイケースにテーラーメードできる。さらに、組成物は、閉経に関連
した容態を処置するために、または、閉経期の女性の神経学的維持を最大化する
ために、特異的に適応させ得る。組成物はまた、骨量の減少を阻害し、閉経期の
女性の必須脂肪酸の欠乏症を予防するのに適応させ得る。さらに、本発明の組成
物は、処方した療法の1成分として使用できる。The compositions of the present invention are adapted to meet the particular physiological needs of menopausal women. For example, the formulation can focus on the particular nutritional needs of menopausal women who are generally or not adequately addressed to non-limiting nutritional or dietary supplements such as essential fatty acids. Iron and calcium, when present, are provided to menopausal women in amounts that optimize nutritional benefits, while minimizing the unpleasant side effects that can be associated with overdose. The formulation may further be tailored to the specific needs, genetic predisposition or identified deficiencies of the individual woman, generally or on a case-by-case basis, due to the higher specificity. In addition, the compositions may be specifically adapted to treat conditions associated with menopause or to maximize neurological maintenance in menopausal women. The composition may also be adapted to inhibit bone loss and prevent deficiency of essential fatty acids in menopausal women. Moreover, the compositions of the invention can be used as a component of a prescribed therapy.
【0094】
本発明の対象の組成物は、ブリスターパックまたは他の前記の医薬パッケージ
に提供し得るがこれに限定されない。さらに、本発明の対象の組成物はさらに、
組成物が閉経期の女性用の製品であると女性が同定できる説明書を含み得るか、
または伴い得る。説明書はさらに、追加的に、前記組成物を使用するための、上
記の特定した期間の指摘を含む。例えば、限定されないが、説明書は、組成物を
投与するための1日の特定または一般的な時間を示した説明書であり得るか、ま
たは説明書は、組成物を投与するための曜日を示した日にちの説明書であり得る
。The subject compositions of the present invention may be provided in, but are not limited to, blister packs or other such pharmaceutical packages. Furthermore, the composition of matter of the invention further comprises
The composition may include instructions to identify a woman as a menopausal women's product,
Or it can be accompanied. The instructions will additionally include an indication of the above specified time period for using the composition. For example, without limitation, the instructions may be instructions indicating a specific or general time of day for administering the composition, or the instructions may indicate the day of the week for administering the composition. It can be a statement of the date shown.
【0095】
本発明の組成物は、閉経前および最中に使用し得る。組成物の使用は、閉経期
の開始時に開始し得る。本発明の対象の組成物は、好ましくは、閉経に関連した
第一症状の出現する前に開始して期間中に投与し、女性の一生を通じて継続する
。より好ましくは、組成物は、閉経直前または閉経の任意の症状の直前に始まる
期間中に投与する。「閉経の直前」および「閉経の任意の症状の前」なる語は、
本明細書で、閉経の開始で一般的に同定される年齢より約1ヶ月から5年前の前
に、組成物の投与を開始することを含むものとする。The compositions of the invention may be used before and during menopause. Use of the composition may begin at the beginning of menopause. The subject compositions of the present invention are preferably administered during the period starting prior to the onset of the first symptoms associated with menopause and continue throughout the life of a woman. More preferably, the composition is administered during the period beginning just before menopause or just before any symptoms of menopause. The words "immediately before menopause" and "before any symptoms of menopause"
It is intended herein to include initiating administration of the composition about 1 month to 5 years prior to the age generally identified at the onset of menopause.
【0096】
好ましくは、組成物の投与の開始は、女性が35から50才である時である。
より好ましくは、投与開始は、女性が40才になる1ヶ月前である。さらにより
好ましくは、投与開始は、女性が40才になる1年前である。最も好ましくは、
投与開始は、女性が40才になる5年前である。Preferably, administration of the composition begins when the woman is 35 to 50 years old.
More preferably, the administration is started one month before the female becomes 40 years old. Even more preferably, the start of administration is one year before the female is 40 years old. Most preferably,
The administration was started 5 years before the woman was 40 years old.
【0097】
本発明の対象は、閉経期の女性に栄養的補助物を提供する方法を含む。該方法
は、重要な期間中での、本発明の組成物の女性への投与を含む。重要な投与期間
は、閉経の直前に開始して、女性の一生の閉経後期間を通じて継続する期間であ
る。Subjects of the present invention include methods of providing nutritional supplements to menopausal women. The method comprises the administration of the composition of the invention to a woman for a significant period of time. A significant dosing period is the period that begins just before menopause and continues throughout the life-long postmenopausal period of a woman.
【0098】
本発明の対象の方法は、閉経期の女性の脂肪酸欠乏症を予防または少なくとも
最小限にし得る。本発明の方法はまた、閉経に関連した症状の予防または処置に
使用し得る。さらに、本発明の方法は、閉経期の女性の一般的に経験する骨量の
減少を阻害し得る。本発明の方法は、閉経の開始を遅延および/または早期閉経
の可能性を低下し得る。The subject methods of the invention may prevent or at least minimize fatty acid deficiency in menopausal women. The methods of the present invention may also be used for the prevention or treatment of symptoms associated with menopause. Moreover, the methods of the invention may inhibit the bone loss commonly experienced in menopausal women. The methods of the invention may delay the onset of menopause and / or reduce the likelihood of premature menopause.
【0099】
本発明の方法は、単独で、または、治療法または処方計画(これに限定されな
い)と共に実施し得る。治療法または処方計画は、閉経に関連した症状の処置用
であり得るか、または閉経には全く関連していない。例えば、限定されることな
く、本発明の方法は、ホルモンまたはエストロゲン療法の一部として、または、
食事操作と組合せて取込み得る。The methods of the invention may be practiced alone or in conjunction with a treatment regimen or regimen. The therapy or regimen may be for the treatment of symptoms associated with menopause or is not associated with menopause at all. For example, without limitation, the method of the invention may be used as part of a hormone or estrogen therapy, or
It can be incorporated in combination with meal operation.
【0100】
前記は、本発明の対象の原則のみを説明するものと考える。さらに、多くの修
飾および変更を当業者は容易に考えつくので、本発明の対象を、示し記載した正
にその作成および操作に限定することは望まず、従って、本発明の対象の範囲内
に該当する、全ての適切な修飾および均等物を使用し得る。The above is considered as illustrative only of the principles of the present subject matter. Moreover, many modifications and variations will readily occur to those skilled in the art, and it is not intended that the subject matter of the invention be limited to the exact construction and manipulations shown and described, and thus fall within the scope of the subject matter of the invention. All suitable modifications and equivalents can be used.
【0101】
以下の実施例は、本発明の対象の好ましい実施形態の説明であり、本発明の対
象を限定するものとは捉えない。全ての比率は、特記しない限り、調製した最終
送達系または処方の重量比率であり、全ての合計は100重量%に等しい。The following examples are illustrative of preferred embodiments of the subject matter of the invention and are not to be construed as limiting the subject matter of the invention. All ratios are weight ratios of the final delivery system or formulation prepared, unless otherwise stated, all sums equal 100% by weight.
【0102】
(実施例)
[実施例1]
以下の処方を使用して、閉経前および閉経期の女性に投与するための組成物を
調製する。Examples Example 1 The following formulation is used to prepare a composition for administration to pre- and menopausal women.
【0103】[0103]
【表1】
上記の組成物の投与時に、平均の正常な閉経期の女性は、慣用的な栄養的処方
計画後に、平均的な正常な閉経期の女性に比べて、栄養欠乏症の発生率の減少お
よび閉経に関連した症状または疾患の減少が期待される。[Table 1] Upon administration of the above composition, an average normal menopausal woman has a reduced incidence of nutritional deficiency and menopause after a conventional nutritional regimen, compared to an average normal menopausal woman. A reduction in associated symptoms or disease is expected.
【0104】
[実施例2]
以下の組成物は、以下に示した処方計画による、閉経前の女性および閉経期の
女性に投与用である。Example 2 The following composition is for administration to pre-menopausal and menopausal women according to the regimen shown below.
【0105】[0105]
【表2】
上記の処方計画後に、平均的な正常な閉経期の女性は、慣用的な栄養処方計画
後に、平均的な正常な閉経期の女性に比べて、栄養欠乏症の発生率の減少および
閉経に関連した症状または疾患の減少が期待される。[Table 2] After the above regimen, average normal menopausal women were associated with a reduced incidence of nutritional deficiency and menopause compared to average normal menopausal women after a conventional nutritional regimen. Expected to reduce symptoms or disease.
【0106】
[実施例3]
上記の実施例1および2の組成物による軟ゼラチン補充物は、最初に、鉱油お
よび大豆油を、第一容器中で合わせ、それをブレンドして均一な油状混合物を形
成し、油状混合物を摂氏45℃まで加熱し、次いでプロピレングリコールを添加
することにより調製し得る。摂氏70℃まで予め加熱した第二の容器に、黄色の
蜜蝋および大豆油を添加し、均一なワックス混合物が形成されるまでブレンドす
る。ワックス混合物を摂氏35℃まで冷却し、次いで油状混合物に添加する。次
いで、この合わせた油およびワックス混合物に、葉酸、ビタミンB6、鉄、マグ
ネシウム、およびカルシウムを添加し、共にブレンドし、均一な生物学的に活性
な混合物を形成する。次いで、混合物を摂氏30℃まで冷却し、粘性の生物学的
に活性なコア組成物を形成し、その後、組成物を、軟ゼラチンカプセルにカプセ
ル化する準備をする。Example 3 A soft gelatin supplement according to the compositions of Examples 1 and 2 above was prepared by first combining mineral oil and soybean oil in a first container and blending it into a uniform oily mixture. Can be prepared by heating the oily mixture to 45 ° C. and then adding propylene glycol. To a second container preheated to 70 ° C, add the yellow beeswax and soybean oil and blend until a uniform wax mixture is formed. The wax mixture is cooled to 35 ° C and then added to the oily mixture. Then, this combined oil and wax mixture, folic acid, vitamin B 6, was added iron, magnesium, and calcium, blended together to form a uniform biologically active mixture. The mixture is then cooled to 30 ° C. to form a viscous, biologically active core composition, after which the composition is ready for encapsulation in soft gelatin capsules.
【0107】
軟ゼラチン殻は、精製水を適切な容器中で加熱し、次いでゼラチンを添加する
ことにより調製する。この水ゼラチン混合物を、ゼラチンが完全に溶けるまで混
合し、次いで、保存剤のグリセリン、1つ以上の香味剤、および1つ以上の着色
剤を添加する。このゼラチン混合物をよくブレンドし、冷却する。次いで、殻を
コア組成物で充填し、一般的に使用され、当業者に公知の軟ゼラチンカプセル技
術に従って形成する。Soft gelatin shells are prepared by heating purified water in a suitable container and then adding the gelatin. The water gelatin mixture is mixed until the gelatin is completely dissolved, then the preservative glycerin, one or more flavoring agents, and one or more colorants are added. The gelatin mixture is blended well and cooled. The shell is then filled with the core composition and formed according to commonly used soft gelatin capsule techniques known to those skilled in the art.
【0108】
[実施例4]
以下の組成物は、以下に示した処方計画による、閉経前の女性および閉経期の
女性への投与用である。Example 4 The following composition is for administration to pre-menopausal and menopausal women according to the regimen shown below.
【0109】[0109]
【表3】
上記の処方計画後に、平均的な正常な閉経期の女性は、慣用的な栄養処方計画
後に、平均的な正常な閉経期の女性に比べて、栄養欠乏症の発生率の減少および
閉経に関連した症状または疾患の減少が期待される。[Table 3] After the above regimen, average normal menopausal women were associated with a reduced incidence of nutritional deficiency and menopause compared to average normal menopausal women after a conventional nutritional regimen. Expected to reduce symptoms or disease.
【0110】
[実施例5]
以下の組成物は、以下に示した処方計画による、閉経前の女性および閉経期の
女性への投与用である。Example 5 The following composition is for administration to pre-menopausal and menopausal women according to the regimen shown below.
【0111】[0111]
【表4】
上記の処方計画後に、平均的な正常な閉経期の女性は、慣用的な栄養処方計画
後に、平均的な正常な閉経期の女性に比べて、栄養欠乏症の発生率の減少および
閉経に関連した症状または疾患の減少が期待される。[Table 4] After the above regimen, average normal menopausal women were associated with a reduced incidence of nutritional deficiency and menopause compared to average normal menopausal women after a conventional nutritional regimen. Expected to reduce symptoms or disease.
【0112】
本発明の対象をかくして記載したが、同じことを多くの様式で変化させ得るこ
とは明らかであろう。前記の変化は、本発明の対象の精神および範囲からの逸脱
とは捉えず、全てのこのような修飾は、添付の特許請求の範囲内であるものとす
る。Having thus described the subject of the invention, it will be clear that the same can be varied in many ways. Such changes are not intended to depart from the spirit and scope of the subject matter of the invention, and all such modifications are intended to be within the scope of the appended claims.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 FI テーマコート゛(参考) A61K 31/07 A61K 31/07 31/138 31/138 31/194 31/194 31/198 31/198 31/202 31/202 31/355 31/355 31/375 31/375 31/4168 31/4168 31/4415 31/4415 31/51 31/51 31/525 31/525 31/565 31/565 31/566 31/566 31/567 31/567 31/57 31/57 31/59 31/59 31/616 31/616 31/663 31/663 31/714 31/714 33/04 33/04 33/06 33/06 33/10 33/10 33/18 33/18 33/24 33/24 33/26 33/26 33/30 33/30 33/32 33/32 33/34 33/34 35/32 35/32 35/56 35/56 38/23 A61P 1/08 A61P 1/08 1/10 1/10 1/12 1/12 5/30 5/30 5/34 5/34 9/00 9/00 15/12 15/12 19/02 19/02 21/00 21/00 25/02 101 25/02 101 25/20 25/20 25/22 25/22 25/24 25/24 29/02 29/02 A61K 37/30 (81)指定国 EP(AT,BE,CH,CY, DE,DK,ES,FI,FR,GB,GR,IE,I T,LU,MC,NL,PT,SE),OA(BF,BJ ,CF,CG,CI,CM,GA,GN,GW,ML, MR,NE,SN,TD,TG),AP(GH,GM,K E,LS,MW,MZ,SD,SL,SZ,TZ,UG ,ZW),EA(AM,AZ,BY,KG,KZ,MD, RU,TJ,TM),AE,AG,AL,AM,AT, AU,AZ,BA,BB,BG,BR,BY,BZ,C A,CH,CN,CR,CU,CZ,DE,DK,DM ,DZ,EE,ES,FI,GB,GD,GE,GH, GM,HR,HU,ID,IL,IN,IS,JP,K E,KG,KP,KR,KZ,LC,LK,LR,LS ,LT,LU,LV,MA,MD,MG,MK,MN, MW,MX,MZ,NO,NZ,PL,PT,RO,R U,SD,SE,SG,SI,SK,SL,TJ,TM ,TR,TT,TZ,UA,UG,UZ,VN,YU, ZA,ZW (72)発明者 キルシュナー、 ミッチェル アイ. アメリカ合衆国 ミズーリ州 63130 セ ントルイス クレヴェリング ドライブ 2735 Fターム(参考) 4C076 AA01 AA11 AA17 AA25 AA26 AA30 AA37 AA43 AA44 AA48 AA49 AA51 AA54 AA69 AA72 BB02 BB22 BB25 BB27 BB29 BB31 BB32 CC01 CC09 CC11 CC17 CC22 CC29 CC40 FF31 FF33 FF66 FF68 4C084 AA02 AA03 DB31 MA13 MA17 MA22 MA23 MA31 MA32 MA34 MA35 MA36 MA41 MA43 MA47 MA52 MA57 MA59 MA60 MA63 MA67 NA12 NA14 ZA082 ZA212 ZA302 ZA362 ZA662 ZA722 ZA812 ZC112 ZC232 ZC242 ZC282 ZC292 ZC512 4C086 AA01 AA02 BA09 BA18 BC18 BC38 BC83 CB09 DA09 DA10 DA17 DA34 DA39 HA01 HA03 HA04 HA08 HA09 HA11 HA16 HA20 HA27 MA03 MA04 MA17 MA22 MA23 MA31 MA32 MA35 MA37 MA41 MA43 MA47 MA56 MA57 MA59 MA60 MA66 MA67 NA06 ZA08 ZA14 ZA21 ZA36 ZA66 ZA72 ZA73 ZC11 ZC12 ZC23 ZC24 ZC25 ZC26 ZC28 ZC51 4C087 AA02 BB46 MA02 MA13 MA22 MA23 MA28 MA32 MA35 MA41 MA43 MA47 MA56 MA57 MA59 MA60 MA63 MA67 NA06 NA14 ZA05 ZA08 ZA12 ZA14 ZA21 ZA30 ZA36 ZA66 ZA71 ZA73 ZA97 ZC11 ZC21 ZC23 ZC26 ZC28 ZC51 4C206 AA01 DA04 DA05 MA03 MA14 MA17 MA21 MA22 MA33 MA42 MA51 MA56 MA57 MA67 MA72 MA76 MA77 MA83 NA06 ZA02 ZA08 ZA14 ZA36 ZA71 ZC11 ZC21 ZC24 ZC28 ZC51 ─────────────────────────────────────────────────── ─── Continuation of front page (51) Int.Cl. 7 Identification code FI theme code (reference) A61K 31/07 A61K 31/07 31/138 31/138 31/194 31/194 31/198 31/198 31 / 202 31/202 31/355 31/355 31/375 31/375 31/4168 31/4168 31/4415 31/4415 31/51 31/51 31/525 31/525 31/565 31/565 31/566 31/566 31/567 31/567 31/57 31/57 31/59 31/59 31/616 31/616 31/663 31/663 31/714 31/714 33/04 33/04 33/06 33 / 06 33/10 33/10 33/18 33/18 33/24 33/24 33/26 33/26 33/30 33/30 33/32 33/32 33/34 33/34 35/32 35/32 35 / 56 35/56 38/23 A61P 1/08 A61P 1/08 1/10 1/10 1/12 1/12 5/30 5/30 5/34 5/34 9/00 9/00 15/12 15 / 12 19/02 19/02 21/00 21/00 25/02 101 25/02 101 25/20 25/20 25/22 25/22 25/24 25/24 29/02 29/02 A61K 37/30 (81) Designated countries EP (AT, BE, CH, CY, DE, DK, ES, FI, F R, GB, GR, IE, IT, LU, MC, NL, PT, SE), OA (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG), AP (GH, GM, K E, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), EA (AM, AZ, BY, KG, KZ, MD, RU, TJ , TM), AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ. , EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, T, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW (72) Inventor Kirschner, Mitchell Eye. United States Missouri 63130 cell Ntoruisu Kureveringu drive 2735 F-term (reference) 4C076 AA01 AA11 AA17 AA25 AA26 AA30 AA37 AA43 AA44 AA48 AA49 AA51 AA54 AA69 AA72 BB02 BB22 BB25 BB27 BB29 BB31 BB32 CC01 CC09 CC11 CC17 CC22 CC29 CC40 FF31 FF33 FF66 FF68 4C084 AA02 AA03 DB31 MA13 MA17 MA22 MA23 MA31 MA32 MA34 MA35 MA36 MA41 MA43 MA47 MA52 MA57 MA59 MA60 MA63 MA67 NA12 NA14 ZA082 ZA212 ZA302 ZA362 ZA662 ZA722 ZA812 ZC112 ZC232 ZC242 ZC282 ZC292 ZC512 4C086 AA83 BC01BAA18 BC01BAA02 BC01 HA03 HA04 HA08 HA09 HA11 HA16 HA20 HA27 MA03 MA04 MA17 MA22 MA23 MA31 MA32 MA35 MA37 MA41 MA43 MA47 MA56 MA57 MA59 MA60 MA66 MA67 NA06 ZA08 ZA14 ZA21 ZA36 ZA66 ZA72 ZA73 ZC11 ZC12 ZC26 ZC12 ZC26 ZC28 Z51 MA32 MA35 MA41 MA43 MA47 MA56 MA57 MA59 MA60 MA63 MA67 NA06 NA14 ZA05 ZA08 ZA12 ZA14 ZA21 ZA30 ZA36 ZA66 ZA71 ZA73 ZA97 ZC11 ZC21 ZC23 ZC26 ZC28 ZC51 4C206 AA01 DA04 DA05 MA03 MA14 MA17 MA21 MA22 MA33 MA42 MA51 MA56 MA57 MA67 MA72 MA76 MA77 MA83 NA06 ZA02 ZA08 ZA14 ZA36 ZA71 ZC11 ZC21 ZC24 ZC28 ZC51
Claims (101)
、約10mgから約1,000mgの量の、リノール酸化合物、リノレン酸化合
物、ドコサヘキサエン酸化合物、ω−3脂肪酸化合物、ω−2脂肪酸化合物、そ
の誘導体および組合せからなる群から選択される必須脂肪酸化合物; 約400mgから約2500mgの量のカルシウム化合物またはその誘導体; 約0.4mgから約5.0mgの量の葉酸化合物またはその誘導体を含み、こ
こで、必須脂肪酸化合物と、カルシウム化合物またはその誘導体の重量比は、約
1:0.4から250である、前記組成物。1. A composition for administration to pre- and post-menopausal women, wherein the amount of linoleic acid compound, linolenic acid compound, docosahexaenoic acid compound, ω-3 fatty acid is about 10 mg to about 1,000 mg. An essential fatty acid compound selected from the group consisting of compounds, omega-2 fatty acid compounds, derivatives and combinations thereof; calcium compounds or derivatives thereof in an amount of about 400 mg to about 2500 mg; folic acid in an amount of about 0.4 mg to about 5.0 mg. The composition comprising a compound or a derivative thereof, wherein the weight ratio of the essential fatty acid compound to the calcium compound or a derivative thereof is about 1: 0.4 to 250.
およびその組合せからなる群から選択される、請求項1に記載の組成物。2. The composition of claim 1, wherein the calcium compound is selected from the group consisting of calcium carbonate, calcium citrate and combinations thereof.
らなる群から選択される、請求項1に記載の組成物。3. The composition of claim 1, wherein the calcium compound is selected from the group consisting of bone meal, oyster shells and combinations thereof.
の組成物。4. The composition of claim 1, wherein the calcium compound is calcium carbonate.
の量で前記組成物中に存在する、請求項4に記載の組成物。5. Calcium carbonate is about 1,000 mg to about 1,400 mg
The composition of claim 4, which is present in the composition in an amount of.
記組成物中に存在する、請求項1に記載の組成物。6. The composition of claim 1, wherein the essential fatty acid compound is present in the composition in an amount of about 10 mg to about 100 mg.
組成物中に存在する、請求項1に記載の組成物。7. The composition of claim 1, wherein the essential fatty acid compound is present in the composition in an amount of about 20 mg to about 60 mg.
量比は、約1:1から20である、請求項1に記載の組成物。8. The composition according to claim 1, wherein the weight ratio of the essential fatty acid compound to the calcium compound or its derivative is about 1: 1 to 20.
量比は、約1:5から15である、請求項1に記載の組成物。9. The composition according to claim 1, wherein the weight ratio of the essential fatty acid compound to the calcium compound or its derivative is about 1: 5 to 15.
含む、請求項1に記載の組成物。10. The composition of claim 1, wherein the composition further comprises a vitamin compound or derivative thereof.
合物、ビタミンC化合物、ビタミンD化合物、ビタミンE化合物、その誘導体お
よびその組合せからなる群から選択される、請求項10に記載の組成物。11. The composition according to claim 10, wherein the vitamin compound is selected from the group consisting of vitamin A compound, B complex vitamin compound, vitamin C compound, vitamin D compound, vitamin E compound, derivatives thereof and combinations thereof. object.
範囲の量で前記組成物中に存在する、請求項11に記載の組成物。12. The composition of claim 11, wherein the Vitamin C compound is present in the composition in an amount ranging from about 25 mg to about 500 mg.
範囲の量で前記組成物中に存在する、請求項11に記載の組成物。13. The composition of claim 11, wherein the Vitamin E compound is present in the composition in an amount ranging from about 10 mg to about 500 mg.
含む、請求項1に記載の組成物。14. The composition of claim 1, wherein the composition further comprises a mineral compound or derivative thereof.
、モリブデン、バイオフラボノイド、マンガン、クロム、ヨウ素、鉄およびその
組合せからなる群から選択される、請求項14に記載の組成物。15. The composition of claim 14, wherein the mineral compound is selected from the group consisting of copper, zinc, selenium, magnesium, molybdenum, bioflavonoids, manganese, chromium, iodine, iron and combinations thereof.
記載の組成物。16. The composition of claim 1, wherein the composition further comprises a non-nutritionally active substance.
ロゲン、黄体ホルモン、鎮静催眠剤、バルビツール酸類、ベンゾジアゼピン類、
抗うつ剤、精神安定剤、鎮静剤、骨粗鬆症剤、生薬、生薬誘導体、植物化学誘導
体、抗血小板剤、アミノビスホスホネートおよびその組合せからなる群から選択
される、請求項16に記載の組成物。17. The non-nutritional active substance is a hormone, steroid, fiber, estrogen, progesterone, sedative hypnotic, barbituric acid, benzodiazepines,
The composition according to claim 16, which is selected from the group consisting of antidepressants, tranquilizers, sedatives, osteoporosis agents, crude drugs, crude drug derivatives, phytochemical derivatives, antiplatelet agents, aminobisphosphonates and combinations thereof.
mgから約11.25mgの範囲の量で前記組成物中に存在する、請求項16に
記載の組成物。18. The non-nutritional active substance is a hormone, and the hormone is about 0.15.
17. The composition of claim 16, which is present in the composition in an amount ranging from mg to about 11.25 mg.
メゲストロール、クロニジン、酢酸ノルエチンドロン、エチニルエストラジオー
ル、複合型エストロゲン、天然エストロゲン、合成エストロゲン、エストラジオ
ール、プロゲステロン、クロミフェン、クエン酸クロミフェン、ズクロミフェン
、クエン酸ズクロミフェン、エンクロミフェン、クエン酸エンクロミフェン、カ
ルシトニン、アスピリン、アレンドロネート、エチドロネート、パミドロネート
、クロドロネート、チルドロネート、レジドロネート、イバドロネートおよびそ
の組合せからなる群から選択される、請求項16に記載の組成物。19. The non-nutritionally active substance is medroxyprogesterone acetate, megestrol acetate, clonidine, norethindrone acetate, ethinyl estradiol, complex estrogen, natural estrogen, synthetic estrogen, estradiol, progesterone, clomiphene, clomiphene citrate, and zu. 17. The composition of claim 16 selected from the group consisting of clomiphene, zuclomiphene citrate, enclomiphene, enclomiphene citrate, calcitonin, aspirin, alendronate, etidronate, pamidronate, clodronate, tiludronate, ledronate, ibadronate and combinations thereof. Composition.
.5mgから約60mgの範囲の量で前記組成物中に存在する、請求項16に記
載の組成物。20. The non-nutritional active substance is an osteoporosis agent, and the osteoporosis agent is about 2
. 17. The composition of claim 16, which is present in the composition in an amount ranging from 5 mg to about 60 mg.
、請求項1に記載の組成物。21. The composition according to claim 1, further comprising an amino acid compound or a derivative thereof.
びその組合せからなる群から選択される、請求項21に記載の組成物。22. The composition of claim 21, wherein the amino acid compound is selected from the group consisting of leucine, isoleucine, valine and combinations thereof.
に適合している、請求項1に記載の組成物。23. The composition of claim 1, wherein the composition is specifically adapted to meet the nutritional needs of menopausal women.
、請求項1に記載の組成物。24. The composition of claim 1, wherein the composition is particularly adapted for the treatment of conditions associated with menopause.
適合している、請求項1に記載の組成物。25. The composition of claim 1, wherein the composition is particularly adapted to maximize neurological maintenance in the woman.
動放出、遅延放出、制御放出およびその組合せからなる群から選択される、請求
項26に記載の組成物。27. The composition of claim 26, wherein the oral dosage form is selected from the group consisting of immediate release, extended release, intermittent release, modified release, delayed release, controlled release and combinations thereof.
チンカプセル、軟ゼラチンカプセル、復元可能な粒子、微粒子、懸濁液、エリキ
シル、キャプレット、強化食品、プリン、ヨーグルト、ゼラチン、シリアル、食
物コーティングおよびその組合せからなる群から選択される、請求項26に記載
の組成物。28. The oral dosage form includes chewable tablets, quick-dissolving tablets, effervescent tablets, hard gelatin capsules, soft gelatin capsules, restorable particles, microparticles, suspensions, elixirs, caplets, fortified foods, puddings, 27. The composition of claim 26, selected from the group consisting of yogurt, gelatin, cereals, food coatings and combinations thereof.
の組成物。29. The composition of claim 1, wherein the composition is formulated in a single dosage unit.
組成物。30. The composition of claim 1, wherein the composition is formulated in multiple dosage units.
その誘導体を含む、請求項30に記載の組成物。31. The composition of claim 30, wherein the multi-dosage unit comprises a non-uniform dose of a calcium compound or derivative thereof.
される、請求項1に記載の組成物。32. The composition of claim 1, wherein the composition is formulated for single administration during a 24 hour period.
めに製剤化される、請求項1に記載の組成物。33. The composition of claim 1, wherein the composition is formulated for at least two administrations during a 24 hour period.
1に記載の組成物。34. The composition of claim 1, wherein the composition comprises instructions indicating the period of use.
に記載の組成物。35. The trial period is before, during and after menopause.
The composition according to.
物。36. The composition of claim 34, wherein the period begins at the onset of menopause.
34に記載の組成物。37. The composition of claim 34, wherein the period begins at the onset of menopause and continues for the duration of menopause.
る、請求項34に記載の組成物。38. The composition of claim 34, wherein the period of time begins when the woman is at least 40 years old.
する、請求項34に記載の組成物。39. The composition of claim 34, wherein the period of use begins when the woman is 40 to 50 years old.
gから約1,000mgの量のリノール酸化合物、その誘導体およびその組合せ
からなる群から選択された第一脂肪酸化合物; 約10mgから約1,000mgの量のリノレン酸化合物、その誘導体および
その組合せからなる群から選択された第二脂肪酸化合物; 約10mgから約1,000mgの量のドコサヘキサエン酸化合物、ω−3脂
肪酸、ω−2脂肪酸、その誘導体およびその組合せからなる群から選択された第
三脂肪酸化合物; 約400mgから約2500mgの量のカルシウム化合物またはその誘導体; 約0.4mgから約5.0mgの量の葉酸化合物またはその誘導体; 約25mgから約500mgの量のビタミンC化合物またはその誘導体; 約10mgから約500mgの量のビタミンE化合物またはその誘導体を含み
、前記第一および第二脂肪酸化合物の量の合計と、前記第三脂肪酸化合物の量の
重量比は、約1:0.5から1.5であり;そして 前記第一、第二および第三脂肪酸化合物の量の合計と、前記カルシウム化合物
またはその誘導体の量の重量比は、約1:0.4から50である、前記組成物。40. A composition for administration to a menopausal woman, the composition being about 10 m
a first fatty acid compound selected from the group consisting of g to about 1,000 mg of linoleic acid compound, its derivatives and combinations thereof; from about 10 mg to about 1,000 mg of linolenic acid compound, its derivatives and combinations thereof A second fatty acid compound selected from the group consisting of: a docosahexaenoic acid compound, an omega-3 fatty acid, an omega-2 fatty acid, a derivative thereof and a combination thereof in an amount of about 10 mg to about 1,000 mg; A calcium compound or derivative thereof in an amount of about 400 mg to about 2500 mg; a folic acid compound or derivative thereof in an amount of about 0.4 mg to about 5.0 mg; a vitamin C compound or derivative thereof in an amount of about 25 mg to about 500 mg; Comprising a vitamin E compound or derivative thereof in an amount of 10 mg to about 500 mg, The weight ratio of the sum of the amounts of the first and second fatty acid compounds to the amount of the third fatty acid compounds is about 1: 0.5 to 1.5; and the first, second and third fatty acids. The composition wherein the weight ratio of the total amount of the compound to the amount of the calcium compound or its derivative is about 1: 0.4 to 50.
に記載の組成物。41. The composition of claim 40, further comprising a non-nutritionally active substance.
The composition according to.
ロゲン、黄体ホルモン、鎮静催眠剤、バルビツール酸類、ベンゾジアゼピン類、
抗うつ剤、精神安定剤、鎮静剤、アミノビスホスホネート、骨粗鬆症剤、生薬、
生薬誘導体、植物化学誘導体、抗血小板剤およびその組合せからなる群から選択
される、請求項41に記載の組成物。42. The non-nutritional active substance is a hormone, steroid, fiber, estrogen, progesterone, sedative hypnotic, barbituric acid, benzodiazepines,
Antidepressant, tranquilizer, sedative, aminobisphosphonate, osteoporosis agent, crude drug,
42. The composition of claim 41, selected from the group consisting of galenical derivatives, phytochemical derivatives, antiplatelet agents and combinations thereof.
5mgから約11.25mgの範囲の量で前記組成物中に存在する、請求項41
に記載の組成物。43. The non-nutritional active substance is a hormone, and the hormone is about 0.1.
42. Present in the composition in an amount in the range of 5 mg to about 11.25 mg.
The composition according to.
メゲストロール、クロニジン、酢酸ノルエチンドロン、エチニルエストラジオー
ル、複合型エストロゲン、天然エストロゲン、合成エストロゲン、エストラジオ
ール、プロゲステロン、クロミフェン、クエン酸クロミフェン、ズクロミフェン
、クエン酸ズクロミフェン、エンクロミフェン、クエン酸エンクロミフェン、カ
ルシトニン、アスピリン、アレンドロネート、エチドロネート、パミドロネート
、クロドロネート、チルドロネート、レジドロネート、イバドロネートおよびそ
の組合せからなる群から選択される、請求項41に記載の組成物。44. The non-nutritionally active substance is medroxyprogesterone acetate, megestrol acetate, clonidine, norethindrone acetate, ethinyl estradiol, complex estrogen, natural estrogen, synthetic estrogen, estradiol, progesterone, clomiphene, clomiphene citrate, and zu. 42. The method of claim 41, selected from the group consisting of clomiphene, zuclomiphene citrate, enclomiphene, enclomiphene citrate, calcitonin, aspirin, alendronate, etidronate, pamidronate, clodronate, tiludronate, ledronate, ibadronate and combinations thereof. Composition.
5mgから約60mgの範囲の量で前記組成物中に存在する、請求項41に記載
の組成物。45. The non-nutritional active substance is an osteoporosis agent, and the osteoporosis agent is about 2.
42. The composition of claim 41, which is present in the composition in an amount ranging from 5 mg to about 60 mg.
、請求項40に記載の組成物。46. The composition of claim 40, further comprising an amino acid compound or derivative thereof.
びその組合せからなる群から選択される、請求項46に記載の組成物。47. The composition of claim 46, wherein the amino acid compound is selected from the group consisting of leucine, isoleucine, valine and combinations thereof.
に適合している、請求項40に記載の組成物。48. The composition of claim 40, wherein the composition is specifically adapted to meet the nutritional needs of menopausal women.
gから約1,000mgの量のリノール酸化合物、その誘導体およびその組合せ
からなる群から選択される第一脂肪酸化合物; 約10mgから約1,000mgの量のリノレン酸化合物、その誘導体および
その組合せからなる群から選択される第二脂肪酸化合物; 約10mgから約1,000mgの量のドコサヘキサエン酸化合物、ω−3脂
肪酸、ω−2脂肪酸、その誘導体およびその組合せからなる群から選択される第
三脂肪酸化合物; 約400mgから約2500mgの量のカルシウム化合物またはその誘導体; 約0.4mgから約5.0mgの量の葉酸化合物またはその誘導体; 約25mgから約500mgの量のビタミンC化合物またはその誘導体; 約10mgから約500mgの量のビタミンE化合物またはその誘導体; 約2,500IUから約6,500IUの量のビタミンA化合物またはその誘
導体を含み、前記第一および第二脂肪酸化合物の量の合計と、前記第三脂肪酸化
合物の量の重量比は、約1:0.5から1.5であり;そして 前記第一、第二および第三脂肪酸化合物の合計と、前記カルシウム化合物また
はその誘導体の量の重量比は、約1:0.4から50である、前記組成物。49. A composition for administration to a menopausal woman having a dose of about 10 m
a first fatty acid compound selected from the group consisting of g to about 1,000 mg of linoleic acid compound, its derivatives and combinations thereof; from about 10 mg to about 1,000 mg of linolenic acid compound, its derivatives and combinations thereof A second fatty acid compound selected from the group consisting of: a docosahexaenoic acid compound, an ω-3 fatty acid, an ω-2 fatty acid, a derivative thereof, and a combination thereof in an amount of about 10 mg to about 1,000 mg; A calcium compound or derivative thereof in an amount of about 400 mg to about 2500 mg; a folic acid compound or derivative thereof in an amount of about 0.4 mg to about 5.0 mg; a vitamin C compound or derivative thereof in an amount of about 25 mg to about 500 mg; Vitamin E compound or derivative thereof in an amount of 10 mg to about 500 mg; about 2 A vitamin A compound or derivative thereof in an amount of 500 IU to about 6,500 IU, wherein the weight ratio of the total amount of the first and second fatty acid compounds to the amount of the third fatty acid compound is about 1: 0.5. To 1.5; and the weight ratio of the sum of the first, second and third fatty acid compounds to the amount of the calcium compound or derivative thereof is about 1: 0.4 to 50. .
gから約1,000mgの量のリノール酸化合物、その誘導体およびその組合せ
からなる群から選択される第一脂肪酸化合物; 約10mgから約1,000mgの量のリノレン酸化合物、その誘導体および
その組合せからなる群から選択される第二脂肪酸化合物; 約10mgから約1,000mgの量のドコサヘキサンエン酸化合物、ω−3
脂肪酸、ω−2脂肪酸、その誘導体およびその組合せからなる群から選択される
第三脂肪酸化合物; 約400mgから約2500mgの量のカルシウム化合物またはその誘導体; 約0.4mgから約5.0mgの量の葉酸化合物またはその誘導体; 約25mgから約500mgの量のビタミンC化合物またはそのエステル誘導
体; 約10mgから約500mgの量のビタミンE化合物またはその誘導体; 約10mgから約50mgの量のビタミンB6化合物またはその誘導体; 約25mcgから約75mcgの量のビタミンB12化合物またはその誘導体
; 約200IUから約625IUの量のビタミンD化合物またはその誘導体を含
み、 前記の第一および第二脂肪酸化合物の量の合計と、前記第三脂肪酸化合物の量
の重量比は、約1:0.5から1.5であり;そして 前記の第一、第二および第三脂肪酸化合物の量の合計と、前記カルシウム化合
物またはその誘導体の量の重量比は、約1:0.4から50である、前記組成物
。50. A composition for administration to a menopausal woman, wherein the composition is about 10 m.
a first fatty acid compound selected from the group consisting of g to about 1,000 mg of linoleic acid compound, its derivatives and combinations thereof; from about 10 mg to about 1,000 mg of linolenic acid compound, its derivatives and combinations thereof A second fatty acid compound selected from the group consisting of: docosahexaneenoic acid compound in an amount of about 10 mg to about 1,000 mg, ω-3
A tertiary fatty acid compound selected from the group consisting of fatty acids, ω-2 fatty acids, derivatives and combinations thereof; calcium compounds or derivatives thereof in an amount of about 400 mg to about 2500 mg; and amounts of about 0.4 mg to about 5.0 mg. Folic acid compound or derivative thereof; Vitamin C compound or ester derivative thereof in amount of about 25 mg to about 500 mg; Vitamin E compound or derivative thereof in amount of about 10 mg to about 500 mg; Vitamin B6 compound or amount thereof in amount of about 10 mg to about 50 mg A derivative; a vitamin B12 compound or derivative thereof in an amount of about 25 mcg to about 75 mcg; a vitamin D compound or derivative thereof in an amount of about 200 IU to about 625 IU, the sum of the amounts of the first and second fatty acid compounds, and The weight ratio of the amount of the tertiary fatty acid compound is about 1: 0.5 to 1.5; and the weight ratio of the sum of the amounts of the first, second and third fatty acid compounds to the amount of the calcium compound or its derivative is about 1: 0.4 to 50. The above composition.
記組成物。51. A composition for administration to a menopausal woman comprising a bioactive agent for treating menopausal symptoms; a calcium compound or derivative thereof in an amount of about 400 mg to about 2500 mg; from about 0.4 mg. The composition comprising a folic acid compound or derivative thereof in an amount of about 5.0 mg.
ゲン、黄体ホルモン、鎮静催眠剤、バルビツール酸、ベンゾジアゼピン、抗うつ
剤、精神安定剤、鎮静剤、骨粗鬆症剤、抗血小板剤およびその組合せからなる群
から選択される、請求項51に記載の組成物。52. The bioactive substance is a hormone, steroid, fiber, estrogen, luteinizing hormone, sedative hypnotic, barbituric acid, benzodiazepine, antidepressant, tranquilizer, sedative, osteoporosis, antiplatelet agent, and the like. 52. The composition of claim 51, selected from the group consisting of combinations.
メゲストロール、クロニジン、酢酸ノルエチンドロン、エチニルエストラジオー
ル、複合型エストロゲン、天然エストロゲン、合成エストロゲン、エストラジオ
ール、プロゲステロン、クロミフェン、クエン酸クロミフェン、ズクロミフェン
、クエン酸ズクロミフェン、エンクロミフェン、クエン酸エンクロミフェン、カ
ルシトニン、アスピリン、アミノビスホスホネート、生薬、生薬誘導体、植物化
学誘導体、アレンドロネート、エチドロネート、パミドロネート、クロドロネー
ト、チルドロネート、レジドロネート、イバンドロネートおよびその組合せから
なる群から選択される、請求項51に記載の組成物。53. The non-nutritional active substance is medroxyprogesterone acetate, megestrol acetate, clonidine, norethindrone acetate, ethinyl estradiol, complex estrogen, natural estrogen, synthetic estrogen, estradiol, progesterone, clomiphene, clomiphene citrate, and zu. Clomiphene, duclomifen citrate, enclomiphene, enclomiphene citrate, calcitonin, aspirin, aminobisphosphonates, herbal medicines, herbal medicine derivatives, phytochemical derivatives, alendronate, etidronate, pamidronate, clodronate, tiludronate, ledronate, ibandronate and its 52. The composition of claim 51, selected from the group consisting of combinations.
を含む、第一投与形; 前記の第一投与形と同時に閉経期の女性に投与する、第二生物活性物質を含む
第二投与形を含み、前記の第一生物活性物質および前記の第二生物活性物質は非
適合性の物質である、薬物送達処方計画。54. A first dosage form, comprising a first bioactive substance, administered to a menopausal woman for a predetermined period of time; a second bioactivity, which is administered to a menopausal woman at the same time as said first dosage form. A drug delivery regimen comprising a second dosage form comprising a substance, said first bioactive substance and said second bioactive substance being incompatible substances.
剤である、請求項54に記載の薬物送達処方計画。55. The drug delivery regimen of claim 54, wherein the first dosage form is a soft gelatin capsule and the second dosage form is a tablet.
した症状の処置に効果的である、請求項54に記載の薬物送達処方計画。56. The drug delivery regimen of claim 54, wherein the first bioactive agent or second bioactive agent is effective in treating a condition associated with menopause.
合物、リノレン酸化合物、ドコサヘキサエン酸化合物、ω−2脂肪酸化合物、ω
−3脂肪酸化合物、ビタミンA化合物、B複合ビタミン化合物、ビタミンC化合
物、ビタミンD化合物、ビタミンE化合物、ホルモン、ステロイド、繊維、エス
トロゲン、黄体ホルモン、鎮静催眠剤、バルビツール酸、ベンゾジアゼピン、抗
うつ剤、精神安定剤、鎮静剤、骨粗鬆症剤、抗血小板剤、その誘導体およびその
組合せからなる群から選択される、請求項54に記載の薬物送達処方計画。57. The first and second bioactive substances are independently linoleic acid compounds, linolenic acid compounds, docosahexaenoic acid compounds, ω-2 fatty acid compounds, ω
-3 fatty acid compound, vitamin A compound, B complex vitamin compound, vitamin C compound, vitamin D compound, vitamin E compound, hormone, steroid, fiber, estrogen, progesterone, sedative hypnotic, barbituric acid, benzodiazepine, antidepressant 55. The drug delivery regimen of claim 54, selected from the group consisting of: tranquilizers, sedatives, osteoporosis agents, antiplatelet agents, derivatives thereof and combinations thereof.
pH感受性化合物、無水環境を必要とする物質、酸性薬物、発泡錠、ゼラチンカ
プセル、4級アンモニウム化合物およびその組合せからなる群から選択され、第
二生物活性物質は、親水性化合物、非オレフィン化合物、非pH感受性化合物、
非無水環境を必要とする物質、塩基性薬物、水分含量の高い薬物または投与形、
アルデヒド、アニオン性物質およびその組合せからなる群から選択される、請求
項54に記載の薬物送達処方計画。58. The first bioactive substance is a hydrophobic compound, an olefin compound,
selected from the group consisting of pH-sensitive compounds, substances requiring an anhydrous environment, acidic drugs, effervescent tablets, gelatin capsules, quaternary ammonium compounds and combinations thereof, the second bioactive substance being a hydrophilic compound, a non-olefin compound, Non-pH sensitive compound,
Substances requiring non-anhydrous environment, basic drugs, drugs or dosage forms with high water content,
55. The drug delivery regimen of claim 54 selected from the group consisting of aldehydes, anionics and combinations thereof.
活性炭、ゼラチンカプセル、塩化コニシン、塩化エチルピリジニウムであり、第
二生物活性物質は、水酸化アルミニウム、重炭酸ナトリウム、炭酸ナトリウム、
炭酸カルシウム、硝酸アミル、ホルムアルデヒド、グルタルアルデヒド、石鹸、
エチルピリジニウム、ステアリン酸ナトリウムおよびその組合せである、請求項
54に記載の薬物送達処方計画。59. The first bioactive substance is ascorbic acid, citric acid, folic acid,
Activated carbon, gelatin capsule, conicin chloride, ethylpyridinium chloride, the second bioactive substance is aluminum hydroxide, sodium bicarbonate, sodium carbonate,
Calcium carbonate, amyl nitrate, formaldehyde, glutaraldehyde, soap,
55. The drug delivery regimen of claim 54, which is ethylpyridinium, sodium stearate and combinations thereof.
AMおよびPMからなる群から選択される、請求項54に記載の薬物送達処方計
画。60. The predetermined period includes morning, afternoon, evening, daytime, daytime, night, night,
55. The drug delivery regimen of claim 54, selected from the group consisting of AM and PM.
に提供される、請求項54に記載の薬物送達処方計画。61. The drug delivery regimen of claim 54, wherein the first and second dosage forms are provided together in a blister pack.
投与形をさらに含む、請求項54に記載の薬物送達処方計画。62. The drug delivery regimen of claim 54, further comprising a third dosage form administered to a menopausal woman before or after a predetermined time.
中、昼間、夜、夜間、AMおよびPMからなる群から選択される、請求項62に
記載の薬物送達処方計画。63. The drug delivery according to claim 62, wherein before or after said predetermined time is selected from the group consisting of morning, afternoon, evening, daytime, daytime, night, nighttime, AM and PM. Prescription plan.
ルであり、第二投与形は、実質的に炭酸カルシウムを含む錠剤である、請求項5
4に記載の薬物送達処方計画。64. The first dosage form is a soft gelatin capsule containing the essential fatty acid compound, and the second dosage form is a tablet containing substantially calcium carbonate.
The drug delivery regimen according to 4.
必須脂肪酸化合物を、閉経期前後の開始の始まる期間中に投与し、前記の必須脂
肪酸化合物は、リノール酸化合物、リノレン酸化合物、ドコサヘキサエン酸化合
物、ω−3脂肪酸化合物、ω−2脂肪酸化合物、その誘導体およびその組合せか
らなる群から選択され; 約400mgから約2500mgのカルシウム化合物またはその誘導体を女性
に、閉経期前後の開始の始まる期間中に投与し; 約0.4mgから約5.0mgの葉酸化合物またはその誘導体を女性に、閉経
期前後の開始の始まる期間中に投与することを含み、そして、必須脂肪酸化合物
と、カルシウム化合物またはその誘導体の重量比は、約1:0.4から250で
ある、前記方法。65. A method of providing nutritional support to a menopausal woman, wherein the woman is administered an essential fatty acid compound during the onset of initiation before and after menopause, wherein the essential fatty acid compound is a linoleic acid compound. , A linolenic acid compound, a docosahexaenoic acid compound, an omega-3 fatty acid compound, an omega-2 fatty acid compound, a derivative thereof and a combination thereof; about 400 mg to about 2500 mg of a calcium compound or a derivative thereof for a female, menopause Administering during the onset of pre- and post-menopausal initiation; about 0.4 mg to about 5.0 mg of a folate compound or derivative thereof to a woman during the onset of pre- and post-menopausal, and essential fatty acids. The above method, wherein the weight ratio of the compound to the calcium compound or derivative thereof is about 1: 0.4 to 250.
前記女性に、前記の第一、第二および第三脂肪酸化合物と共に提供することを含
む、請求項65に記載の方法。66. The method further comprises a vitamin compound or derivative thereof,
66. The method of claim 65, comprising providing the woman with the first, second and third fatty acid compounds.
合物、ビタミンC化合物、ビタミンD化合物、ビタミンE化合物、その誘導体お
よびその組合せからなる群から選択される、請求項66に記載の方法。67. The method of claim 66, wherein the vitamin compound is selected from the group consisting of vitamin A compounds, B complex vitamin compounds, vitamin C compounds, vitamin D compounds, vitamin E compounds, derivatives thereof and combinations thereof. .
の量で前記組成物中に存在する、請求項67に記載の方法。68. The method of claim 67, wherein the Vitamin C compound is present in the composition in an amount ranging from about 25 mg to about 500 mg.
の量で前記組成物中に存在する、請求項67に記載の方法。69. The method of claim 67, wherein the Vitamin E compound is present in the composition in an amount ranging from about 10 mg to about 400 mg.
前記女性に、前記の第一、第二および第三脂肪酸化合物と共に提供することを含
む、請求項65に記載の方法。70. The method further comprises a mineral compound or derivative thereof,
66. The method of claim 65, comprising providing the woman with the first, second and third fatty acid compounds.
リブデン、バイオフラボノイド、マンガン、クロム、ヨウ素、鉄およびその組合
せからなる群から選択される、請求項70に記載の方法。71. The method of claim 70, wherein the mineral compound is selected from the group consisting of copper, zinc, selenium, magnesium, molybdenum, bioflavonoids, manganese, chromium, iodine, iron and combinations thereof.
ることを含む、請求項65に記載の方法。72. The method of claim 65, wherein the method further comprises providing the woman with a non-nutritional active.
ロゲン、黄体ホルモン、鎮静催眠剤、バルビツール酸類、ベンゾジアゼピン類、
抗うつ剤、精神安定剤、鎮静剤、アミノビスホスホネート、生薬、生薬誘導体、
植物化学誘導体、骨粗鬆症剤、抗血小板剤およびその組合せからなる群から選択
される、請求項72に記載の方法。73. The non-nutritional active substance is a hormone, steroid, fiber, estrogen, luteinizing hormone, sedative hypnotic, barbituric acid, benzodiazepines,
Antidepressant, tranquilizer, sedative, aminobisphosphonate, crude drug, crude drug derivative,
73. The method of claim 72, selected from the group consisting of phytochemical derivatives, osteoporosis agents, antiplatelet agents and combinations thereof.
メゲストロール、クロニジン、酢酸ノルエチンドロン、エチニルエストラジオー
ル、複合型エストロゲン、天然エストロゲン、合成エストロゲン、エストラジオ
ール、プロゲステロン、クロミフェン、クエン酸クロミフェン、ズクロミフェン
、クエン酸ズクロミフェン、エンクロミフェン、クエン酸エンクロミフェン、ア
スピリン、カルシトニン、アレンドロネート、エチドロネート、パミドロネート
、クロドロネート、チルドロネート、レジドロネート、イバドロネートおよびそ
の組合せからなる群から選択される、請求項73に記載の方法。74. The non-nutritionally active substance is medroxyprogesterone acetate, megestrol acetate, clonidine, norethindrone acetate, ethinyl estradiol, complex estrogen, natural estrogen, synthetic estrogen, estradiol, progesterone, clomiphene, clomiphene citrate, and zu. 74. The method of claim 73 selected from the group consisting of clomiphene, zuclomiphene citrate, enclomiphene, enclomiphene citrate, aspirin, calcitonin, alendronate, etidronate, pamidronate, clodronate, tiludronate, ledronate, ibadronate and combinations thereof. the method of.
特に適合している、請求項65に記載の方法。75. The method of claim 65, wherein the method is specifically adapted to meet the nutritional needs of menopausal women.
る、請求項65に記載の方法。76. The method of claim 65, wherein the method is particularly adapted for treatment of conditions associated with menopause.
に適合している、請求項65に記載の組成物。77. The composition of claim 65, wherein the method is particularly adapted to maximize neurological maintenance in the woman.
る、請求項65に記載の方法。78. The method of claim 65, wherein each first, second and third fatty acid is provided in an oral dosage form.
延放出、制御放出およびその組合せからなる群から選択される、請求項65に記
載の方法。79. The method of claim 65, wherein the oral dosage form is selected from the group consisting of immediate release, extended release, intermittent release, delayed release, controlled release and combinations thereof.
、発泡錠、硬ゼラチンカプセル、軟ゼラチンカプセル、復元可能な粒子、微粒子
、懸濁液、エリキシル、キャプレット、強化食品、プリン、ヨーグルト、ゼラチ
ン、シリアルおよびその組合せからなる群から選択される、請求項65に記載の
方法。80. The oral dosage form includes chewable tablets, fast dissolving tablets, effervescent tablets, hard gelatin capsules, soft gelatin capsules, reconstitutable particles, microparticles, suspensions, elixirs, caplets, fortified foods. 66. The method of claim 65, wherein the method is selected from the group consisting of: pudding, yogurt, gelatin, cereals and combinations thereof.
回投与される、請求項65に記載の方法。81. Each primary, secondary and tertiary fatty acid is 1 during a 24 hour period.
66. The method of claim 65, wherein the method is administered once.
なくとも2回投与される、請求項65に記載の方法。82. The method of claim 65, wherein each first, second and third fatty acid is administered at least twice during a 24 hour period.
均一な投与量で投与される、請求項65に記載の方法。83. The method of claim 65, wherein each first, second and third fatty acid is administered in a non-uniform dose during a 24 hour period.
に1回投与される、請求項65に記載の方法。84. The method of claim 65, wherein the calcium compound or derivative thereof is administered once during a 24 hour period.
に少なくとも2回投与される、請求項65に記載の方法。85. The method of claim 65, wherein the calcium compound or derivative thereof is administered at least twice during a 24 hour period.
に不均一な投与量で投与される、請求項65に記載の方法。86. The method of claim 65, wherein the calcium compound or derivative thereof is administered in a non-uniform dose over a 24-hour period.
方法。87. The method of claim 65, wherein the method inhibits bone loss.
予防する、請求項65に記載の方法。88. The method of claim 65, wherein the method prevents deficiency of essential fatty acids in menopausal women.
合物の投与の期間を示した説明書を備えることを含む、請求項65に記載の方法
。89. The method of claim 65, wherein the method further comprises providing instructions indicating a period of administration of the first, second and third fatty acid compounds.
求項65に記載の方法。90. The method of claim 65, wherein the method further comprises a treatment method or regimen.
するためである、請求項65に記載の方法。91. The method of claim 65, wherein the treatment regimen or regimen is for treating a condition associated with menopause.
らなる群から選択される、投与形態を使用して、閉経期の女性に非栄養活性物質
を投与することをさらに含む、請求項65に記載の方法。92. Administration of a non-nutritional active substance to a post-menopausal woman using a dosage form selected from the group consisting of oral, injection, transdermal, inhalation, buccal, vaginal, urological and anus. 66. The method of claim 65, further comprising.
請求項65に記載の方法。93. The non-nutritional active is provided in a blister pack.
66. The method of claim 65.
助を提供する方法であって、女性に脂肪酸化合物を、閉経期の開始の始まる期間
中に投与し、前記の脂肪酸化合物は、リノール酸化合物、リノレン酸化合物、ド
コサヘキサエン酸化合物、ω−3脂肪酸、ω−2脂肪酸、その誘導体およびその
組合せからなる群から選択され; 約400mgから2500mgのカルシウム化合物またはその誘導体を前記女
性に投与し;そして 非栄養活性物質を前記女性に投与することを含む、前記方法。94. A method of providing nutritional support to a menopausal woman while alleviating symptoms associated with menopause, wherein the fatty acid compound is administered to the woman during the beginning of menopause. The fatty acid compound is selected from the group consisting of linoleic acid compounds, linolenic acid compounds, docosahexaenoic acid compounds, ω-3 fatty acids, ω-2 fatty acids, derivatives and combinations thereof; about 400 mg to 2500 mg of calcium compounds or derivatives thereof. Administering to a female; and administering to said female a non-nutritionally active substance.
助を提供する方法であって、女性に第一脂肪酸化合物を、閉経期の開始の始まる
期間中に投与し、前記の第一脂肪酸化合物は、リノール酸化合物、その誘導体お
よびその組合せからなる群から選択され; 前記女性に第二脂肪酸化合物を、閉経期の開始の始まる期間中に投与し、前記
の第二脂肪酸化合物は、リノレン酸化合物、その誘導体およびその組合せからな
る群から選択され; 前記女性に第三脂肪酸化合物を、閉経期の開始の始まる期間中に投与し、前記
の第三脂肪酸化合物は、ドコサヘキサエン酸化合物、ω−3脂肪酸、ω−2脂肪
酸、その誘導体およびその組合せからなる群から選択され、前記の第三の脂肪酸
化合物は、女性に、前記の第一および第二脂肪酸化合物と共に提供され; 約400mgから2500mgのカルシウム化合物またはその誘導体を前記女
性に投与し; 非栄養活性物質を前記女性に投与することを含み、 ここでの前記の第一および第二脂肪酸化合物の量の合計と、前記の第三脂肪酸
化合物の量の重量比は、約1:0.5から1.5であり;そして ここでの前記の第一、第二および第三脂肪酸化合物の合計と、前記カルシウム
化合物またはその誘導体の量の重量比は、約1:0.4から50である、前記方
法。96. A method of providing nutritional support to a menopausal female while alleviating symptoms associated with menopause, wherein the female is administered a first fatty acid compound during the beginning of the onset of menopause, The first fatty acid compound is selected from the group consisting of linoleic acid compounds, derivatives thereof, and combinations thereof; the female is administered a second fatty acid compound during the beginning of the onset of menopause, and the second fatty acid compound is administered. The compound is selected from the group consisting of linolenic acid compounds, their derivatives and combinations thereof; said woman is administered a tertiary fatty acid compound during the beginning of the onset of menopause, said tertiary fatty acid compound being docosahexaenoic acid. A third fatty acid compound selected from the group consisting of a compound, an omega-3 fatty acid, an omega-2 fatty acid, a derivative thereof and a combination thereof, Administering about 400 mg to 2500 mg of a calcium compound or a derivative thereof to the woman; and administering a non-nutritionally active substance to the woman, wherein the amount of the first and second fatty acid compounds is And a weight ratio of the amount of said tertiary fatty acid compound is about 1: 0.5 to 1.5; and where said sum of said first, second and third fatty acid compounds, The method wherein the weight ratio of the amount of the calcium compound or its derivative is about 1: 0.4 to 50.
ロゲン、黄体ホルモン、鎮静催眠剤、バルビツール酸類、ベンゾジアゼピン類、
抗うつ剤、精神安定剤、鎮静剤、抗リウマチ剤、生薬、生薬誘導体、アミノビス
ホスホネート、植物化学誘導体、骨粗鬆症剤、抗血小板剤およびその組合せから
なる群から選択される、請求項96に記載の方法。97. The non-nutritional active substance is a hormone, steroid, fiber, estrogen, progesterone, sedative hypnotic, barbituric acid, benzodiazepines,
97. The anti-depressant, tranquilizer, sedative, anti-rheumatic drug, herbal medicine, herbal medicine derivative, aminobisphosphonate, phytochemical derivative, osteoporosis agent, anti-platelet agent, or a combination thereof, according to claim 96. Method.
メゲストロール、クロニジン、酢酸ノルエチンドロン、エチニルエストラジオー
ル、複合型エストロゲン、天然エストロゲン、合成エストロゲン、エストラジオ
ール、プロゲステロン、クロミフェン、クエン酸クロミフェン、ズクロミフェン
、クエン酸ズクロミフェン、エンクロミフェン、クエン酸エンクロミフェン、ア
スピリン、カルシトニン、アレンドロネート、エチドロネート、パミドロネート
、クロドロネート、チルドロネート、レジドロネート、イバドロネートおよびそ
の組合せからなる群から選択される、請求項96に記載の方法。98. The non-nutritionally active substance is medroxyprogesterone acetate, megestrol acetate, clonidine, norethindrone acetate, ethinyl estradiol, complex estrogen, natural estrogen, synthetic estrogen, estradiol, progesterone, clomiphene, clomiphene citrate, and zu. Claim 97. The method of claim 96 selected from the group consisting of clomiphene, zuclomiphene citrate, enclomiphene, enclomiphene citrate, aspirin, calcitonin, alendronate, etidronate, pamidronate, clodronate, tiludronate, ledronate, ibadronate and combinations thereof. the method of.
ノール酸化合物、リノレン酸化合物、ドコサヘキサエン酸化合物、ω−3脂肪酸
化合物、ω−2脂肪酸化合物、その誘導体およびその組合せからなる群から選択
され;前記必須脂肪酸は、閉経の開始を遅延するに十分な量で投与する、前記方
法。99. A method of delaying the onset of menopause, which comprises administering an essential fatty acid to a pre-menopausal woman, wherein the fatty acid is a linoleic acid compound, a linolenic acid compound, a docosahexaenoic acid compound, omega. -3 fatty acid compounds, omega-2 fatty acid compounds, derivatives thereof and combinations thereof; said essential fatty acid being administered in an amount sufficient to delay the onset of menopause.
化合物、リノレン酸化合物、ドコサヘキサエン酸化合物、ω−3脂肪酸化合物、
ω−2脂肪酸化合物、その誘導体およびその組合せからなる群から選択され; 前記の必須脂肪酸は、早期閉経の危険性を低下するに十分な量で投与する、前
記方法。100. A method of reducing the likelihood of premature menopause, comprising administering an essential fatty acid to a pre-menopausal woman, wherein the fatty acid is a linoleic acid compound, a linolenic acid compound, a docosahexaenoic acid compound, ω- 3 fatty acid compounds,
selected from the group consisting of omega-2 fatty acid compounds, derivatives thereof and combinations thereof; said essential fatty acid being administered in an amount sufficient to reduce the risk of premature menopause.
方法であって、 閉経前の女性または閉経期の女性に、閉経の症状を処置するための生物活性物
質を投与し; 閉経前の女性または閉経期の女性に、約400mgから約2500mgの量の
カルシウム化合物またはその誘導体を投与し;そして 閉経前の女性または閉経期の女性に、約0.4mgから約5.0mgの量の葉
酸化合物またはその誘導体を投与することを含む、前記方法。101. A method of providing nutritional support to a pre-menopausal woman or a menopausal woman, wherein a pre-menopausal woman or a menopausal woman is administered a bioactive substance for treating symptoms of menopause. Administering a calcium compound or derivative thereof in an amount of about 400 mg to about 2500 mg to a premenopausal or menopausal woman; and from about 0.4 mg to about 5.0 mg to a premenopausal or menopausal woman; Said method comprising administering an amount of a folate compound or derivative thereof.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/409,059 US6479545B1 (en) | 1999-09-30 | 1999-09-30 | Formulation for menopausal women |
US09/409,059 | 1999-09-30 | ||
PCT/US2000/023527 WO2001024772A1 (en) | 1999-09-30 | 2000-08-28 | Formulation for menopausal women |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2003510344A true JP2003510344A (en) | 2003-03-18 |
Family
ID=23618887
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001527771A Pending JP2003510344A (en) | 1999-09-30 | 2000-08-28 | Prescription for menopausal women |
Country Status (14)
Country | Link |
---|---|
US (5) | US6479545B1 (en) |
EP (1) | EP1216024B1 (en) |
JP (1) | JP2003510344A (en) |
KR (1) | KR100831511B1 (en) |
CN (1) | CN1391464A (en) |
AT (1) | ATE357213T1 (en) |
AU (1) | AU778507B2 (en) |
BR (1) | BR0014438A (en) |
CA (2) | CA2645397A1 (en) |
DE (2) | DE60034046T2 (en) |
ES (1) | ES2195798T3 (en) |
MX (1) | MXPA02003101A (en) |
WO (1) | WO2001024772A1 (en) |
ZA (1) | ZA200202633B (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004091641A1 (en) * | 2003-04-11 | 2004-10-28 | Original Image Co., Ltd. | Follicle-stimulating hormone releasing agent |
JP2005075804A (en) * | 2003-09-03 | 2005-03-24 | Toyo Capsule Kk | Medicinal composition including menatetrenone |
JP2007023010A (en) * | 2005-07-19 | 2007-02-01 | Toshiro Azegami | Oral composition for adjusting hormone balance after menopause and for preventing and improving parkinson disease |
JP2008525441A (en) * | 2004-12-22 | 2008-07-17 | ドラッグテック コーポレイション | Cardiovascular composition |
JP2018503636A (en) * | 2015-01-14 | 2018-02-08 | ファイザー・インク | Oral delivery products |
JP2020072673A (en) * | 2013-10-09 | 2020-05-14 | 味の素株式会社 | Anti-fatigue composition |
Families Citing this family (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU7258996A (en) * | 1995-10-06 | 1997-04-28 | Arch Development Corporation | Methods and compositions for viral enhancement of cell killing |
EP1175158A1 (en) * | 1999-05-07 | 2002-01-30 | Trustees Of Tufts College | Immune stimulating dietary supplement and methods of use thereof |
US6479545B1 (en) * | 1999-09-30 | 2002-11-12 | Drugtech Corporation | Formulation for menopausal women |
CA2427681A1 (en) * | 2000-11-29 | 2002-06-06 | Smithkline Beecham Corporation | Dietary composition containing conjugated linoleic acid and calcium for improved health |
HUP0303520A2 (en) * | 2001-03-16 | 2004-01-28 | Wyeth | Methods and compositions for providing of hormone replacement therapy |
AT411327B (en) * | 2001-08-23 | 2003-12-29 | Heil Bettina | Fast absorption rectal suppository for treating hormone deficiency, comprises progesterone or its precursor dehydroepiandrosterone and unsaturated, unesterified fatty acid(s) |
US6911438B2 (en) * | 2001-09-12 | 2005-06-28 | Jonathan V. Wright | Hormone replacement formulation |
US7704542B2 (en) * | 2001-09-12 | 2010-04-27 | Xanodyne Pharmaceuticals, Inc. | Vitamin/mineral compositions with DHA |
NL1019368C2 (en) * | 2001-11-14 | 2003-05-20 | Nutricia Nv | Preparation for improving receptor performance. |
US6821532B2 (en) * | 2001-11-16 | 2004-11-23 | Unitel Technologies, Inc. | Methods and compositions for the treatment of benign prostatic hypertrophy |
PL209558B1 (en) * | 2002-02-21 | 2011-09-30 | Bayer Schering Pharma Ag | Pharmaceutical compositions comprising one or more steroids one or more tetrahydrofolate components and vitamin b12 |
AU2003218319A1 (en) * | 2002-03-22 | 2003-10-13 | Doc's Guide, Inc. | Multivitamin and mineral nutritional supplement |
US6610331B1 (en) * | 2002-05-30 | 2003-08-26 | Scott M. Sweazy | Fertility kit |
US20040048919A1 (en) * | 2002-07-02 | 2004-03-11 | Dreon Darlene M. | Compositions and methods for reduction of inflammatory symptoms and/or biomarkers in female subjects |
CA2490308A1 (en) * | 2002-07-12 | 2004-01-22 | University Of Rochester | Use of amino acids for treatment of various conditions |
NZ539624A (en) | 2002-09-27 | 2008-08-29 | Martek Biosciences Corp | Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation |
US20050064013A1 (en) * | 2002-10-11 | 2005-03-24 | Jeffrey Liebrech | Ready to drink beverage composition having liquid form HGH pre-cursor and method of making same |
GB0228571D0 (en) * | 2002-12-06 | 2003-01-15 | Novartis Ag | Organic compounds |
US20040253319A1 (en) * | 2003-06-11 | 2004-12-16 | Shrirang Netke | Pharmaceutical compositions and method for alleviating side-effects of estrogen replacement therapy |
US7857913B2 (en) * | 2003-06-26 | 2010-12-28 | Spindler William E | Cleaning compound for cleaning surfaces in a food processing environment |
IL156670A0 (en) * | 2003-06-26 | 2004-01-04 | Zvi Zolotariov | Aloe suppositories |
US20050032741A1 (en) * | 2003-08-06 | 2005-02-10 | Balaji Venkataraman | Vitamin Compositions |
US20050032740A1 (en) * | 2003-08-06 | 2005-02-10 | Balaji Venkataraman | Vitamin compositions for the treatment and prevention of vascular disease and dementia |
US7875291B1 (en) | 2003-09-05 | 2011-01-25 | Glu-Pro, Inc. | Composition for managing diabetes, obesity, and hyperlipidemia and associated methods |
EP1667619A4 (en) * | 2003-09-19 | 2007-10-10 | Drugtech Corp | Pharmaceutical delivery system |
US20060140990A1 (en) * | 2003-09-19 | 2006-06-29 | Drugtech Corporation | Composition for topical treatment of mixed vaginal infections |
US20050112215A1 (en) * | 2003-10-09 | 2005-05-26 | Valerie Otto | Cramp bark extract and method of extraction |
US20050158404A1 (en) * | 2003-11-18 | 2005-07-21 | Goodless Dean R. | Composition and method for treatment of acne |
US20050202038A1 (en) * | 2004-03-10 | 2005-09-15 | Green Roger E. | Composition and method for minimizing residual fecal matter in the perianal area |
US7265101B2 (en) * | 2004-04-07 | 2007-09-04 | Rutgers, The State University Of New Jersey | Appetite-suppressing compositions and methods |
GB2414181A (en) * | 2004-05-19 | 2005-11-23 | Merck & Co Inc | compositions containing a bisphosphonate and a Vitamin D derivative |
US20050266130A1 (en) * | 2004-05-28 | 2005-12-01 | Henry Aoki | Method for solidification and storing of components extracted from plant, animal, or mineral matter and extract components extracted from held plant, animal, or mineral matter |
US20060039971A1 (en) * | 2004-08-19 | 2006-02-23 | Lee Robert E | Effervescent composition including alternative hormone replacement therapy agent |
CA2605341A1 (en) * | 2005-05-09 | 2006-11-16 | Drugtech Corporation | Modified-release pharmaceutical compositions |
UY29527A1 (en) | 2005-05-13 | 2006-12-29 | Schering Ag | PHARMACCUTIC COMPOSITION CONTAINING GESTRGENS AND / OR ESTRNGENS AND 5-METHYL - (6S) - TETRHYDROPHOLATE. |
US8263137B2 (en) | 2005-08-04 | 2012-09-11 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
US7998500B2 (en) | 2005-08-04 | 2011-08-16 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
US8202546B2 (en) | 2005-08-04 | 2012-06-19 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
US7901710B2 (en) | 2005-08-04 | 2011-03-08 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
US20070048367A1 (en) * | 2005-08-31 | 2007-03-01 | Mom Enterprises, Inc. | Herbal composition for treating morning sickness |
WO2007073525A2 (en) * | 2005-11-28 | 2007-06-28 | Yvonne Daily | Hot-flash wipes and clothing |
JP2009522362A (en) * | 2006-01-05 | 2009-06-11 | ドラッグテック コーポレイション | Drug delivery system |
AU2006332518A1 (en) * | 2006-01-05 | 2007-07-12 | Drugtech Corporation | Composition and method of use thereof |
CN101405006A (en) * | 2006-01-20 | 2009-04-08 | 梨树医药公司 | Method of treating atrophic vaginitis |
EP2034984A4 (en) | 2006-06-02 | 2013-03-06 | Pear Tree Women S Health Care | Method of treating atrophic vaginitis |
US20080057144A1 (en) * | 2006-09-01 | 2008-03-06 | Cathy Beggan | Wake up on time dietary supplement and method of use |
WO2008073779A2 (en) * | 2006-12-07 | 2008-06-19 | Drugtech Corporation | Compositions and methods for treating seizures |
US20080241290A1 (en) * | 2007-03-30 | 2008-10-02 | Wayne Jeffrey Perry | Sinus relief composition and method of producing the same |
US20130115320A1 (en) | 2007-03-30 | 2013-05-09 | Dynova Laboratories, Inc. | Therapeutic agent for intranasal administration and method of making and using same |
US20080242741A1 (en) * | 2007-03-30 | 2008-10-02 | Wayne Jeffrey Perry | Intranasal drug delivery system |
US7871648B2 (en) * | 2007-04-02 | 2011-01-18 | Alfredo Avila | Herbal formulation for the treatment of bone fractures and osseous defects |
US20090053319A1 (en) * | 2007-08-21 | 2009-02-26 | Wayne Jeffrey Perry | Sore Throat Relief Composition And Method of Producing Same |
US20090069446A1 (en) * | 2007-09-06 | 2009-03-12 | Wayne Jeffrey Perry | Dendritic salt therapeutic agent delivery system |
CA2639512A1 (en) * | 2007-09-10 | 2009-03-10 | Sicap Industries, Llc | Nasal rinse additive |
US7964189B1 (en) | 2007-09-25 | 2011-06-21 | Argent Development Group, Llc | Nutritional supplements for women desiring to become pregnant, and pregnant and nursing women |
US9125844B1 (en) | 2007-09-25 | 2015-09-08 | Argent Development Group, Llc | Nutritional supplements for women desiring to become pregnant, and pregnant and nursing women |
UY31410A1 (en) * | 2007-10-30 | 2009-05-29 | COMPOSITION THAT INCLUDES POLYINSATURATED FATTY ACIDS AND ACTIVATED VEGETABLE CARBON | |
US7824716B1 (en) * | 2008-04-11 | 2010-11-02 | Van De Pol Sylvia | Herbal women's health formula |
US20090264520A1 (en) * | 2008-04-21 | 2009-10-22 | Asha Lipid Sciences, Inc. | Lipid-containing compositions and methods of use thereof |
US8535659B1 (en) | 2008-05-27 | 2013-09-17 | Argent Development Group, Llc | Nutritional supplements for pregnant women |
US8535660B1 (en) | 2008-05-27 | 2013-09-17 | Argent Development Group, Llc | Nutritional supplements for pregnant women |
US20100040708A1 (en) * | 2008-08-13 | 2010-02-18 | Vicki Boynton | Herbal composition |
WO2010107505A1 (en) | 2009-03-20 | 2010-09-23 | Milk Specialties Company | Non-settling galacto-oligosaccharide-rich liquid concentrate and related methods and nutritional compositions |
IT1397405B1 (en) * | 2009-06-23 | 2013-01-10 | A M S A S R L | SUPPLEMENTARY FORMULATION AIMED AT THE CHECK OF THE RECURRENT MULTIFACTORIAL ORGANIC ALTERATIONS IN THE MENOPAUSE PERIOD |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
ES2885523T3 (en) | 2011-11-23 | 2021-12-14 | Therapeuticsmd Inc | Natural combination hormone replacement formulations and therapies |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
KR101400913B1 (en) * | 2014-03-12 | 2014-05-28 | 주식회사 파미니티 | Pharmaceutical composition and food composition for preventing, treating or improving woman hormone controlling disorder |
RU2016143081A (en) | 2014-05-22 | 2018-06-26 | Терапьютиксмд, Инк. | NATURAL COMBINED HORMONE SUBSTITUTION COMPOSITIONS AND THERAPIES |
US9392814B2 (en) * | 2014-06-06 | 2016-07-19 | Nicholas J. Singer | Delivery system for drinks |
CN104027339B (en) * | 2014-06-12 | 2017-01-18 | 王淑芳 | Vitamin composition and application thereof in regulating ovarian function |
JP2017523138A (en) | 2014-07-29 | 2017-08-17 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | Transdermal cream |
USD773313S1 (en) | 2015-06-23 | 2016-12-06 | Nicholas J. Singer | Package |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
CN105944088A (en) * | 2016-06-29 | 2016-09-21 | 中国人民解放军第三军医大学第附属医院 | Composition for regulating ovarian function and application of composition |
US10357529B2 (en) * | 2016-11-07 | 2019-07-23 | Rvrs, Llc | Natural formulation for treating hangover |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08198753A (en) * | 1994-09-21 | 1996-08-06 | Scotia Holdings Plc | Medical treatment with fatty acid |
WO1997027764A1 (en) * | 1996-01-31 | 1997-08-07 | South Alabama Medical Science Foundation | Food and vitamin preparations containing the natural isomer of reduced folates |
WO1998004248A1 (en) * | 1996-07-30 | 1998-02-05 | Energetics, Inc. | Dietary supplements |
WO1999003365A1 (en) * | 1997-07-14 | 1999-01-28 | N.V. Nutricia | Nutritional composition containing methionine |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US471387A (en) * | 1892-03-22 | Photographic album | ||
NL8403433A (en) * | 1984-11-09 | 1986-06-02 | Holland Melkunie | FOOD SUPPLY PREPARATION BASED ON MILK COMPONENTS. |
GB8524276D0 (en) | 1985-10-02 | 1985-11-06 | Efamol Ltd | Pharmaceutical & dietary compositions |
US4752479A (en) | 1986-05-27 | 1988-06-21 | Ciba-Geigy Corporaton | Multi vitamin and mineral dietary supplement with controlled release bioavailable iron |
GB8621816D0 (en) | 1986-09-10 | 1986-10-15 | Efamol Ltd | Therapeutic composition |
US4851431A (en) | 1986-11-26 | 1989-07-25 | Bar Ilan University | Physiologically active and nutritional composition |
US4900734A (en) | 1987-08-27 | 1990-02-13 | Maxson Wayne S | Novel pharmaceutical composition containing estradiol and progesterone for oral administration |
DE3854664T2 (en) | 1987-10-14 | 1996-05-02 | Kao Corp | Process for producing a polyol fatty acid ester and glyceride mixture obtained thereby. |
IL91802A (en) | 1988-10-27 | 1994-05-30 | Univ Bar Ilan | Compositions containing linolenic acid derivativesfor treating Alzheimer's disease, related dementias and epilepsy |
US5012761A (en) * | 1988-11-17 | 1991-05-07 | Oh Suk Y | Chicken egg having relatively high percentage of long chain fatty acids and method of reducing heart related disease in humans using such eggs |
US4945103A (en) | 1989-01-17 | 1990-07-31 | Michael Cohen | Method of treating pre-menstrual syndrome |
US5514392A (en) * | 1989-08-30 | 1996-05-07 | Seawell Corporation N.V. | Packaging for perishable goods |
GB9112052D0 (en) | 1991-06-05 | 1991-07-24 | Efamol Holdings | Fatty acid treatment |
US5670201A (en) | 1991-06-21 | 1997-09-23 | Snow Brand Milk Co., Ltd. | Low allergenic nutrient composition and method of using same |
US5087586A (en) * | 1991-07-03 | 1992-02-11 | Micron Technology, Inc. | Process for creating fully-recessed field isolation regions by oxidizing a selectively-grown epitaxial silicon layer |
US5223285A (en) | 1992-03-31 | 1993-06-29 | Abbott Laboratories | Nutritional product for pulmonary patients |
GB9211229D0 (en) | 1992-05-27 | 1992-07-08 | Efamol Holdings | Fatty acid treatment |
GB9217780D0 (en) | 1992-08-21 | 1992-10-07 | Efamol Holdings | Fatty acid treatment |
WO1994006415A1 (en) | 1992-09-23 | 1994-03-31 | Kv Pharmaceutical Corporation | Multi-vitamin and mineral supplement for pregnant women |
AU679020B2 (en) | 1992-12-23 | 1997-06-19 | Abbott Laboratories | Medical foods for the nutritional support of infant/toddler metabolic diseases |
US5576666A (en) | 1993-11-12 | 1996-11-19 | Nippondenso Technical Center Usa, Inc. | Fractional-N frequency synthesizer with temperature compensation |
US5855949A (en) * | 1994-01-10 | 1999-01-05 | Mclean; Linsey | Dietary system high in oil intake |
US5484623A (en) | 1994-01-10 | 1996-01-16 | Mclean; Linsey | Dietary system high in oil intake for the treatment of obesity and for the lowering of saturated fats |
US5869084A (en) * | 1994-06-20 | 1999-02-09 | K-V Pharmaceuticals Co. | Multi-vitamin and mineral supplements for women |
US5514382A (en) | 1994-10-17 | 1996-05-07 | Sultenfuss; Sherry | Daily vitamin and mineral supplement for women |
US5589468A (en) | 1995-01-13 | 1996-12-31 | Clintec Nutrition Co. | Method for providing nutrition to elderly patients |
US5569459A (en) | 1995-02-15 | 1996-10-29 | Bio-Virus Research Incorporated | Pharmaceutical compositions for the management of premenstrual syndrome and alleviation of menopausal disorders |
US5514328A (en) | 1995-05-12 | 1996-05-07 | Stoody Deloro Stellite, Inc. | Cavitation erosion resistent steel |
GB9510636D0 (en) | 1995-05-25 | 1995-07-19 | Scotia Holdings Plc | Fatty acid treatment |
US5807586A (en) | 1996-07-30 | 1998-09-15 | Energetics, Inc. | Method of dietary supplementation |
US5922704A (en) * | 1997-12-24 | 1999-07-13 | Feeling Fine Company Llc | Optimal nutritional supplement for men |
US6048846A (en) | 1998-02-26 | 2000-04-11 | Cochran; Timothy M. | Compositions used in human treatment |
WO1999065337A1 (en) | 1998-06-19 | 1999-12-23 | Beth Israel Deaconess Medical Center | Dietary supplement for post-menopausal women |
US6569857B1 (en) | 1999-05-03 | 2003-05-27 | Drugtech Corporation | Dietary supplement |
US6258846B1 (en) | 1999-06-01 | 2001-07-10 | Drugtech Corporation | Nutritional supplements |
US6479545B1 (en) | 1999-09-30 | 2002-11-12 | Drugtech Corporation | Formulation for menopausal women |
JP2008056612A (en) | 2006-08-31 | 2008-03-13 | Koei Chem Co Ltd | Process for preparing aminopyridines |
-
1999
- 1999-09-30 US US09/409,059 patent/US6479545B1/en not_active Expired - Lifetime
-
2000
- 2000-08-28 JP JP2001527771A patent/JP2003510344A/en active Pending
- 2000-08-28 KR KR1020027004093A patent/KR100831511B1/en not_active IP Right Cessation
- 2000-08-28 BR BR0014438-0A patent/BR0014438A/en not_active IP Right Cessation
- 2000-08-28 DE DE60034046T patent/DE60034046T2/en not_active Expired - Lifetime
- 2000-08-28 AU AU69416/00A patent/AU778507B2/en not_active Ceased
- 2000-08-28 EP EP00957857A patent/EP1216024B1/en not_active Expired - Lifetime
- 2000-08-28 AT AT00957857T patent/ATE357213T1/en not_active IP Right Cessation
- 2000-08-28 MX MXPA02003101A patent/MXPA02003101A/en active IP Right Grant
- 2000-08-28 CA CA002645397A patent/CA2645397A1/en not_active Abandoned
- 2000-08-28 ES ES00957857T patent/ES2195798T3/en not_active Expired - Lifetime
- 2000-08-28 WO PCT/US2000/023527 patent/WO2001024772A1/en active IP Right Grant
- 2000-08-28 DE DE00957857T patent/DE00957857T1/en active Pending
- 2000-08-28 CA CA002385854A patent/CA2385854C/en not_active Expired - Fee Related
- 2000-08-28 CN CN00815270A patent/CN1391464A/en active Pending
-
2002
- 2002-03-27 US US10/106,381 patent/US7687485B2/en not_active Expired - Fee Related
- 2002-04-04 ZA ZA200202633A patent/ZA200202633B/en unknown
- 2002-04-25 US US10/131,236 patent/US20020173510A1/en not_active Abandoned
-
2004
- 2004-12-22 US US11/023,871 patent/US20050106266A1/en not_active Abandoned
-
2008
- 2008-11-14 US US12/271,500 patent/US20090068289A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08198753A (en) * | 1994-09-21 | 1996-08-06 | Scotia Holdings Plc | Medical treatment with fatty acid |
WO1997027764A1 (en) * | 1996-01-31 | 1997-08-07 | South Alabama Medical Science Foundation | Food and vitamin preparations containing the natural isomer of reduced folates |
WO1998004248A1 (en) * | 1996-07-30 | 1998-02-05 | Energetics, Inc. | Dietary supplements |
WO1999003365A1 (en) * | 1997-07-14 | 1999-01-28 | N.V. Nutricia | Nutritional composition containing methionine |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004091641A1 (en) * | 2003-04-11 | 2004-10-28 | Original Image Co., Ltd. | Follicle-stimulating hormone releasing agent |
US7691421B2 (en) | 2003-04-11 | 2010-04-06 | Original Image Co., Ltd. | Follicle-stimulating hormone reduction agent |
JP2005075804A (en) * | 2003-09-03 | 2005-03-24 | Toyo Capsule Kk | Medicinal composition including menatetrenone |
JP2008525441A (en) * | 2004-12-22 | 2008-07-17 | ドラッグテック コーポレイション | Cardiovascular composition |
JP2007023010A (en) * | 2005-07-19 | 2007-02-01 | Toshiro Azegami | Oral composition for adjusting hormone balance after menopause and for preventing and improving parkinson disease |
JP2020072673A (en) * | 2013-10-09 | 2020-05-14 | 味の素株式会社 | Anti-fatigue composition |
JP2018503636A (en) * | 2015-01-14 | 2018-02-08 | ファイザー・インク | Oral delivery products |
Also Published As
Publication number | Publication date |
---|---|
ES2195798T1 (en) | 2003-12-16 |
AU6941600A (en) | 2001-05-10 |
CA2385854A1 (en) | 2001-04-12 |
US7687485B2 (en) | 2010-03-30 |
US20050106266A1 (en) | 2005-05-19 |
US20090068289A1 (en) | 2009-03-12 |
ES2195798T3 (en) | 2007-11-16 |
DE60034046D1 (en) | 2007-05-03 |
WO2001024772A1 (en) | 2001-04-12 |
CA2645397A1 (en) | 2001-04-12 |
KR100831511B1 (en) | 2008-05-22 |
US6479545B1 (en) | 2002-11-12 |
AU778507B2 (en) | 2004-12-09 |
CN1391464A (en) | 2003-01-15 |
US20020137749A1 (en) | 2002-09-26 |
DE60034046T2 (en) | 2007-12-06 |
DE00957857T1 (en) | 2005-03-31 |
CA2385854C (en) | 2005-04-12 |
BR0014438A (en) | 2002-08-20 |
US20020173510A1 (en) | 2002-11-21 |
ZA200202633B (en) | 2003-04-30 |
MXPA02003101A (en) | 2003-08-20 |
EP1216024A1 (en) | 2002-06-26 |
EP1216024A4 (en) | 2005-02-02 |
ATE357213T1 (en) | 2007-04-15 |
KR20020048424A (en) | 2002-06-22 |
EP1216024B1 (en) | 2007-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6479545B1 (en) | Formulation for menopausal women | |
US6352713B1 (en) | Nutritional composition | |
IL146831A (en) | Nutritional supplements for pregnant and/or lactating women | |
EP1883406A2 (en) | Compositions and methods for the sustained release of beta-alanine | |
JP2022064912A (en) | Method and composition for increasing muscle protein synthesis and/or functional strength in mammals as well as method of producing composition | |
JP2002543107A (en) | Folic acid supplements | |
JP2005520816A (en) | Composition for oral or rectal administration | |
WO2015001329A1 (en) | Chewable tablet | |
AU2005200907B2 (en) | Formulation for menopausal women | |
JPH07118148A (en) | Preventive for hepatoma | |
CA2492417C (en) | Formulation for menopausal women | |
EP1661575A1 (en) | Use of magnesium in the treatment of disorders related to hormonal variations in women | |
EP1148882B1 (en) | Use of a plasma homocysteine content reducing agent for the reduction of the thromboembolic side effect risk induced by gestagen type hormones | |
US20050238739A1 (en) | Composition comprising a combination of calcium, cimicifugae racemosae rhizoma and vitamin D and its use as a pharmaceutical in conditions or disorders associated with or resulting from calcium deficiency or as a nutritional supplement | |
EP1591143A1 (en) | Composition comprising a combination of Calcium, Cimicifugae racemosae rhizoma and vitamin D and its use as a pharmaceutical in conditions or disorders associated with or resulting from calcium deficiency or as a nutritional supplement | |
JPH10231250A (en) | Antiosteoporotic agent | |
EP1588739A1 (en) | Composition comprising a combination of calcium, Cimicifugae racemosae rhizoma and vitamin D and its use as a pharmaceutical in conditions or disorders associated with or resulting from calcium deficiency or as a nutritional supplement | |
RU2002111556A (en) | Composition for menopausal women and method of administering the composition to a patient | |
CA2777233A1 (en) | Compositions and methods for treating varicose veins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070625 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101026 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110405 |